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Abstract 
Modular total syntheses of the biologically active resorcylic acid lactones (RALs) L-783,277 (1) 
and L-783,290 (128) are reported. The three key buildings blocks employed for this purpose 
were the aromatic 133, the enantiopure alcohol (R)-25 or (R)-166 and the protected diol 127. 
The building blocks (R)-25, (R)-166 and 127 were prepared by chemoenzymatic methods with 
the last of these being derived from the cis-1,2-dihydrocatechol 82 (X = Cl) which is itself 
obtained through the whole-cell biotransformation of chlorobenzene.  
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These building blocks have been linked to one another using Heck and Mitsunobu chemistries 
and the fourteen-membered macrolide rings formed using either a RCM reaction (as applied to 
compound 132) or through intramolecular addition of an acetylide anion to a tethered Weinreb 
amide (as applied to compound 165). 
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Attempts to extend the RCM-based route to the RAL aigialomycin C (131) are also described.  
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1 Chapter One 
Introduction 
The Resorcylic Acid Lactones (RALs) 
 
 
 
1.1 Introductory Comments  
Resorcylic acid lactones (RALs) represent a fascinating class of fungal metabolites 
(mycotoxins) that has attracted the attention of pharmaceutical companies and synthetic groups 
alike due to their broad range of biological activities. The intense interest in these polyketides 
has resulted in the development of numerous total syntheses, the generation of significant 
analogue libraries and the establishment of comprehensive structure activity relationship 
profiles for the class.1-3 
RALs are comprised of a !-resorcylic acid unit (highlighted in red) that is annulated to a 
fourteen-membered macrolactone (highlighted in blue) incorporating an S-configured 
stereogenic centre at C10´ that invariably bears a methyl group (Figure 1.1).  
O (S)
OR1
R2
3
!-resorcyclic
acid unit
14-membered
macrolactone ring
1'
10'1
6
R3
R1 = OH, OMe
R2 = OH, OMe
R3 = H, OMe, Cl  
Figure 1.1: General structural features associated with the resorcylic acid lactones (RALs). 
To date, a large number of RALs have been isolated and these compounds differ in their 
embodied functionality that includes epoxides, as well as variations in the degree of 
unsaturation and the geometry of the olefinic residues incorporated within the macrolactone 
ring. Variations are also encountered in the nature of substituents associated with the aromatic 
ring, which may include methyl, chlorine or oxygen-based groups (Figure 1.2). 
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Figure 1.2: Selected members of the RAL family that inhibit kinases. 
1.2 Biological Activity of RALs 
1.2.1 Overview 
The RAL-type natural products have been screened for a diverse range of biological activities 
and shown to display anti-bacterial,4 anti-malarial,5 anti-inflammatory6 and estrogenic agonist 
activities.7 However, it is their anti-tumour activity that has generated the most attention and 
this arises from the capacity of the compounds to suppress cellular replication and 
differentiation through the inhibition of kinases and growth factors. 
Kinases, also known as phosphotransferases, are enzymes that catalyse the phosphorylation of 
proteins associated with receptors and enzymes by transferring a molecule of phosphate from 
adenosine triphosphate (ATP) onto either a tyrosine, serine or threonine amino acid residue.8,9 
Once a protein is phosphorylated, it often undergoes changes in its conformation, cellular 
location and activity or selectively phosphorylates the next kinase in a multi-step cascade.8 
While kinases facilitate and regulate many biological processes, their main role is to act as a 
messenger for the transmission of intracellular signals. The protein kinases are an important 
subclass and their role is to control, upon extracellular stimulation, the intra-cellular signalling 
of critical biological processes such as mitosis (cellular replication), apoptosis (programmed cell 
death), homeostasis and cell movement.10 
Introduction 
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A pivotal type of protein kinase, and one which is involved in a number of important cellular 
processes, is the mitogen-activating protein kinase (MAPK). These mediate gene regulation 
which may lead to apoptosis or may activate a separate group of kinases called the cyclin-
dependent kinases (CDKs) which lead to cell proliferation (Figure 1.3).11,12 Tumour growth can 
occur when kinase signalling favours mitosis over apoptosis.13 
MAP3K
MAP2K
CDK
cell
proliferation
phosphorylation
gene
regulation
apoptosis
extracellular
stimuli
cell
MAPK
 
Figure 1.3: MAPK cellular signalling pathway. 
Through the application of various biological assays, it was shown that the RALs described in 
this thesis target either MAPKs or CDKs. As such, these RALs are attractive agents for 
targeting cancer at the signalling level, for probing kinase activity and for understanding the 
involvement of kinases in a number of diseases. On the basis of various studies, it is believed 
that the mechanism of kinase inhibition exerted by RALs involves their binding in the ATP 
active site of the enzyme and so preventing it from phosphorylating the relevant amino acid 
residue.14 The following section provides a brief summary of RALs that have been found to 
inhibit MAPKs and CDKs.  
1.2.1.1 Mitogen-Activating Protein Kinases (MAPKs) 
The pivotal involvement of MAPKs in a number of critical cellular processes suggests that they 
are a suitable target for treating patients with disorders regulated by this kinase and thus the 
RALs that inhibit these are potentially useful therapeutic agents.  
The capacity of RALs to inhibit kinases was first reported in 1998 by Zhao et al.,15 who showed 
that L-783,277 (1) and hypothemycin (2) were potent inhibitors of MEK1 (a type of MAPK) 
displaying IC50 values of 15 and 4 nM, respectively (MEK1 participates in the Erk cascade, a 
process that regulates several important cellular events such as mitosis, apoptosis and cellular 
differentiation).11,12 The inhibitory mechanism of these compounds is believed to involve a 
conjugate addition of the thiol moiety of a cysteine residue within the ATP active site to the 
",%-unsaturated ketone residue within these biologically active RALs.15,16,17 
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A study by Matsumoto et al. revealed that the RAL 5Z-7-oxozeanol (3, a.k.a LL-Z1640-2) was 
a potent inhibitor of TAK1 (IC50 of 8 nM) but a weak inhibitor of MEK 1 (IC50 of 411 nM), 
both of which are types of MAPKs, and thus indicating that there can be selectivity in the 
interaction of these macrolides with different MAPKs.6 
Radicicol A (4) is a cis-configured enone RAL discovered by the workers at Sandoz who found 
that it caused the degradation of the mRNA associated with interleukin 1 beta (Il1%), a protein 
responsible for certain inflammatory effects.18 The biological activity exhibited by RAL 4 led to 
an evaluation of this compound against a kinase panel by Winssinger et al. where it was found 
to be capable of inhibiting several kinases (at micro- and nano-molar concentrations) involved 
in the MAPK cascade.19 Consequently, Winssinger et al. postulated that the cause of Il1%’s 
mRNA degradation was the deactivation of these MAPKs by radicicol A (4).19 This observation 
highlights the importance of MAPKs in protein translation through stabilisation of mRNA.  
1.2.1.2 Cyclin-Dependent Kinases (CDKs) 
CDKs are critical enzymes that regulate and facilitate various stages of the cell division and 
differentiation cycle. A particular kinase of this class that has the potential for suppressing 
tumour growth is CDK1, an enzyme that regulates the division of a mother cell into two 
daughter cells (a.k.a mitosis).8,20,21 Aigialomycin D (5) is a RAL that has attracted a significant 
amount of interest since its isolation by Isaka et al. in 2002 due to its potent inhibitory activity 
against CDK1 and 5 in Winssinger’s kinase screening panel, with IC50 values of 5.7 and 5.8 
µM, respectively, being observed.1,5,22 
1.3 Synthetic Approaches to RALs 
1.3.1 Overview 
The abovementioned biological activity highlights the importance of RALs as potential 
therapeutic agents. As such, a significant number of total and formal syntheses of various RALs 
have been reported and an assessment of these reveals a common strategy for their assembly, 
involving construction of the C6–C1´, C7´-C8´ and macrolactone bonds. The fragments 
required in such an approach are the aromatic (blue), secondary alcohol (green) and diol (red) 
units shown in Figure 1.4. A brief description of the means for preparing each of these 
fragments is presented in the following sections. 
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Figure 1.4: Common disconnections associated with many RAL syntheses. 
1.3.2 Synthesis of Fragments 
1.3.2.1 Synthesis of the Aromatic Unit 
With the exception of the Barrett and Danishefsky groups’ syntheses of RALs, both of which 
are detailed in Section 1.4, the aromatic fragment of each RAL was prepared from resorcinol 
derivatives that contained “handles” for the installation of the secondary alcohol and/or the diol 
moieties associated with the macrolactone ring. As a result, the functionality present on the 
resorcinol unit is introduced at an early stage and examples of RAL syntheses involving this 
approach are now presented. In most of these cases a substituent (usually bromine) is 
incorporated on the aromatic ring at the position which corresponds to the desired point for the 
attachment of the secondary alcohol or diol fragment. For example, Pan et al. (Scheme 1.1) 
efficiently assembled the required aromatic fragment 7 from the MOM-protected resorcinol 
derivative 6 through an electrophilic aromatic substitution reaction using N-bromosuccinimide 
as the bromine source.23 The bromide 7 so-formed was used to introduce the carboxylic acid 
functionality, via a carboxylation involving sequential treatment with n-BuLi and carbon 
dioxide, for the attachment of the secondary alcohol residue. 
 
MOMO
OMOM OMOM
MOMO
O
Br O
OH
HO
O
OH
OH
aigialomycin D
(5)7
Reagents and conditions: (i) NBS, CHCl3, rt, 0.5 h; (ii) PCC, NaOAc, CH2Cl2, rt, 4 h.
i, ii
83%
6
H
OH
 
Scheme 1.1: Synthesis of aigialomycin D (5) by Pan et al. from resorcinol 6.23 
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In the two examples shown in Scheme 1.2, Lett et al. and Altmann et al. prepared the required 
aromatic fragment 10 by generating bromide 9 from precursor 8 using directed-metallation 
followed by bromination. Several straight-forward steps were then used to elaborate compound 
9 to key building block 10. Both Altmann et al. and Lett et al. employed this same 
functionalised aromatic fragment, namely compound 10, in their syntheses of targets 1 and 2, 
respectively, and thus highlighting the potential of a common aromatic fragment for assembling 
several different RALs. 
 
OH
MeO
O
OH
TBSO
MeO
O
NEt2
Br
OH
MeO
O
OH
Br
OH
MeO
O
O
HO OH
OO
OH
MeO
O
O
HO OH
O
Reagents and conditions: (i) TBSCl, i-Pr2NEt, DMF, rt, 2 h; (ii) (a) (COCl)2, DMF, CH2Cl2, –10 °C ! rt, overnight, (b) Et2NH, 
1h, rt; (iii) (a) t-BuLi, Et2O, –78 °C, 0.2 h (b) Br2; (iv) Me3O+BF4-, CH2Cl2, rt, overnight, then evaporation; (v) aq. saturated
Na2CO3/MeOH v/v 1:1, rt, 6 h; (vi) conc. NaOH/DME v/v 1:1, reflux, overnight.
i – iii iv – vi
10
L-783,277
(1)
hypothemycin
(2)
Altmann's
synthesis
Lett's
synthesis
88% 57%
8 9
 
Scheme 1.2: Altmann’s synthesis of L-783,277 (1) and Lett’s synthesis of hypothemycin (2) from 
aromatic fragment 10.24-26 
The aromatic fragment can also be generated in a biomimetic fashion as seen in Harvey’s 
synthesis of aigialomycin D (5) (Scheme 1.3) wherein the arene 12 was prepared by 
cyclodimerisation reaction of methyl acetoacetate (11).27 The readily derived bromide 14 was 
then used as the building block to which the diol unit associated with the macrocycle was 
attached. 
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Reagents and conditions: (i) (a) NaH, THF, 0 °C ! rt, (b) n-BuLi, THF, –78 °C ! rt, 12 h, (c) HCl, H2O, rt, 12 h; (ii) Ac2O, NEt3, 
CH2Cl2, rt, 12 h; (iii) NBS, [PhC(O)O2]2, CCl4, reflux ! rt, 6 h.
i
40%
11
OR
RO
O
OMe
iii71%
R = H – 12
R = Ac – 13
ii
98%
 
Scheme 1.3: Biomimetic synthesis of the aromatic fragment 14 associated with Harvey’s synthesis of 
aigialomycin D (5).27 
1.3.2.2 Synthesis of the Diol Unit 
The diol unit is commonly prepared by one of two methods, namely through a regioselective 
ring-opening of a chiral epoxide or through the manipulation of a monosaccharide precursor. 
The ring-opening strategy was exploited in Pan’s synthesis of aigialomycin D (5) (Scheme 1.4) 
wherein the protected diol fragment 18 was prepared by a titanium-assisted regioselective 
epoxide ring-opening of compound 16 (itself obtained by a SAE of allylic alcohol 15) with 
benzoic acid to afford the benzoate 17. Compound 17 was then converted into the target diol 
fragment 18 in a further six steps.23 
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Scheme 1.4: Pan’s synthesis of aigialomycin D (5) from allylic alcohol 15 using Sharpless asymmetric 
epoxidation and epoxide ring-opening protocols.23 
The second method for generating the diol fragment involves the manipulation of 
monosaccharides that possess the diol motif in the desired configuration. Such an approach was 
exploited in Tatsuta’s synthesis of 5Z-7-oxozeanol (3) wherein D-ribose (19) was converted into 
the diol fragment 21 in six steps (Scheme 1.5).28 
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MeO OHO OH
Reagents and conditions: (i) CSA, BnOH, 80 °C; (ii) MOMCl, i-Pr2NEt, MeCN, 50 °C, 4 h; (iii) H2, Pd(OH)2, EtOH, 3 h; (iv) TMS-
acetylene, n-BuLi, BF3•Et2O, THF, –78 °C ! rt; (v) PivCl, pyridine, 0 °C, 1 h; (vi) TBAF, AcOH, THF, 2 h.
i – iii
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20
OPiv
OMOM
OMOM
MOMO
OH
 
Scheme 1.5: Construction of the protected diol fragment 21 associated with Tatsuta’s synthesis of 5Z-7-
oxozeanol (3) from D-ribose (19).28  
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1.3.2.3 Synthesis of the Secondary Alcohol Unit 
The precise choice of the secondary alcohol is dependent on the coupling strategy planned for 
linking this unit to the aromatic fragment. If the coupling strategy results in retention of 
stereochemistry, by virtue of using a Mukaiyama or Yamaguichi esterification or 
macrolactonisation protocol, then the S-configured alcohol is used, as exemplified in Pan’s 
synthesis of aigialomycin D (5) (Scheme 1.6).23 
 
Reagents and conditions: (i) 2,4,6-trichlorobenzoyl chloride, Et3N, THF, rt, 2 h; (ii) DMAP, PhMe, reflux, 36 h.
O
MOMO
MOMO
O
O
O
51%
23
i,ii O
OH
HO
O
OH
OH
aigialomycin D
(5)
OH
MOMO
MOMO
O
O
O
22
(S)HO
 
Scheme 1.6: Synthesis of aigialomycin D (5) utilising a Yamaguchi macrolactonisation as employed by 
Pan et al.23 
Conversely, if an inversion of the stereochemistry is involved, as would be the case, for 
example, when Mitsunobu conditions are employed, then the R-configured alcohol is used. 
Harvey’s synthesis of aigialomycin D (5) (Scheme 1.7) demonstrates this approach.27 
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Scheme 1.7: Synthesis of aigialomycin D (5) using a Mitsunobu esterification by Harvey et al.27 
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In many previous syntheses, the commercially available R- and S- enantiomers of 4-penten-2-ol 
(25) were used as the secondary alcohol unit due to the capacity for the terminal olefin to 
engage in a subsequent ring-closing metathesis (RCM) process as a means for constructing the 
macrolactone ring. This alcohol fragment can also be readily prepared by chemical means (e.g. 
through the nucleophilic ring-opening of the appropriate enantiomer of propylene oxide 27)29,30 
or using enzymatic techniques31,32 [in particular, through the resolution of the corresponding 
racemate (±)-25 (Scheme 1.8 and Scheme 1.9), as described in Chapter 2].  
 
HO (S)
(S)-(+)-4-penten-2-ol
[(S)-25]
commercially available
HO
(±)-4-penten-2-ol
[(±)-25]
ii
(S)
O
(S)-propylene oxide
[(S)-27]
Reagent and conditions: (i) vinylmagnesium bromide, THF, CuI, –20 °C; (ii) (a) C. antarctica lipase B, vinyl acetate, 30 °C, 1 h.
89%
i
60%
 
Scheme 1.8: Methods for the generation of (S)-(+)-4-penten-2-ol [(S)-25].29,30,31,32 
 
HO (R)
(R)-(–)-4-penten-2-ol
[(R)-25]
commercially available
HO
(±)-4-penten-2-ol
[(±)-25]
(R)
O
(R)-propylene oxide
[(R)-27]
Reagent and conditions: (i) vinylmagnesium bromide, THF, CuI, –20 °C; (ii) (a) C. antarctica lipase B, vinyl acetate, 30 °C, 1 h; 
(b) C. antarctica lipase B, phosphate buffer (pH = 7.3), 30 °C, 10 h.
89%
i ii
30%
(over 2
steps)
 
Scheme 1.9: Methods for the generation of (R)-(–)-4-penten-2-ol [(R)-25].29,30,31,32 
1.3.3 Strategies for Fragment Coupling 
An assessment of the RAL syntheses reported to date reveals that several reaction types have 
been used repeatedly to couple the abovementioned fragments due to their reliability in 
achieving the desired outcomes. These reactions are discussed below together with a review of 
the details of several recently reported and significant syntheses of enone-containing RALs and 
aigialomycin D (5). 
1.3.3.1 Union of Aromatic and Diol Units 
Winssinger’s synthesis of radicicol A (4), wherein the $-anion of selenide 28 was alkylated by 
iodide 29 (Scheme 1.10), highlights one method for the coupling of the aromatic and diol units, 
namely through a nucleophilic substitution reaction. The C1´-C2´ double bond of target alkene 
31 was then revealed through an oxidation and elimination of the phenylselenyl moiety within 
product 30. As such, this strategy can be used to prepare RALs incorporating unsaturation 
between C1´ and C2´. 
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Scheme 1.10: Coupling of aromatic fragment 28 and protected diol fragment 29 associated with 
Winssinger’s synthesis of radicicol A (4).*33 
That having been said, the application of the nucleophilic substitution strategy has also been 
extended to the preparation of RALs, such as 33, which are saturated at this position – a state 
that can be achieved through reductive desulfurisation of lactones such as 32 (Scheme 1.11) to 
give compound 33.34 
 
O
EOMO
EOMO
O
OBz
SPh O O
O
EOMO
EOMO
O
OBzO O
Reagents and conditions: (i) tris(1H,1H,2H,2H-perfluorooctyl)tin hydride, AIBN, PhMe, 150 °C, µwave, 0.2 h; (ii) 1% 
NaOH/MeOH, 23 °C, 12 h.
i, ii
76-80%
32 33
 
Scheme 1.11: Access to saturated C1´-C2´ RALs as achieved by Winssinger et al.34 
 
* Winssinger et al. employed fluorous tags in their synthesis to simplify the isolation of products using 
chromatography.33 
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Another strategy used to link the title fragments involves Suzuki-Miyaura or Sonogashira cross-
coupling reactions. An example of the former approach is seen in Altmann’s synthesis of L-
783,277 (1) wherein the alkene residue of protected diol fragment 35 was hydroborated with 9-
BBN and the resulting borane cross-coupled with the aryl bromide 34 to afford compound 36 in 
81% yield (Scheme 1.12).24 
 
Reagents and conditions: (i) (a) 35, 9-BBN, THF, rt, 2 h, (b) 2 M K3PO4, [Pd(OAc)2 + 4TFP], DME, reflux, 5.5 h.
i
81%
OH
MeO
O
OTMSE
Br
+
34
O O
OMOM
TBSO
35
O
OTMSE
OH
MeO
O O
OMOM
36
TBSO
 
Scheme 1.12: Suzuki-Miyaura cross-coupling reaction employed in Altmann’s synthesis of L-783,277 
(1).24 
1.3.3.2 Union of the Secondary Alcohol and Diol Units  
The union of the secondary alcohol and diol fragments, prior to the attachment to the aromatic 
unit, is a strategy that is employed heavily in the syntheses of cis-configured enone RALs. This 
approach often involves a nucleophilic addition of an organolithium (generated from a reaction 
between the secondary alcohol fragment and a butyl lithium) to an aldehyde residue on the diol 
unit. An example of this strategy is seen in Lett’s synthesis of 5Z-7-oxozeanol (3), wherein the 
organolithium, prepared from the reaction of alkyl iodide 47 and t-BuLi, undergoes an addition 
to the aldehyde moiety within compound 48 (Scheme 1.13).26 Compounds 29 (Scheme 1.10) 
and 35 (Scheme 1.12) were also prepared in a similar manner and the details of their syntheses 
can be found in Section 1.4.1. 
 
TBSO
O
H
O OTMS O OTMS
OH
TBSO
+
56%I
Reagents and conditions: (i) (a) 47, Et2O, –78 ! 0 °C, (b) t-BuLi, pentane, 0.25 h, (c) 48, pentane, –78 ! 0 °C.
4847 49
i
 
Scheme 1.13: Assembly of the secondary alcohol 47 and the protected diol fragment 48 in Lett’s 
synthesis of 5Z-7-oxozeanol (3).26 
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1.3.4 Modes of Macrocycle Preparation 
Analysis of previous syntheses of RALs indicates that there have been two major approaches 
employed for the construction of the macrolactone moiety. The first is a coupling between the 
secondary alcohol unit and the aromatic carboxylic acid fragment of the open-chain precursor, 
and the second being a reaction between the secondary alcohol unit and the diol fragment.  
1.3.4.1 Macrolactonisation Between the Termini of the Secondary Alcohol and Aromatic 
Units 
In the first instance, as mentioned earlier, the precise choice of conditions required for the 
macrolactonisation between the secondary alcohol and aromatic carboxylic acid fragments is 
dependent on the stereochemistry of the secondary alcohol used and the mode of ring-closure. 
For example, macrolactonisation has been achieved using compound 37 under Yamaguchi or 
Mukaiyama protocols (Scheme 1.14), or with the related R-enantiomer 40 by employing 
Mitsunobu conditions (Scheme 1.15) to invert the stereochemistry of the C10´ methyl group.  
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OMOM
(S)HO
N Cl
MeI
Reagents and conditions: (i) 38, Et3N, MeCN, 50 °C, 1 h.
OR1
MeO
O
O
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(S)
OMOM43%from methyl
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i
 
Scheme 1.14: Mukaiyama macrolactonisation protocol employed in Tatsuta’s synthesis of 5Z-7-
oxozeanol (3).28 
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Scheme 1.15: Mitsunobu macrolactonisation protocol employed in Altmann’s synthesis of L-783,277 
(1).24 
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1.3.4.2 Ring-closing Metathesis Reaction Between the Termini of the Secondary Alcohol 
and Diol Units 
The second approach to creating the macrolactone moiety, involving a linking of the secondary 
alcohol and diol units, is a RCM reaction between the unsaturated termini associated with the 
respective units. This method is common amongst the aigialomycin D (5) syntheses (Scheme 
1.16 and 1.17). 
 
OH
HO
O
O
O
O
OH
HO
O
O
O
O
81%
Reagents and conditions: (i) Grubbs-Hoveyda 2nd generation catalyst, CH2Cl2, µwave, 85 °C, 3 h.
42 43
i
7'
8'
O
O
44
+
43:44 – 1:0.06
 
Scheme 1.16: RCM reaction employed in Barrett’s synthesis of aigialomycin D (5).35 
However, difficulties are sometimes encountered in using this reaction due to the potential for 
formation of a cyclohexene by-product, such as compound 44, (Scheme 1.17) in substrates such 
as 42 and 45 incorporating three alkene moieties. 
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O
O
O
O
O
O
EOMO
EOMO
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O
O
O
Reagents and conditions: (i) Grubbs' 2nd generation catalyst, PhMe, 80 °C, 12 h.
ii
90%
44 45 46
7'
8'
 
Scheme 1.17: Cyclohexene-containing by-product 44 obtained in Winssinger’s synthesis of aigialomycin 
D (5).1  
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The difference in the outcomes of the RCM reactions shown in Scheme 1.16 and Scheme 1.17 
may be due to the RCM precursor 42 (Scheme 1.16) containing a single mono-substituted 
terminal olefin with the second terminal olefin replaced with a 1,2-disubstituted alkene (at C7´-
C8´ position). As discussed in more detail in Chapter Four, the two now quite distinct olefinic 
residues allow the catalyst to differentiate between double bonds and initiate metathesis at the 
more reactive olefin, namely the sterically less hindered mono-substituted alkene. In contrast, 
the presence of two very similar mono-substituted olefinic termini in RCM substrate 45 
(Scheme 1.17), may result in initiation of the metathesis process at either end and where 
commencement of the process at the C7´-C8´ residue may produce the presumably kinetically 
favoured, but undesired, by-product 44. 
1.4 Significant RAL Syntheses 
The large number of RAL syntheses reported to date reflects the increased interest, especially 
by pharmaceutical companies, in their biological activity. Detailed summaries of several 
significant syntheses of enone-containing RALs and aigialomycin D (5) are presented herein.  
1.4.1 Syntheses of Enone-containing RALs 
The synthesis of cis-configured enone-containing RALs is not a trivial task as the enone 
functionality is susceptible to nucleophilic addition/elimination reactions and, thereby, 
isomerisation to the more stable trans-isomer. Consequently, most syntheses establish this 
sensitive moiety towards the end of the reaction sequence. Three noteworthy syntheses of 
biologically significant, cis-enone-containing RALs that exemplify this approach are presented 
below. 
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Tatsuta’s Synthesis of 5Z-7-oxozeanol (3, LL-Z1640-2, 2001)28 
Tatsuta et al. completed the first synthesis of 5Z-7-oxozeanol (3) in 2001 by employing D-
ribose (19) (Scheme 1.18) to prepare the protected diol 21 in six steps. Fragment 21 was 
coupled to the aromatic fragment 50 via a Sonogashira reaction to give alkyne 51. Compound 
51 was then subjected to a Lindlar reduction and a Tsuji hydrogenolysis to convert the alkyne 
into the E-alkene while the pivolyl-protected hydroxyl group was deprotected, oxidised to an 
aldehyde (under Swern conditions) and then olefinated under Corey-Fuchs conditions to afford 
di-bromoolefin 52. Installation of the secondary alcohol was accomplished by a ring-opening of 
S-propylene oxide [(S)-27] with an acetylide anion generated using a Corey-Fuchs reaction of 
the dibromo-olefin 52 to give alkyne 53 which was, in turn, subjected to a Lindlar reduction to 
furnish the Z-configured alkene. A base-promoted hydrolysis, followed by acidic work up, of 
the methyl ester provided acid 37.† Compound 37 was subjected to a Mukaiyama 
macrolactonisation reaction to give macrocycle 39 which, in turn, was globally deprotected and 
then the so formed allylic alcohol was oxidised with Dess-Martin periodinane (DMP) to deliver 
5Z-7-oxozeanol (3). 
 
† Results obtained from the work completed in Chapter Three indicate that the alkyne can be incorporated 
into the macrocycle due to the large ring size. 
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Scheme 1.18: Tatsuta’s synthesis of 5Z-7-oxozeanol (3).28 
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Winssinger’s Synthesis of Radicicol A (4) (2007)33 
In 2007 Winssinger et al. completed an enantioselective total synthesis of radicicol A (4) 
(Scheme 1.19). The preparation of this target commenced with the secondary alcohol (R)-(–)-4-
penten-2-ol [(R)-25] which was converted into the Z-configured and 1,2-disubstituted olefin 54 
by cross-metathesis with vinyl pinacolborolane followed by a regioselective bromination. The 
organolithium generated from olefin 54 participated in a nucleophilic addition to the aldehyde 
functionality of protected diol fragment 56 [synthesised from 2-deoxy-D-ribose (55)]. The 
resulting alcohol, 57, was protected as the EOM ether, while the TBDPS-protected alcohol was 
liberated and converted into the alkyl halide 29. Fragment 29 was subsequently coupled to the 
aromatic unit 28 (prepared from the %-resorcylic acid derivative 58 in two steps) via a 
nucleophilic substitution reaction to afford selenide 30. Intermediate 30 was itself subjected to 
an oxidation and elimination of the selenide functionality to reveal the C1´-C2´ olefin which 
underwent a subsequent desilylation to deliver acid 59. Compound 59 was subjected to a 
Mitsunobu macrolactonisation reaction to provide the fourteen-membered macrocyclic ring 60 
in 81% yield. The protecting groups within compound 60 were carefully removed with BCl3 and 
the allylic alcohol so revealed was oxidised with IBX to furnish radicicol A (4). 
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Scheme 1.19: Synthesis of radicicol A (4) by Winssinger et al.33 
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Altmann’s Synthesis of L-783,277 (1) (2008)24  
In 2008 Altmann et al. reported the first enantioselective synthesis of L-783,277 (1) (Scheme 
1.20). The preparation of this RAL commenced with the manipulation of isopropylidene-D-
erythrono-1,4-lactone (61) which was ring-opened and olefinated, under Wittig conditions, to 
afford $,%-unsaturated ethyl ester 62. The associated double bond was hydrogenated and the 
primary alcohol was protected as the silyl ether before the ethyl ester was reduced to give the 
alcohol 63. The alcohol residue within compound 63 was dehydrated under Grieco conditions to 
provide the corresponding alkene while removal of the silyl ether and oxidation of the resulting 
primary alcohol afforded fragment 64. The organolithium generated from secondary alcohol 
(R)-65 then participated in a nucleophilic addition to the aldehyde functionality of fragment 64 
and the resulting alcohol was protected as the MOM ether to afford compound 35. 
Hydroboration of olefin 35 with 9-BBN followed by a Suzuki-Miyaura reaction with the 
aromatic fragment 34 provided intermediate 36 that was subjected to a Lindlar reduction to 
convert the alkyne into the Z-configured alkene and a global desilylation of this material using 
TBAF then gave acid 40. Compound 40 participated in a Mitsunobu macrolactonisation 
reaction to provide the fourteen-membered ring product 41 which was globally deprotected and 
the allylic alcohol unit so revealed was subsequently oxidised with IBX to afford L-783,277 (1). 
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Scheme 1.20: Synthesis of L-783,277 (1) by Altmann et al.24 
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1.4.2 Previous Syntheses of Aigialomycin D (5) 
Another biologically significant RAL is aigialomycin D (5) due to its potent inhibition of CDKs 
1 and 5 which could, therefore, serve as new therapeutic agents. Numerous syntheses of RAL 5 
have been reported to date and some of these, most notably those due to Danishefsky et al. and 
Barrett et al., possess unique features. In particular, an aromatic fragment is not employed at the 
outset with this functionality being installed towards the end of the sequence. These two 
syntheses are outlined below, together with a more recent one and they all serve to further 
emphasise the utility of the common reactions discussed in Section 1.3.  
Danishefsky Synthesis of Aigialomycin D (5) (2004)36 
The first enantioselective total synthesis of aigialomycin D (5) (Scheme 1.21) was 
accomplished by Danishefsky et al. in 2004 by employing a Diels-Alder cycloaddition reaction 
between cyclohexadiene 71 and ynolide 70 to establish the aromatic functionality. Thus, the 
preparation of aigialomycin D (5) commenced with 2-deoxy-D-ribose (55) which was converted 
into the protected diol fragment 66 through several standard functional group manipulations. 
The required alkyne and allylic ether functionalities were installed in three steps from protected 
diol 66, via a Barbier-type reaction and an oxidation-Wittig olefination reaction sequence, to 
give enyne 67. The secondary alcohol fragment (R)-25 was coupled to the carboxylated 
derivative of compound 67 (obtained through reaction of compound 67 with n-butyl lithium and 
carbon dioxide) under Mitsunobu conditions to furnish compound 68. To prevent RCM 
precursor 68 from undergoing an yne-ene metathesis reaction, the alkyne functionality was 
protected as the cobalt complex 69 before being subjected to Grubbs’ 2nd generation catalyst.37 
A ceric ammonium nitrate (CAN) deprotection step then afforded ynolide 70. The aromatic 
functionality was introduced through the aforementioned Diels-Alder cycloaddition reaction of 
the propargylic ketone 70 with cyclohexadiene 71 which resulted in the loss of isobutene (via a 
retro-Diels-Alder reaction) and the trimethylsilyl ethers (during flash chromatography on silica). 
With the phenols now protected as MOM ethers, the TBS group within compound 72 was 
cleaved and the resulting C2´ alcohol was dehydrated with Martin’s sulfurane to establish the 
C1´-C2´ olefin. This material was subsequently deprotected to complete the synthesis of 
aigialomycin D (5). 
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Scheme 1.21: Synthesis of aigialomycin D (5) by Danishefsky et al.36 
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Barrett’s Synthesis of Aigialomycin D (5) (2009)35  
In 2009 Barrett et al. completed a synthesis of aigialomycin D (5) (Scheme 1.22) that revolved 
around a particularly elegant ketene-generation-trapping-aromatization sequence to introduce 
the %-resorcylic functionality and establish the RCM precursor 42 in one pot from compound 
77. Thus, the preparation of RAL 5 commenced with O-isopropylidene-D-erythronolactone (61) 
which was converted into the protected diol fragment 73 via several functional group 
interconversions. Compound 73 was itself coupled with the enolate generated by treatment of 
fragment 76 (dioxine 76 was prepared from reaction of compound 74 with acyl chloride 75) 
with pyridine and MgCl2. With the crucial intermediate 77 synthesised, it was heated in the 
presence of Pd(OAc)2 and morpholine to initiate a retro-Diels-Alder reaction to afford ketene 78 
that was trapped in situ with (S)-(+)-4-penten-2-ol [(S)-25] to afford ester 79. Compound 79 was 
aromatised by treatment with caesium acetate and then acetic acid to furnish triene 42. 
Compound 42 itself was subjected to a RCM reaction with Hoveyda-Grubbs 2nd generation 
catalyst38 to furnish a macrolactone that was then globally deprotected to provide aigialomycin 
D (5).‡  
 
‡ For this RCM reaction, protection of the C1´-C2´ alkene moiety of 42 was not required to obtain the 
desired product due to catalyst selectivity for the olefin associated with the homoallylic ester over that 
associated with the C7´-C8´ fragment.  
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Scheme 1.22: Synthesis of aigialomycin D (5) by Barrett et al.35 
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Harvey’s Synthesis of Aigialomycin D (5) (2009)27 
A recent synthesis of aigialomycin D (5) completed by Harvey et al. (Scheme 1.23) is also 
representative of an approach utilising the common reactions described in Section 1.3. A 
significant feature of Harvey’s synthesis is the masking of the C1´-C2´ alkene as a sulfone to 
prevent unwanted cyclohexene formation during the RCM reaction of diene 26. The olefin was 
then unmasked using a Ramberg-Bäcklund reaction. Thus, the synthesis of target 5 commenced 
with D-ribose (19) which was converted into the protected diol fragment 80 in seven steps. 
Compound 80 was itself coupled to the aryl bromide 14 via a nucleophilic substitution reaction 
followed by an immediate re-protection of the phenols as MOM ethers to afford sulfide 24. 
Compound 24 was, in turn, coupled to (R)-(–)-4-penten-2-ol [(R)-25] under Mitsunobu 
conditions and subsequently oxidised with m-CPBA to the sulfone 26. Compound 26 was 
treated with Grubbs’ 2nd generation catalyst37 to deliver macrocycle 81 which was, in turn, 
subjected to a Ramburg-Bäcklund reaction to reveal the C1´-C2´ olefin. Global deprotection of 
the four hydroxyl groups associated with the target then provided aigialomycin D (5). 
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Scheme 1.23: Harvey’s synthesis of aigialomycin D (5).27 
1.4.3 Overview of Previous Synthetic Efforts 
The foregoing commentary should serve to highlight the continuing popularity of RALs as 
synthetic targets. Despite this attention, there remains a need for shorter and more flexible 
approaches which would deliver collections of analogues for drug development. Given the great 
interest in RALs and the Banwell group’s successes in synthesising related macrolides using 
enantiopure cis-1,2-dihydrocatechols as starting materials, the use of these novel metabolites in 
the preparation of the title compounds formed the basis of the research reported in this thesis. 
Accordingly, it is appropriate to now provide some background on the generation and synthetic 
utility of cis-1,2-dihydrocatechols.  
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1.5 cis-1,2-Dihydrocatechols as Starting Materials for the Enantiospecific 
Synthesis of Macrolides 
1.5.1 Overview  
In an approach that differs from those outlined previously, it was anticipated that the diol unit of 
the RALs could be generated from the enzymatically-derived and readily available metabolite, 
cis-1,2-dihydrocatechol (cDHC) 82 (Figure 1.5). 
X
OH
OH
X = Me, Br, Cl, I, CN, CF3, CO2H, CH=CH2, etc
82
 
Figure 1.5: Commonly available cis-1,2-dihydrocatechols (cDHCs, 82). 
These synthetically valuable metabolites have been employed previously in various total 
syntheses, including those of macrolides such as (+)-aspicilin.39 Accordingly, it was anticipated 
that the use of cDHCs in the synthesis of RALs would be ideal due to the correlation of diol 
stereochemistry in the cDHCs with its counterparts present in the majority of RALs. 
Furthermore, by using a cDHC as a starting material, it was envisaged that the number of steps 
required to generate the diol unit could be reduced when compared to previous RAL syntheses. 
Before detailing this work, the biosynthesis, reactivity and use of such starting material in 
macrolide preparations is described.  
1.5.2 Enzymatic Production of cis-1,2-Dihydrocatechols from Arenes 
Since Pasteur’s discovery of whole-cell alcoholic fermentation,40 the use of enzyme-mediated 
transformations has become a particularly useful tool in chemical synthesis. Some significant 
uses of enzymes in organic chemistry include the kinetic resolution of racemates and, thereby, 
the preparation of enantiopure compounds. These enzymatic transformations are not confined to 
laboratory-scale syntheses and an example of their use on an industrial scale is seen in the 
GlaxoSmithKline synthesis of the reverse transcriptase inhibitor Abacavir (86) (ZiagenTM) 
(Scheme 1.24).41,42 
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Scheme 1.24: Industrial synthesis of Abacavir (86) by GlaxoSmithKline using enzymes.41,42  
The enzymatic pathway associated with the biosynthesis of cDHCs, namely microbial aromatic 
metabolism, was first discovered by Strömer et al., when they demonstrated that the bacterium 
Bacillus hexacarovorum consumed toluene or xylene as a source of carbon.40 In 1968, studies 
carried out by Gibson et al. led to the identification of a possible pathway for the metabolism of 
arenes by the soil bacterium Pseudomonas putida (Scheme 1.25). It was proposed that the first 
stage of the process involves a stereoselective dihydroxylation and dearomatisation of aromatic 
substrates 87 with the enzyme toluene dioxygenase (TDO) to afford the cDHC metabolites 
82.40,43,44 These primary metabolites were themselves converted into the corresponding catechol 
88 by the enzyme dihydrodiol dehydrogenase.40,43,44 
 
X
toluene
dioxygenase
X
OH
OH
cis-dihydrodiol
dehydrogenase
X
OH
OHPseudomonas
 putida 39D
87 82 88
X = Me, Br, Cl, I, etc  
Scheme 1.25:  The microbial aromatic oxidation pathway of P. putida elucidated by Gibson et al.40,43,44 
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Gibson et al. later sequenced and over-expressed the genes encoding for TDO in host 
organisms, such as Escherichia coli JM109, to afford clones, such as JM109(pDTG601), 
lacking the dihydrodiol dehydrogenase and thus allowing for the accumulation of significant 
amounts (up to 25 g per litre of fermentation broth) of enantiopure cDHC [> 99% enantiomeric 
excess (e.e.)] that could then be isolated and subjected to the normal modes of chemical 
characterisation (Scheme 1.26).45 
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Scheme 1.26: Whole-cell biotransformation used for generating cDHCs 82 as developed by Gibson et 
al.43-45 
The versatility of these enzymes is highlighted by the fact that at least 400 such metabolites 
have now been isolated (Figure 1.6).46 
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Figure 1.6: Various metabolites prepared by whole-cell biotransformation of the corresponding 
aromatic.46 
1.6 Acquisition of Either Enantiomer of cDHC 
A limitation of using cDHCs in the synthesis of non-racemic chiral natural products is the 
seeming inability to access its enantiomer, viz ent-cDHC [ent-82 (X = Cl)]. To overcome this 
difficulty, Boyd et al. developed a process called ‘enantiomeric switching’ which involved 
exposing p-iodochlorobenzene (97) to TDO and thus generating a mixture of metabolites 98 and 
ent-98 (with the latter being the major product) (Scheme 1.27).47 The observed preference for 
ent-98 arises from the larger iodo-substituent directing the enzymatic dihydroxylation process. 
The iodo-group within compounds 98 and ent-98 was then reductively cleaved to afford the 
corresponding mixture of cDHC 82 (X = Cl) and ent-cDHC ent-82 (X = Cl). By subjecting 
this mixture to P. putida NCIMB 8859 (dihydrodiol dehydrogenase) the undesired enantiomer 
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82 (X = Cl) was selectively aromatised to provide a chromatographically separable mixture of 
the catechol 88 (X = Cl) and the enantiomerically pure ent-cDHC ent-82 (X = Cl). This 
chemoenzymatic process could be applied to various p-disubstituted benzene substrates and so 
allowing access to either enantiomeric form of the desired cDHC. 
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Scheme 1.27: Access to ent-cDHC [ent-82 (X = Cl)] through “enantiomeric switching”.47 
1.7 Synthetic Utility of Halogenated cDHC 
The enantiopure halogenated cDHCs of the general form 82 represent important “building 
blocks” because they can be subjected to an array of regio- and/or stereo-selective chemical 
transformations including electrophilic addition, [4+2] cycloaddition, oxidative cleavage and 
cross-coupling reactions to give a range of useful products (Figure 1.7). The following sections 
provide a summary of these types of transformations.  
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Figure 1.7: Sites of reactions within cDHC 82 and their derivatives. 
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1.7.1.1 cis-Configured Diols  
The two cis-related hydroxyl groups embedded within the halogenated cDHCs (82) allow, 
through chelation with the relevant reagents, for the regioselective functionalisation of the C3-
C4 and C5-C6 olefins on the $-face. Conversely, if the hydroxyl groups are derivatised using 
bulky groups (such as acetonides for example), the functionalisation of the two olefins will 
occur on the %-face due to steric effects. This feature has been exploited in Hudlicky’s synthesis 
of (+)-pinitol [(+)-101],48 wherein the non-halogenated olefin within cDHC acetonide derivative 
99 (X = Br) was dihydroxylated on the opposite face to the protected diol to give product 100 
(Scheme 1.28).48 
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Scheme 1.28: Synthesis of (+)-pinitol [(+)-101] by Hudlicky et al.48 
1.7.1.2 Diene Moiety 
As observed in the above example (Scheme 1.28), the diene moiety of the cDHCs contains two 
non-equivalent alkenes due to the presence of a halogen at the C3 position which results in a 
more electron-deficient C3-C4 olefin. As a consequence, the C5-C6 olefin is more susceptible 
to electrophilic addition reactions such as epoxidation, dihydroxylation and aziridination. With 
the non-halogenated olefin removed, the remaining olefin can undergo an oxidative cleavage 
under ozonolytic conditions to provide, depending on the reaction conditions used, ring 
expanded, contracted and/or acyclic products, with the stereochemistry of the diols remaining 
intact. The differentiation between the two olefins was exploited in Hudlicky’s synthesis of 
mannojirimycin (104) (Scheme 1.29) wherein the C5-C6 olefin was first aziridinated and the 
remaining, halogenated, olefin then oxidatively cleaved to afford lactone 10349 (the strategy of 
cleaving the C3-C4 olefin with ozone has been used in the preparation of the diol fragment 
described in this thesis). 
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Scheme 1.29: Hudlicky’s synthesis of mannojirimycin (104).49 
The presence of the diene moiety within the cDHCs also allows for various regioselective [4+2] 
Diels-Alder cycloaddition reactions to be carried out. This strategy was employed by Banwell et 
al. in their formal total synthesis of the anti-bacterial platencin (108) (Scheme 1.30) wherein an 
intramolecular Diels-Alder cycloaddition reaction was undertaken with compound 106, and 
leading, via the initial adduct 107, to the rapid assembly of the tricyclic core of the target natural 
product.50 
 
X
O
O
O
O
TBDMSO
O
O
TBDMSO
O
O
N
HHO
HO
OH
platencin
(108)
I
OTBDMS
Reagents and conditions: (i) (a) t-BuLi, ZnI2, Et2O/THF, –78 ! 18 °C, 1 h, (b) Pd(PPh3)4, THF, 18 °C, 3 h; (ii) BHT, PhMe, 110 
°C, 16 h.
ii
+
65%
i
89%
1:1 mixture of
diastereomers
105 106
107
99
(X = I)
 
Scheme 1.30: Banwell’s synthesis of platencin (108).50 
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1.7.1.3 Halogen Substituent 
The halogen substituent at C3 in the cDHCs provides a handle for radical-based and metal-
based cross-coupling reactions. The platencin synthesis shown in Scheme 1.30 provides one 
example of this. Another is seen in Fang’s synthesis of Tamiflu® (111) wherein the bromine of 
cDHC 82 (X = Br) was converted into the reactive iodide analogue and then subjected to a 
palladium-catalysed carbonylation reaction to afford the ethyl ester 110 (Scheme 1.31).51 
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Scheme 1.31: Synthesis of Tamiflu® (111) by Fang et al.51 
1.8 Oxidative Cleavage of cis-1,2-Dihydrocatechols  
It is evident from the examples shown above that halogenated cDHCs serve as valuable 
synthons for accessing natural products that contain six-membered rings bearing the same diol 
stereochemistry or related functionality. However, by engaging the C3-C4 double bond in an 
oxidative cleavage reaction, the synthetic utility of these halogenated metabolites can be 
expanded to the preparation of both acyclic and heterocyclic systems. The ability to access 
linear and open-chain compounds incorporating the intact diol unit from the cDHCs provides a 
vehicle for preparing macrolides. Two syntheses that highlight the potential of such processes, 
are those leading to (+)-aspicilin and (–)-cladospolide A. These are detailed below. 
Banwell’s Synthesis of (+)-Aspicilin [(+)-119] (2000)39 
Banwell et al. reported the synthesis of (+)-aspicilin [(+)-119] (Scheme 1.32) from 
chlorobenzene-derived cDHC 82 (X = Cl) by employing the oxidative cleavage strategy to 
deliver a fragment incorporating the requisite triol with the correct stereochemistry. The 
synthesis began with the protection of the diol functionality of cDHC 82 (X = Cl) with an 
acetonide which was itself converted into the TBS ether 112 in four steps. Cyclohexene 112 was 
oxidatively cleaved with ozone and a reductive workup using NaBH4 gave the unstable 
aldehyde 113. Compound 113 was immediately subjected to a Wittig olefination reaction to 
afford the terminal alkene 114. The acetonide functionality within compound 114 was 
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hydrolysed and the resulting diol re-protected as the bis-silyl ether to give lactol 115.§ 
Compound 115 was coupled to the phosphonate fragment 116 under Horner Wadsworth 
Emmons (HWE) conditions to furnish the RCM precursor 117. Treatment of triene 117 with 
Grubbs’ 1st generation catalyst,52,53 followed by a selective reduction of the newly formed 
alkene then afforded macrolactone 118. Finally, a global deprotection of macrocycle 118 
provided the macrolide (+)-aspicilin [(+)-119]. 
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Scheme 1.32: Banwell’s synthesis of (+)-aspicilin [(+)-119].39 
Banwell’s Synthesis of (–)-Cladospolide A [(–)-126] (2002)31,32 
Following the completion of the synthesis of (+)-aspicilin [(+)-119] by Banwell et al.,39 a 
similar modular strategy was employed to prepare (–)-cladospolide A [(–)-126] (Scheme 1.33) – 
a fungal metabolite that was isolated from various Cladosporium species and found to inhibit 
shoot elongation in rice and lettuce seedlings.31,32 The synthesis commenced with the 
conversion, in two steps, of the chlorobenzene-derived cDHC (X = Cl) 82 into the TBS ether-
protected compound 120. The latter material was subjected to an oxidative cleavage and a 
reductive workup to furnish the unstable aldehyde 121 which was immediately subjected to a 
Wittig olefination reaction to give olefin 122. The methyl ester moiety present in compound 122 
was hydrolysed and the ensuing acid was coupled to (S)-(–)-4-penten-2-ol [(S)-25] under 
 
§ This swapping of protecting groups was required because when the acetonide group was retained the 
planned late-stage macrolide-forming RCM reaction failed. 
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Yamaguchi conditions to afford diene 123. Compound 123 was itself converted into the methyl 
ester 124 over several steps that included a RCM and a HWE reaction with trimethyl 
phosphonoacetate. The free acid derived from the hydrolysis of product 124 was subjected to a 
Yamaguchi macrolactonisation reaction to give the ten-membered macrocycle 125 that was then 
deprotected to provide (–)-cladospolide A [(–)-126]. 
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Scheme 1.33: Banwell’s synthesis of (–)-cladospolide A [(–)-126].31,32 
1.9 Aims of Research Work Described in this Thesis 
The intense interest in the biologically active RALs coupled with the need for quicker and more 
efficient routes to these natural products and their analogues prompted an investigation of the 
capacity of the enantiopure cDHC to serve as starting materials for RAL synthesis. Thus, 
Chapter Two describes the first enantioselective synthesis of the enone-containing RAL L-
783,290 (128) from the chlorobenzene-derived cDHC 82 (X = Cl). A key step in the 
eventually successful synthesis involved a coupling of the cDHC-derived alkene 127 with the 
relevant aromatic bromide to produce a key precursor to target 128 (Scheme 1.34). 
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Scheme 1.34: Synthesis of L-783,290 (128) from cDHC 82 (X = Cl). 
Chapter Three describes an efficient synthesis of the RAL L-783,277 (1) (Scheme 1.35), using 
the advanced intermediate, 129, generated during the course of the work described in Chapter 
Two. In this approach, an unusual intramolecular nucleophilic addition of an acetylide anion 
onto a tethered Weinreb amide was used to generate the macrocycle. 
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Scheme 1.35: Synthesis of L-783,277 (1) from intermediate 129. 
Chapter Four describes efforts directed towards the synthesis of aigialomycin C (131) (Scheme 
1.36). The approach draws upon the modular strategy described in Chapter Two, while 
demonstrating the synthetic usefulness of the C1´-C2´ double bond obtained from the Heck 
reaction between aromatic and diol units. 
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Scheme 1.36: Efforts towards the synthesis of aigialomycin C (131) from cDHC 82 (X = Cl). 
Chapter Five outlines the potential for the extension of the research described in Chapters Two 
to Four to syntheses of other biologically active RALs. 
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2 Chapter Two 
The Total Synthesis of  
L-783,290 (trans-isomer) 
 
 
 
2.1 Introduction 
2.1.1 Isolation and Characterisation 
In 1999 Zhao et al. reported on the bioassay-guided isolation of the enone resorcylide L-
783,290 (128), its cis-isomer, (L-783,277) (1), and hypothemycin (2) (Figure 2.1) from the 
fruiting bodies of the mushroom Helvella acetabulum.1 
OH
MeO
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HO OH
O
O
O
OH
OH
MeO
OHO
OH
MeO
O
O
HO OH
OO
hypothemycin
(2)
L-783,290
(trans-isomer)
(128)
L-783,277
(cis-isomer)
(1)  
Figure 2.1 The structures of L-783,290 (128), L-783,277 (1) and hypothemycin (2) isolated from the 
fruiting bodies of Helvella acetabulum. 
The structures of compounds 128 and 1 were determined using 1H-1H COSY, HMQC and 1H-
13C HMBC NMR techniques.1 
2.1.2 Biological activity 
Both compounds 128 and 1 were found to be competitive inhibitors of the ATP active site of the 
kinase MEK, with L-783,290 (128) (IC50 = 300 nM) exhibiting a weaker inhibitory activity 
than congener 1 (IC50 = 4 nM).1 They also acted as weak and reversible inhibitors of LCK 
kinase.1 The biological activities of compounds 1 and 128 most likely arise from their capacities 
to engage in 1,4–conjugate addition reactions with the thiol moiety of a cysteine residue within 
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the kinase active site. The significant difference in potency between the two compounds is 
believed to be due to the superior Michael acceptor properties of the cis-enone residue within 
compound 1. 
2.2 Retrosynthetic Analysis of L-783,290 (128) 
Given the Banwell group’s successful modular syntheses of various macrolides, including (+)-
aspicilin [(+)-(119)] and certain members of the cladospolide family of natural products,2-6 it 
was anticipated that L-783,290 (128) could be prepared using a similar approach. 
A retrosynthetic analysis of L-783,290 (128) based on such thinking is presented in Scheme 2.1 
and this highlights the use of a ring-closing metathesis (RCM) reaction of diene 132 to establish 
the fourteen-membered macrocyclic ring of this RAL. The substrate 132 required for this 
process would be assembled from three fragments via two crucial reactions, these being, in 
order of execution, a Heck reaction between the olefin 127 and the aryl iodide 133, and a 
Mitsunobu esterification to effect coupling of enantiopure alcohol (R)-25 with the acid derived 
from the oxidation of aldehyde 129.  
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Scheme 2.1: Retrosynthetic analysis of L-783,290 (trans-isomer) (128). 
In this synthesis, the C1´-C2´ alkene residue associated with compound 129 would be reduced 
to the corresponding alkane. In other instances, however, this double bond could be retained in 
order to provide other RALs incorporating functionality at these positions.  
Compound 127 would, in turn, be derived from enantiopure cDHC 82 (X = Cl) in a manner 
similar to that employed by Banwell, McRae and Loong in their syntheses of (+)-aspicilin [(+)-
119] and certain members of the cladospolide family.2-6 The enantiopure alcohol [(R)-25] would 
be prepared using a well-established double enzymatic kinetic resolution of racemate [(±)-25].2,3 
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2.3 Synthesis of the Aromatic Fragment 133  
The synthesis of the title fragment (133) was readily achieved following a protocol originally 
reported by Abe et al. (Scheme 2.2).7 Thus, the amine group within 3,5-dimethoxyaniline (134) 
was converted into the corresponding iodide 135 via a Sandmeyer reaction. This involved 
formation of the diazonium salt followed by its displacement with an iodide anion. As a result, 
the aryl halide 135 was obtained in 71% yield. The EI mass spectrum of this material displayed 
the expected molecular ion at m/z 264 and an accurate mass measurement on this species 
established that it had the anticipated molecular composition, viz C8H9IO2. All the other spectral 
data obtained on this compound were in accord with the assigned structure and matched those 
reported earlier.8 
 
OMe
MeO NH2
OMe
MeO I
Reagents and conditions: (i) conc. H2SO4, H2O, NaNO2, –5 °C, 0.5 h then KI, H2O, –5 °C, 3 h; (ii) POCl3, DMF, 100 °C, 19 h.
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Scheme 2.2: Synthesis of the aromatic fragment 133. 
Regioselective formylation of the aryl iodide 135 was achieved under Vilsmeier-Haack 
conditions, and thus delivered the target aromatic fragment 133 in 63% yield (Scheme 2.2). The 
1H NMR spectrum of compound 133 showed a one-proton singlet at ! 10.14 arising from the 
newly introduced aldehyde proton, while the corresponding EI mass spectrum revealed a 
molecular ion at m/z 292 and an accurate mass measurement on this species established that it 
was of the expected molecular composition, viz C8H9IO3.  
2.4 Synthesis of the (Protected) Diol Fragment 127 
With the synthesis of the aromatic unit 133 complete, attention was directed towards the 
synthesis of the protected diol unit 127 (Scheme 2.3) from the chlorobenzene-derived cDHC 82 
(X = Cl). This was accomplished using protocols established earlier.2-6,9,10 Thus, the synthesis 
commenced with a regioselective reduction of the less sterically hindered and more electron rich 
double bond in cDHC 82 (X = Cl) using dihydrogen in the presence of catalytic amounts of 
rhodium on alumina (Scheme 2.3).10 By such means, cyclohexene 136 was obtained in 64% 
yield. Small amounts (10 – 15%) of the corresponding fully saturated congener of compound 
136 were also obtained but these were readily removed by column chromatography. All the 
spectral data obtained on compound 136 were completely in accord with the assigned structure 
and consistent with these reported earlier.10 Diol 136 was then protected, under standard 
conditions,11 as the corresponding acetonide 137. 
The Total Synthesis of L-783,290 (trans-isomer) 
45 
 
X
OH
OH
Cl
OH
OH
OMe
OO O
HO
Reagents and conditions: (i) H2, 5% Rh on Al2O3, EtOH, 18 °C, 1 h; (ii) 2,2-dimethoxypropane, p-TSA, 0 ! 18 °C, 19 
h; (iii) (a) O3, MeOH, pyridine, –78 °C, 0.3 h; (b) Me2S, –78 ! 0 °C, 2 h; (iv) NaBH4, 0 °C, 1 h.
i
iii
Cl
O
Oii
OMe
OO O
O
iv
H
137136
138139
82
(X = Cl)
64% 97%
76%
from 137
 
Scheme 2.3: Synthesis of the primary alcohol 139, via oxidative cleavage of 137. 
With the cyclohexene 137 in hand, ozonolytic cleavage of the associated alkene residue was 
undertaken (Scheme 2.3). Once again, protocols established earlier were employed for this 
purpose.2-6,10 Thus, a methanolic solution of cyclohexene 137 maintained at –78 °C was 
subjected to a stream of ozone. Reductive workup with dimethylsulfide and sodium borohydride 
then afforded, presumably via the intermediate aldehyde 138, the primary alcohol 139 in 76% 
yield. Monitoring of reaction temperature and time were crucial, especially during the reductive 
workup step, to ensure maximum yields of product.12,13 While it has been shown that prolonged 
exposure of peroxidic intermediates to sodium borohydride furnishes primary alcohols,14,15 
when a direct reduction of the product(s) of the ozonolysis of alkene 137 with sodium 
borohydride was attempted, the yield of 139 obtained was lower (40 – 50%) than when a 
combination of dimethylsulfide and sodium borohydride was employed. The IR spectrum of 
compound 139 exhibited a broad OH absorption band at 3452 cm-1 while examination of the 
corresponding 1H NMR spectrum revealed the two oxymethine protons resonating as a doublet 
(at ! 4.60) and a doublet of triplets (at ! 4.36). A three-proton singlet, due to the three protons 
on the methyl ester group, appeared at ! 3.75. The 13C NMR spectrum of compound 139 
displayed the expected ten carbon resonances with the most downfield signal, at ! 171.0, being 
assigned to the ester-carbonyl carbon and the signal due to the carbon of the primary alcohol 
appearing at ! 62.2. 
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Following a procedure reported by Williams et al,16 the methyl ester 139 was converted into the 
corresponding Weinreb amide 140 (89% yield) using N,O-dimethylhydroxylamine 
hydrochloride and iso-propylmagnesium chloride (Scheme 2.4). The 1H NMR spectrum of 
amide 140 displayed two, three-proton, singlets at ! 3.14 and 3.66, corresponding to the protons 
of the N-methyl and N-methoxy groups, respectively. The ESI mass spectrum of the amide 140 
exhibited ions at m/z 248 and 270 that are associated with its protonated and sodiated 
derivatives, respectively. 
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Scheme 2.4: Synthesis of Weinreb amide 140 from methyl ester 139. 
It was anticipated that the dehydration of the primary alcohol 140 could be accomplished via 
tosylation of the alcohol followed by its elimination. Accordingly, alcohol 140 was converted 
into the tosylate 141 (80% yield) using p-toluenesulfonyl chloride and n-triethylamine (Scheme 
2.5). Unfortunately, exposure of tosylate 141 to DBU failed to effect the desired elimination and 
thereby generate target alkene 127. Only decomposition of the starting material was observed 
under these conditions. 
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Scheme 2.5: First attempt at dehydrating primary alcohol 140. 
As a result, an alternate method for dehydration of the primary alcohol 140 was sought. To such 
ends, and with a view to employing protocols first established by Grieco et al.,17 the primary 
alcohol 140 was smoothly converted into the selenide 142 using o-nitrophenyl selenocyanate 
and n-butyl phosphine (Scheme 2.6). The spectral data obtained on selenide 142, which was 
obtained in 89% yield, were in complete accord with the assigned structure. 
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Scheme 2.6: Synthesis of the protected diol fragment 127 via, a Grieco elimination of primary alcohol 
140. 
Oxidation of the selenide 142 with m-CPBA proceeded efficiently to give a labile selenoxide 
that underwent smooth elimination on treatment with diethylamine to deliver the desired 
crystalline alkene 127 in 93% yield. The 1H NMR spectrum of this compound (Figure 2.2) not 
only lacked the aromatic resonances that were associated with the precursor selenide, 142, but 
also displayed a doublet of doublet of triplets at ! 5.81 and a complex multiplet at ! 5.08 that 
correspond to the protons of the newly installed olefinic residue. A single-crystal X-ray analysis 
of this material was undertaken and the derived ORTEP is shown in Figure 2.3. 
 
 
Figure 2.2: 300 MHz 1H NMR spectrum of diol unit 127 (recorded in CDCl3). 
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Figure 2.3: Ball and stick model of the protected diol fragment 127 generated using the data derived 
from a single-crystal X-ray analysis. 
2.5 Synthesis of the Alcohol Fragment [(R)-25] 
With the aromatic 133 and protected diol 127 fragments in hand, the remaining fragment 
required for the synthesis of target L-783,290 (128) was the enantiopure homoallylic alcohol 
(R)-(–)-4-penten-2-ol [(R)-25]. A common method for preparing this known alcohol involves 
the nucleophilic epoxide ring-opening of R-propylene oxide [(R)-27] with vinyl lithium, vinyl 
cuprate or a Grignard reagent.18-20 The required R-propylene oxide [(R)-27] can, in turn, be 
obtained by a hydrokinetic resolution of racemic propylene oxide [(±)-27] using the (S,S)-form 
of Jacobsen’s catalyst.18-20 Another method for generating alcohol (R)-25 involves the 
enzymatic kinetic resolution of the corresponding racemate, viz. (±)-4-penten-2-ol [(±)-25].2,3 In 
particular, it was discovered, through an extensive study conducted by Banwell and Loong, that 
Candida antarctica Lipase B (CALB) could also be used to generate the desired alcohol (R)-25 
in > 99% ee through a double kinetic resolution sequence.2,3 
Although both of the abovementioned methods could yield the desired alcohol (R)-25 with 
exceptional ee’s, the double kinetic resolution protocol was considered more attractive because 
it follows a major theme being pursued in the Banwell Group, namely the use of enzymes in 
synthesis. Accordingly, the racemic alcohol (±)-25 was treated with CALB in vinyl acetate 
(Scheme 2.7) which served as both a reaction medium and an acyl donor, to furnish a mixture of 
enantio-enriched acetate (R)-143 and unreacted alcohol (S)-25 (not isolated). The two 
compounds were readily separated by flash chromatography. 
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Scheme 2.7: Synthesis of enantiopure secondary alcohol (R)-25.2,3 
The acetate (R)-143 was then hydrolysed using CALB, which resulted in the recovery of 
alcohol (R)-25 in 28% yield [from the racemic alcohol (±)-25] and > 99% ee (as determined by 
chiral GC analysis of the derived acetate). The modest recovery of the alcohol (R)-25 was 
attributed to its high volatility (b.p. 115 °C) and water solubility. Nevertheless, this procedure 
could be carried out on a multi-gram scale with no reduction in ee. 
2.6 Assembly of Macrocycle Through the Union of Fragments 127, 133 and (R)-
25 
2.6.1 The Heck Reaction 
With all fragments synthesised, the stage was set for the assembly of the target macrolactone 
from them. The first fragment coupling to be undertaken was that between the aryl iodide 133 
and alkene 127. Before describing the Heck coupling of fragments 127 and 133 a general 
discussion of the utility of this reaction and its mechanism (Figure 2.4) are presented. It is 
appropriate to do so because the conversion of fragment 127 and 133 into product 129 is a 
pivotal aspect of the synthetic plan leading to the target RAL. 
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The catalytic variant of the Heck reaction involves the initial oxidative insertion of palladium(0) 
(146) into the carbon-halogen bond of aryl iodide 133 to afford the Pd(II) complex 147. This 
complex then co-ordinates with the target alkene 127 to give the &-palladium(II) complex 148 
which, in turn, engages in a syn-addition reaction with the double bond to provide '-
palladium(II) complex 149. Compound 149 itself undergoes a %-hydride elimination reaction to 
give complex 150 that immediately collapses to give the “Heck product 129” and 
hydridopalladium(II) halide  151. The final step of the catalytic cycle involves the regeneration 
of the catalytically active palladium(0) species (146) from compound 151 via a reductive 
elimination process effected by the added base.  
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Figure 2.4: The catalytic cycle associated with the Heck reaction.  
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The Heck reaction is powerful and versatile in that it links an alkene with an aryl halide in a C–
C bond-forming process. Today, this reaction is extensively employed in both laboratory scale 
syntheses as well as on the tonne scale in industry.21,22 Since Heck’s seminal work on the 
coupling of stoichiometric amounts of organopalladium halide with various alkenes,23 the 
reaction has matured to become a catalytic process that provides a powerful tool for creating 
pivotal C–C bonds including those embodied in complex ring systems. An example of the Heck 
reaction being applied in a complex natural product synthesis is seen in Danishefsky and co-
worker’s elegant construction of the B-ring of Taxol™ via the conversion of compound 144 
into the pentacyclic derivative 145 as shown in Scheme 2.8.24 
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Scheme 2.8: Construction of the B-ring of Taxol via a Heck-mediated ring closure.24 
2.6.2 Investigation of Conditions for the Heck Cross-coupling Between the Aromatic 133 
and Protected Diol 127 Units 
While various palladium-catalysed cross-coupling reactions, especially the Suzuki-Miyaura and 
Sonogashira processes, have been used in several syntheses of RALs, the Heck reaction has not. 
Nevertheless, it was confidently anticipated that the aryl iodide 133 and the alkene moiety 
within compound 127 could be coupled by such means so as to deliver product 129. However, 
the coupling of these two fragments was considered likely to be challenging since each contains 
functionalities that might degrade the catalyst or interfere with its activity. As a result, a 
comprehensive examination of the various conditions used for effecting Heck reactions was 
undertaken and the outcomes of these are presented in Table 2.1. All reactions were conducted 
for 19 hours since after this time yields of target 129 were observed to decline. 
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As a result of the studies summarised in Table 2.1, it became clear that very specific conditions 
were required in order to ensure a useful outcome. Thus, the optimum conditions established for 
effecting the Heck reaction between the aryl halide 133 and alkene 127 involved using 20 mol% 
palladium(II) acetate, tetra-n-butylammonium bromide (TBAB) as additive, potassium 
carbonate as base and 10:1 v/v DMF/water as solvent. Although the yield for the Heck reaction 
was, even after much optimisation, a moderate 50 – 65%, these conditions provided a 
reproducible outcome and reliably delivered compound 129. The 1H NMR spectrum of this 
material established that it was composed of a ca. 9:1 mixture of E- and Z- isomers. The E-
configured alkene could be obtained in pure form after flash chromatography with the spectrum 
of this material (Figure 2.5) showing two mutually-coupled proton resonances at ! 7.41 and 
6.20. The magnitude of this coupling (J = 16.0 Hz) suggested a trans-relationship between them 
and, therefore, an E-configuration about the associated double bond. A molecular associated ion 
observed at m/z 416 in the ESI mass spectrum corresponded to the sodiated derivative of 
compound 129 and an accurate mass measurement on this species established it was of the 
expected composition, viz C20H27NNaO7.  
 
Figure 2.5: 300 MHz 1H NMR spectrum of compound 129 (recorded in CDCl3). 
2.6.3 Union of the Final Fragment: Formation of the Diastereomerically Pure Ester 154 
With compound 129 in hand, attention could be focused on its elaboration to diene 132, the 
substrate required for the pivotal macrolide-forming RCM reaction. To such ends, benzaldehyde 
129 was oxidised, under Pinnick conditions (Scheme 2.9),25 to the corresponding acid 152 
which was obtained in 75% yield. The absence of a one-proton singlet at ! 10.45 in the 1H 
NMR spectrum of compound 152 and the presence of an ion at m/z 408 in the negative ESI 
mass spectrum (corresponding to its conjugate base) clearly indicated that the desired oxidation 
reaction had taken place.  
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The C1´-C2´ alkene residue associated with compound 152 was reduced by hydrogenation in 
the presence of catalytic amounts of palladium on charcoal (Scheme 2.9) to give the 
corresponding alkane 153 in 97% yield. The absence of the olefinic resonances in the 1H NMR 
spectrum of this product and the lack of a C=C absorption band (as seen at 1578 cm-1 in the 
analogous spectrum of the precursor) in its IR spectrum clearly suggests that the desired alkane 
had been formed.  
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Reagents and conditions: (i) 2-methyl-2-butene, NaH2PO4•2H2O, NaClO2, t-BuOH, H2O, 18 °C, 1 h; (ii) H2 (50 psi),
10% Pd on carbon, EtOH, 18 °C, 24 h; (ii) (R)-25, DIAD, PPh3, PhMe, 0 ! 18 oC, 0.5 h.
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Scheme 2.9: Synthesis of ester 154. 
The alcohol (R)-25 was coupled to the acid 153 via a Mitsunobu esterification reaction (Scheme 
2.9) to give the desired ester 154 (90% yield) possessing the illustrated S-configuration at C10´ 
as a result of the expected inversion process. The 1H NMR spectrum of ester 154 featured a two-
proton multiplet at ! 5.10 and a one-proton multiplet at ! 5.82, which are attributed to the 
hydrogens attached to the terminal alkene residue of the homoallylic ester. The resonance 
appearing at ! 167.8 in the 13C NMR spectrum is assigned to the carbonyl carbon of the newly 
introduced ester moiety. In addition, the ions appearing at m/z 480 and 502 in the ESI spectrum 
of compound 154 are assigned to the protonated and sodiated molecular ions, respectively. 
Accurate mass measurements on these species established their molecular formulae as 
C25H38NO8 and C25H37NNaO8, respectively. 
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2.6.4 Completion of Synthesis using a RCM Protocol 
With all three fragments assembled into compound 154, attention was now focused on closing 
the macrocycle using RCM techniques. To that end, diene 132 was required and the preparation 
of this involved converting Weinreb amide 154 into the vinyl ketone 132 (Scheme 2.10). 
However, initial attempts to do so resulted in low yields, an outcome attributed to the conjugate 
addition of the displaced N,O-dimethylhydroxylamine to the initially formed product 132 and so 
generating compound 155. The formation of similar by-products by analogous processes has 
been reported previously.26-29 Support for the structure of compound 155 came from the 
observation of two three-proton singlets at ! 3.48 and 2.57 in the 1H NMR spectrum of this 
material. These are assigned to the N-methyl and N-methoxy groups, respectively, of the 
nitrogen centred residue incorporated in this by-product. The ESI mass spectrum of this material 
displayed a molecular associated ion at m/z 530 (M+Na+)+. 
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Scheme 2.10: Synthesis of macrolide 156 via RCM of precursor 132. 
Through careful monitoring of reaction time as well as by quenching the reaction mixture with 
5:1 v/v acetic acid/water, the vinyl ketone 132 was obtained with minimal concomitant 
formation of by-product 155. Since the possibility of conjugate addition by adventitious 
nucleophiles to the vinyl ketone 132 was a serious concern, the manipulation of this sensitive 
material was kept to a minimum. Accordingly, once obtained diene 132 was immediately 
subjected to a RCM reaction with Grubbs’ 2nd generation catalyst30 (Scheme 2.10) to give the 
E-configured enone 156 in 48% yield from Weinreb amide 154. Evidence for the exclusive 
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generation of the E-configured enone came from the presence of a mutual coupling between the 
olefinic protons in the 1H NMR spectrum (Figure 2.6), at ! 6.96 (ddd, J = 15.8, 12.8 and 6.8 Hz) 
and ! 6.64 (d, J = 15.8 Hz), which is indicative of the assigned configuration. Confirmation of 
the presence of the ",!-unsaturated ketone moiety followed from the appearance of a resonance 
at ! 197.4 in the 13C NMR spectrum, which is assigned to the carbonyl carbon of the enone 
moiety. Absorption bands observed at 1627 and 1604 cm-1 in the IR spectrum are assigned to 
C=C and C=O stretching bands. The ESI mass spectrum revealed molecular associated ions at 
m/z 419 and 441 and accurate mass measurements on these established that they were of the 
expected compositions, viz C23H31O7 and C23H30 NaO7, respectively. 
 
 
Figure 2.6: 500 MHz 1H NMR spectrum of macrolactone 156 (recorded in CDCl3). 
The acquisition of macrolactone 156 provided the protected form of target L-783,290 (128) so 
attention was focused on the final deprotection step so as to provide the natural product 128 
itself. In the event, careful treatment of macrolactone 156 with BCl3 (Scheme 2.11) led to the 
selective cleavage of the methyl ether adjacent to the carbonyl group of the macrolactone ring to 
reveal the C2 phenol. Upon quenching the reaction mixture with water, HCl was generated and 
this effected cleavage of the acetonide residue to afford the natural product, L-783,290 (128), as 
an off-white powder in 60% yield. 
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Scheme 2.11: Deprotection to give L-783,290 (128). 
The 800 MHz 1H NMR spectrum of product 128 (Figure 2.7) displayed a one-proton singlet at ! 
11.83 which is attributed to an intramolecularly hydrogen-bonded (to the adjacent lactone C=O) 
phenolic proton and lacked two three-proton singlets associated with the two methyl groups on 
the acetonide of the precursor. The remaining resonances in the spectrum were in complete 
accord with the assigned structure. The 13C NMR spectrum of this material (Figure 2.8) 
displayed the expected nineteen resonances, with the most downfield signal, at ! 197.0, being 
assigned to the enone-carbonyl carbon. The EI mass spectrum displayed an ion at m/z 364 and 
an accurate mass measurement of this species established the composition C19H24O7. All in all, 
the spectral data collected on this material were entirely consistent with the assigned structure, 
however final confirmation of this was secured through a single-crystal X-ray analysis. The 
derived ORTEP plot is shown in Figure 2.9 while further details of this analysis are presented in 
the Experimental Section. 
 
Figure 2.7: 800 MHz 1H NMR spectrum of L-783,290 (128) (recorded in CD2Cl2). 
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Figure 2.8: 200 MHz 13C NMR spectrum of L-783,290 (128) (recorded in CD2Cl2). 
 
Figure 2.9: Ball and stick model of L-783,290 (128) generated using the data derived from a single-
crystal X-ray analysis. 
Unfortunately, no spectral data derived from the natural product have been published that would 
allow for comparison with the synthetic product obtained as described above. Efforts to secure 
these data through email correspondence with the investigators at Merck have been 
unsuccessful. As a result, relevant comparisons between spectral data for the synthetic L-
783,290 (128) and the natural product were not possible. 
2.7 Conclusion 
In the work detailed above, the RAL L-783,290 (128) has been synthesised in 16 steps from the 
biocatalytically-derived starting material cDHC 82 (X = Cl). Two of the stereocentres in L-
783,290 (128) were derived from the cDHC 82 while the final one originated from alcohol (R)-
O
HO
OH
OH
MeO
O
O
L-783,290
(128)
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25 which was itself established using enzymatic resolution techniques. Target 128 was 
assembled in a modular and completely diastereoselective fashion.  
A study of the Heck reaction between the aromatic 133 and the protected diol 127 units was 
undertaken and the coupled product derived from this contained a double bond that was 
removed in the latter stages of the synthesis. The option to retain the C1´-C2´ alkene derived 
from the Heck reaction offers the potential to synthesise natural products that contain this or 
related functionality at the homo-benzylic position such as is seen in aigialomycin C (131). 
Work directed towards these latter targets is now under way in the Banwell laboratories. 
Biological testing of the synthetic sample of L-783,290 (128) will be carried out in the near 
future. 
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3 Chapter Three 
The Total Synthesis of  
L-783,277 (cis-isomer) 
 
 
 
3.1 Introduction 
Three syntheses of L-783,277 (1) (Figure 3.1) have been reported thus far, with two of these 
surfacing during the course of the work described in this chapter. The first was reported by 
Altmann et al. in 2008 and this was followed by Winssinger’s in 2009.1,2 The final synthesis 
was published in 2010 by Sim et al.3 and essentially at the same time as the one detailed here 
appeared in print.4 A comparison of these three syntheses together with the one reported here is 
presented at the end of this chapter.  
After completing an enantioselective synthesis of L-783,290 (128) using the microbially-
derived chlorobenzene building block cDHC 82 (X = Cl), it was anticipated, based on earlier 
work in the group, that a synthesis of compound L-783,277 [(1), the cis-isomer of L-783,290 
(128)] could be achieved directly from the trans-isomer 128 through a late-stage 
photoisomerisation reaction. Details associated with this approach are discussed in the 
following section.  
OH
MeO
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HO OH
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OH
MeO
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L-783,290
(trans-isomer)
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L-783,277
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Figure 3.1: Structures of L-783,277 (1), L-783,290 (128) and cDHC 82 (X = Cl). 
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3.2 Attempted Synthesis of L-783,277 (1) From L-783,290 (128) via 
Photoisomerisation 
3.2.1 Related trans-cis Photoisomerisation Processes 
In 2005 Banwell and Loong reported the photoisomerisation reaction of the E-configured 
$,%-unsaturated macrolactone 157 to its Z-configured isomer (–)-158 and thereby completing a 
total synthesis of (–)-cladospolide B [(–)-158] (Scheme 3.1).5 
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Scheme 3.1: Banwell and Loong's synthesis of (–)-cladospolide B [(–)-158] via photoisomerisation 
reaction of compound 157.5 
This conversion involved irradiating a benzene solution of compound 157 at 300 nm (Scheme 
3.1) and by such means (–)-cladospolide B [(–)-158] was obtained, albeit in just 31% yield (at 
43% conversion).5 
In related work, Murphy et al. were able to effect the photoisomerisation of the E-configured 
enone 159 to its Z-isomers 160 (30%) and 161 (20%) by irradiation of the former compound 
with 350 nm wavelength light (Scheme 3.2).6 
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Scheme 3.2: Photochemically-promoted conversion of diene 159 to isomers 160 and 161 reported by 
Murphy et al.6  
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Similarly, the dihydro-analogue of 159, namely enone 162, was efficiently converted into its Z-
isomer 163 (97% at 83% conversion) under the same conditions (Scheme 3.3).6 
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Scheme 3.3: Photoisomerisation reaction of RAL 162 to 163 reported by Murphy et al.6 
3.2.2 Attempted Photoisomerisation Reaction of L-783,290 (128) to L-783,277 (1) 
On the basis of the work described above, a benzene solution of the trans-compound 128 was 
irradiated at 300 nm (Scheme 3.4). However, after 3 hours of irradiation only decomposition of 
the starting material was observed. Unfortunately, the conditions reported by Murphy et al. for 
affecting the photoisomerisation reaction of compound 162 into congener 163 (Scheme 3.3) 
could not be applied to substrate 128 due to a lack of additional material. 
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Scheme 3.4: Attempt to photoisomerise L-783,290 (128) to L-783,277 (1). 
3.3 Revised Retrosynthetic Analysis of L-783,277 (1) 
Given the difficulties encountered during attempts to prepare L-783,277 (1) from the 
corresponding trans-isomer (128) through a photoisomerisation reaction, a new approach was 
pursued. In particular, it was anticipated that the Z-configured enone in L-783,277 (1) could be 
prepared through a Lindlar reduction (Scheme 3.5) of the corresponding propargylic ketone 
164. The synthesis of such an alkyne was thought achievable through an intramolecular 
nucleophilic addition of an acetylide anion onto the tethered Weinreb amide such as 
encountered in compound 165. A review of the relevant literature clearly established that this 
ring-forming process has not been exploited in any previous RAL syntheses and it was believed 
that the incorporation of the alkyne functionality into the target macrocycle by this means was 
realistic due to the length of the tether linking the two reaching centres (and which should, 
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therefore, allow the required reaction trajectory to the adopted with relative ease). The substrate 
required for the formation of the alkyne-containing macrocycle would come from a Mitsunobu 
esterification of the relevant-enantiopure homo-propargylic alcohol, viz (R)-(–)-4-pentyn-2-ol 
[(R)-166], with the benzoic acid 153 obtained during the course of the work described in 
Chapter Two. The alcohol (R)-166 should be accessible through a double kinetic enzymatic 
resolution of the corresponding racemate (±)-166 using protocols analogous to those described 
in Chapter Two for the preparation of compound (R)-25. 
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Scheme 3.5: Retrosynthetic analysis of L-783,277 (1). 
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3.4 Synthesis of Enantiopure Propargylic Alcohol [(R)-166] via the Lipase–
catalysed Resolution of Racemate (±)-166 
With the required benzoic acid 153 available through the protocols described in Chapter Two, 
the early stages of efforts associated with implementing the plan defined in Scheme 3.5 focused 
on preparing the chiral alcohol (R)-166. Like its congener (R)-(–)-4-penten-2-ol [(R)-25], 
compound (R)-166 could be generated by either chemical or enzymatic means. A previous 
chemical synthesis of this fragment [(R)-166] involved the nucleophilic epoxide ring-opening of 
(R)-propylene oxide [(R)-27] with lithium acetylide,1,7 while a second approach involved an 
enzymatic kinetic resolution of the racemate (±)-166. The first reported enzymatic resolution of 
alcohol (R)-166 was undertaken by Takano et al., who achieved a 91.2% ee by using a double 
kinetic resolution protocol (with the lipase Amano PS) similar to that described in Chapter 
Two.8 It was anticipated that the ee associated with the enzymatic resolution of alcohol (±)-166 
to give the R-enantiomer could be improved by drawing directly upon the protocols described in 
Chapter 2. Accordingly, racemic 4-pentyn-2-ol [(±)-166] was exposed to CALB using vinyl 
acetate as both solvent and acyl donor (Scheme 3.6) to afford a chromatographically separable 
mixture of unreacted S-configured alcohol (S)-166 (not isolated) and the corresponding acetate 
now enriched with the R-enantiomer. By such means, the acetate (R)-167 was obtained in 40% 
yield and 89% ee (as determined by chiral GC analysis).  
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Scheme 3.6: Synthesis of (R)-(–)-4-pentyn-2-ol [(R)-166)]. 
The second stage of the resolution process involved the hydrolysis of the acetate (R)-167 with 
CALB in phosphate buffer (Scheme 3.6) to afford the target alcohol (R)-166 (60% yield) with 
an ee of 98.9% (as determined by chiral GC of the acetate derivative). The optical rotation 
recorded for this sample of (R)-166 was found to be levorotary {["]D = – 16.3 (c 0.46, CHCl3)} 
which matched that reported for the compound prepared by Dimitriadis et al. {["]D = – 17.7 (c 
0.13, CHCl3)}.9  
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The successful resolution of (R)-(–)-4-penten-2-ol [(R)-25] (Section 2.5) and its dehydro-
analogue (R)-(–)-4-pentyn-2-ol [(R)-166] as described here highlights the utility of the CALB-
based method for resolving racemic mixtures of various secondary alcohols.  
3.5 Synthesis of Substrate for the Formation of Macrocycle 164 
With the homopropargyl alcohol (R)-166 successfully obtained in high ee, it was coupled to 
acid 153 under the same (Mitsunobu) conditions used in preparing ester 154 (Scheme 2.9). By 
such means ester 165 was obtained in 70% yield (Scheme 3.7). 
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Scheme 3.7: Synthesis of substrate 165 for the formation of macrocycle 164. 
The 13C NMR spectrum of compound 165 (Figure 3.2) displayed a resonance at ! 167.5 which 
is assigned to the newly introduced ester functionality. The 1H NMR spectrum obtained on 
compound 165 was in full agreement with the assigned structure. The ESI mass spectrum 
revealed two molecular associated ions at m/z 478 and 500 that corresponded to the protonated 
and sodiated derivatives of compound 165, respectively. Accurate mass measurements on these 
species established that they were of the expected composition, viz C25H36O8 and C25H35NaO8, 
respectively. 
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Figure 3.2: 75 MHz 13C NMR spectrum of compound 165 (recorded in CDCl3). 
3.6 Macrocyclisation of Compound 165  
With the macrocyclisation substrate 165 in hand, the stage was set for the key intramolecular 
acetylide anion addition onto the tethered Weinreb amide and thereby generating the 
macrolactone ring incorporating a propargylic ketone. Success was achieved when a pre-cooled 
(–35 °C) and dilute solution of excess lithium hexamethyldisilazide (LiHMDS) was treated, 
dropwise, with a dilute solution of the terminal alkyne 165 (Scheme 3.8). By such means, the 
crystalline propargylic ketone 164 was obtained in 45% yield. 
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Scheme 3.8: Macrocyclisation of substrate 165 using an intramolecular acetylide anion addition. 
The 1H NMR spectrum of compound 164 lacked any resonances due to a terminal alkyne proton 
(as seen at ! 2.04 in precursor 165) or the N(Me)OMe residue associated with the Weinreb 
amide. The 13C NMR of this material (Figure 3.3) displayed the expected 23 carbon resonances, 
with the most downfield signal at ! 184.7 being assigned to the ynone-carbonyl carbon. The ESI 
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mass spectrum of product 164 displayed the protonated and sodiated associated molecular ions 
at m/z 417 and 439, respectively, and accurate mass measurements on these established that they 
were of the expected composition, viz C23H29O7 and C23H28NaO7. The IR spectrum of 
compound 164 displayed a weak C#C stretching band at 2215 cm-1. While all of the data were 
completely consistent with the assigned structure final confirmation of this followed from a 
single-crystal X-ray analysis. The derived ORTEP is shown in Figure 3.4 while further details 
are presented in the Experimental Section.  
 
Figure 3.3: 75 MHz 13C NMR spectrum of macrolide 164 (recorded in CDCl3). 
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Figure 3.4: Ball and stick model of macrolactone 164 generated from the data derived from a single-
crystal X-ray analysis. 
3.7 Completion of the Synthesis of L-783,277 (1) 
With the macrocycle 164 in hand, completion of a synthesis of L-783,277 (1) could be pursued. 
The conversion of compound 164 into target 1 necessarily involves the stereoselective (Lindlar) 
reduction of the alkyne 164 (Scheme 3.9) to the Z-configured enone, cleavage of the C2 methyl 
ether and accompanying hydrolysis of the acetonide group. Clearly there are two distinct ways 
in which these transformations could be carried out. The first involves the (Lindlar) reduction of 
macrocycle 164 followed by a BCl3 deprotection step (and hydrolysis of the acetonide residue 
by the HCl generated on quenching the reaction mixture with water). The alternate sequence 
would involve carrying out the ether and acetonide cleavage processes prior to the Lindlar 
reduction. Both approaches were examined and the outcomes of these are detailed below.  
Chapter Three 
74 
 
OMe
MeO
O
O
O
O O
OH
MeO
O
O
O
HO OH
OMe
MeO
O
O
O
O
O
OH
MeO
O
O
HO
OH
O
L-783,277
(1)
i
i
ii ii
pathway A
pathway B
i. global deprotection with BCl3; ii. Lindlar reduction
164 166
167
2
 
Scheme 3.9: The two possible end game sequences for completing the synthesis of L-783,277 (1). 
3.7.1 First Approach to the Completion of the Synthesis of L-783,277 (1) 
In the first study undertaken to complete the synthesis of the target L-783,277 (1), macrocycle 
164 was treated with BCl3 (Scheme 3.10) and thus affording compound 166 which proved to be 
unstable to flash chromatography. 
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Scheme 3.10: Deprotection of macrolactone 164 with BCl3. 
As a consequence, it was immediately subjected to the Lindlar reduction using dihydrogen in 
the presence of catalytic quantities of palladium on calcium carbonate poisoned by lead and 
pyridine (Scheme 3.11). A mixture of products was thus obtained. The ESI mass spectrum of 
the crude reaction mixture displayed two distinct molecular associated ions m/z 387 and 389. 
The first was attributed to the sodiated derivative of the expected enone (E/Z ratio not 
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determined) while the second is presumed to be due to the sodiated derivative of the “over-
reduced” macrocycle 168.  
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Scheme 3.11: Lindlar reduction of compound 166. 
Since these products could not be separated from one another by conventional chromatography, 
the reaction mixture was subjected to reverse phase HPLC. Two of the three compounds had 
very similar retention times (tR = 38.0 and 38.5 min) with the less mobile of the two being 
identified as the over-reduced macrocycle 168 and the more mobile being L-783,277 (1). The 
remaining compound was the trans-isomer 128, the identity of which was confirmed by 
comparison with the authentic sample prepared by the route described in Chapter Two.  
The confirmation of the structure of macrolide 168 followed from its comparison with an 
authentic sample which was produced (in 60% yield) using the protocol shown in Scheme 3.11, 
involving a prolonged Lindlar reduction (13 hours). The 1H NMR spectrum of this material 
lacked any olefinic resonances due to the protons associated with an enone moiety. When a 
sample of compound 168 was subjected to HPLC analysis, its retention time matched that of the 
less mobile product (38.5 min) derived from the initial reduction mixture [Scheme 3.11 – i(a)], 
and so confirming its identity as the over-reduced macrocycle. Despite exhaustive 
investigations, it proved impossible to prevent the over-reduction of target 1 to its dihydro-
congener 168.  
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3.7.2 Second and Successful Approach to L-783,277 (1) 
Given the inability to access a pure sample of L-783,277 (1) by the means outlined above, 
pathway B shown in Scheme 3.9 was pursued in an effort to achieve such ends. Accordingly, 
compound 164 was subjected to the Lindlar reduction with dihydrogen in the presence of 
catalytic quantities of palladium on calcium carbonate poisoned by lead and pyridine (Scheme 
3.12) to furnish the cis-configured enone 167.  
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Scheme 3.12: Completion of a synthesis of L-783,277 (1) from ynone (164). 
Without purification, the crude product obtained from this reaction was treated carefully with 
BCl3 then subjected to an aqueous work-up. By such means, a 5:1 mixture of compounds 1 and 
128 was obtained. The mixture was subjected to semi-preparative reverse phase HPLC and thus 
affording compounds 1 and 128 in pure form and 60% and 12% yield, respectively. 
The 1H NMR spectral data obtained on synthetic L-783,277 (1) (Figure 3.5) were in full accord 
with those reported for the natural product by the researchers at Merck.10 Furthermore, the 
resonances for each carbon of the synthetic sample observed in the corresponding 13C NMR 
spectrum (Figure 3.6) compared favourably with those reported for the natural product, with the 
exception of the carbon bearing the phenolic group. This discrepancy can be attributed to the 
differences in concentration, solvent and pH. The ESI mass spectrum of compound 1 revealed a 
molecular associated ion at m/z 387 which is attributed to the sodiated form of the target 
compound. An accurate mass measurement on this species established it was of the expected 
composition, viz C13H24NaO7.  
The Total Synthesis of L-783,277 (cis-isomer) 
77 
 
Figure 3.5: 800 MHz 1H NMR spectrum of synthetically-derived L-783,277 (1) (recorded in CD2Cl2). 
 
Figure 3.6: 200 MHz 13C NMR spectrum of synthetically-derived L-783,277 (1) (recorded in CD2Cl2). 
3.7.3 Comparison of Data Sets Derived from Various Samples of L-783,277 (1) 
With the 1H and 13C NMR spectral data of synthetic L-783,277 (1) in hand through the work 
detailed above, a comparison between these and these reported previously was undertaken.1,2,3,4 
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Such comparison were complicated by the differing solvents used in recording the NMR 
spectrum of the various samples of L-783,277 (1) (Table 3.1). 
 1H NMR spectral solvent 13C NMR spectral solvent 
Natural product10 CD2Cl2 CD2Cl2 
Altmann group1 d6 DMSO d6 DMSO 
Winssinger group2 CDCl3 Not Reported 
Sim group3 CD2Cl2 and CDCl3 CDCl3 
Banwell group4 CD2Cl2 CD2Cl2 
Table 3.1: The different NMR solvents used to analyse L-783,277 (1). 
Comparison of the 13C NMR Spectral Data 
A comparison of the relevant sets of 13C NMR spectra data is shown in Figure 3.7 (Author’s 
synthesis in blue and Sim’s synthesis in red). At first glance, the carbon resonances associated 
with Sim’s synthetic sample consistently deviates from the baseline by ca. 0.3 ppm. This is 
attributed to the sample being analysed in CDCl3 as rather than CD2Cl2.  
 
Figure 3.7: Comparison of the 13C NMR spectral data derived from various samples of compound 1. 
Nevertheless, even making allowance for this, there are “worrying” carbon chemical shift 
differences associated with Sim’s sample of RAL 1. In particular, the chemical shift attributed 
to the C10´ (adjacent to the macrolactone functionality bearing the methyl group), differs 
OH
MeO
O
O
HO
OH
O
L-783,277
(1)
2 10'
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significantly which suggests that Sim’s assignment of the S-stereochemistry at C10´ may be 
incorrect. An inversion in the C10´ stereochemistry would also explain the difference in the 
observed optical rotation between Sim’s product [+8.8 (c 0.5, CHCl3)]3 and the Author’s sample 
of L-783,277 (1) [–15.3 (c 0.5, CHCl3)] (no other optical rotation data have been reported for 1). 
Efforts to resolve this discrepancy through email correspondence with Sim et al. have been 
unsuccessful. 
The greater consistency observed between the spectral data recorded on the Author’s sample of 
L-783,277 (1) and the natural product suggests they are one and the same. Therefore, the 
specific rotation for L-783,277 (1) reported here, is more likely to represent the specific rotation 
that would be recorded for the naturally isolated material. 
3.8 Conclusion 
In the work detailed above the versatile building block cDHC 82 (X = Cl) derived from 
microbial oxidation of chlorobenzene was converted into the natural product L-783,277 (1) over 
16 steps. This synthetic sequence is shorter than those reported by Altmann et al. (17 steps),1 
Winssinger et al. (21 steps)2 and Sim et al. (18 steps).3 A comparison of the assembly of the 
fragments involved in all the reported syntheses of L-783,277 (1) is described in Table 3.2.  
OH
MeO
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HO
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Lead Author Date Reported Number of Steps 
Overall 
Yield 
Sequence of key bond forming 
events 
Altmann1 2008 17 9.1% B ! A ! C 
Winssinger2 2009 21 2.7% B ! A ! C  
Sim3 2010 18 0.1% A ! B ! C 
Present Work4 2010 16 2.1% A ! C ! B 
Table 3.2: Comparison of the four reported syntheses of L-783,277 (1). 
The present synthesis exploits the many features that were used to prepare L-783,290 (128), 
namely the use of the benzoic acid synthon 153, constructed from a Heck reaction between the 
aromatic 133 and diol 127 units, and the use of a double kinetic enzymatic resolution to 
generate substantial quantities of enantiomerically pure (R)-(–)-4-pentyn-2-ol [(R)-166]. 
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In the present synthesis, a novel mode of macrocyclisation, viz one involving an intramolecular 
nucleophilic addition of an acetylide anion onto a tethered Weinreb amide, was used to access 
macrolactone 164 incorporating a propargylic ketone. The application of this type of 
cyclisation, followed by a Lindlar reduction, should provide a useful means for obtaining other 
Z-configured ",!-unsaturated ketone-containing RALs. A discussion of other possible 
applications of this approach is presented in Chapter Five. 
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4 Chapter Four 
Towards The Total Synthesis of  
Aigialomycin C 
 
 
 
4.1 Introduction 
4.1.1 Overview and Isolation 
The aigialomycins (A to G) are a new family of RALs that were isolated, together with 
hypothemycin (2) (Figure 4.1), from the extracts of a marine mangrove fungus Aigialus parvus 
BCC531 by Isaka et al. using activity-guided fractionation techniques.1,2 
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Figure 4.1: Structures of aigialomycins A to G and hypothemycin (2), isolated from the mangrove 
ascomycete, Aigialus parvus BCC531.1,2 
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The structures assigned to aigialomycins A to G were determined using a combination of 
chemical correlation, X-ray crystallographic and spectroscopic (NMR, MS, IR and UV) 
techniques.1,2 
4.1.2 Biological Activity 
Initial screening of aigialomycins A to E for biological activity by Isaka et al. revealed that only 
aigialomycin D (5) exhibited anti-malarial activity (IC50 = 6.6 µg/mL).1 Further testing of this 
RAL against a kinase panel by Winssinger et al. revealed that it was a potent inhibitor of CDKs 
1 and 5 (IC50 = 5.7 and 5.8 µM, respectively).3 Unfortunately, no other aigialomycin analogues 
were screened by Winssinger et al. and, thus, the kinase inhibitory activities of the remaining 
members of the class have yet to be determined. 
4.2 Retrosynthetic Analysis of Aigialomycin C (131) 
Despite showing no biological activity in the initial screening,1 it was anticipated that any 
progress made towards the synthesis of aigialomycin C (131) could provide access to the other 
members of the aigialomycin family, as well as analogues, for the purpose of establishing their 
kinase inhibitory activities. 
Given the successful modular synthesis of L-783,290 (128) as described in Chapter Two, it was 
envisaged that natural product 131 could be prepared using a similar approach. Thus, it was 
anticipated this could be achieved (Scheme 4.1) through regio- and diastereo-selective 
epoxidation of macrolactone 174, a compound that can be obtained from the RCM reaction of 
substrate 175. Triene 175 would itself be assembled from three fragments in a similar sequence 
to that presented in Chapter Two these being, in order of execution, a Heck coupling between 
the aryl halide 133 and olefin 177 and a Mitsunobu esterification to couple the enantiopure 
alcohol (R)-25 to the acid derived from an oxidation reaction of aldehyde 176. While the 
aromatic fragment 133 and homoallylic alcohol (R)-25 are readily available as a result of the 
work described in Chapter Two, olefin 177 (a known compound) would be prepared in the same 
manner as reported by Banwell et al. in their synthesis of ent-cladospolide C from the 
enantiopure cDHC 82 (X = Cl).4,5,6 
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Scheme 4.1: Retrosynthetic analysis of aigialomycin C (131). 
4.3 Synthesis of the (Protected) Diol Fragment 177 
With the aromatic 133 and alcohol (R)-25 fragments readily available, the remaining unit 
required for the proposed synthesis of RAL 131 was the protected diol 177. Following the 
sequence reported by Banwell et al.,4,5,6 the electron-rich double bond within the chlorobenzene-
derived cDHC 82 (X = Cl) was selectively reduced (Scheme 4.2) using the same conditions 
described earlier to give cyclohexene 136 in 65% yield. All the spectral data derived from this 
material were consistent with those reported previously.4,6  
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Scheme 4.2: Synthesis of nitrobenzoate ester 178 from cDHC 82 (X = Cl).4,6 
The C6 hydroxyl group within diol 136 selectively participated in a Mitsunobu esterification 
with p-nitrobenzoic acid to furnish the R-configured C6 p-nitrobenzoate 178 (77% yield). The 
1H NMR spectrum obtained on this material was in complete accord with the assigned structure 
and the EI mass spectrum of compound 178 displayed molecular ions at m/z 297 and 295 in the 
ratio (3:1) expected for a mono chlorinated material. Accurate mass measurements of this 
species established that they were of the expected molecular composition, viz C13H1237ClNO5 
and C13H1235ClNO5. 
Hydrolysis of the p-nitrobenzoate ester 178 with potassium carbonate (Scheme 4.3) provided 
the trans-configured diol 179 in 68% yield. The lack of any aromatic resonances in the 1H NMR 
spectrum of this compound together with the observation of molecular ions at m/z 150 and 148 
in the EI mass spectrum suggested the trans-configured diol 179 had been obtained.  
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Scheme 4.3: Synthesis of cyclohexene 180 from benzoate 178. 
Diol 179 was protected as the corresponding bis-acetal 180 using the Ley/Frost protocol,5,7,8 
which was chosen for its capacity to protect trans-related vicinal diols and the greater tolerance 
of the resulting protecting group to acidic conditions.  
With the required cyclohexene, 180, in hand ozonolytic cleavage of the associated alkene 
residue was undertaken by employing the protocols reported earlier (Scheme 4.4). Thus, a 
methanolic solution of cyclohexene 180 maintained at –78 °C was subjected to a stream of 
ozone. Reductive workup with dimethyl sulfide afforded the unstable aldehyde 181 which was 
immediately subjected to a Wittig olefination reaction to furnish alkene 177. This was obtained 
in 60% yield from cyclohexene 180. The 1H NMR spectrum of compound 177 (Figure 4.2) 
displayed a doublet of doublet of triplets at ! 5.58 and a complex multiplet at ! 4.99 as would be 
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expected for the compound embodying a terminal olefinic residue. A three-proton singlet, due 
to the three protons on the methyl ester group, appeared at ! 3.76. The EI mass spectrum 
revealed a fragment ion at m/z 257, which is associated with the loss of a methoxy radical from 
the molecular ion. All of the remaining spectral data acquired on this material were consistent 
with the assigned structure and matched those reported previously.4,5 
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Scheme 4.4: Synthesis of protected diol fragment 177. 
 
 
Figure 4.2: 300 MHz 1H NMR spectrum of the diol fragment 177 (recorded in CDCl3). 
4.4 Assembly of the RCM Precursor 175 
4.4.1 Heck Cross-coupling of Aryl Iodide 133 and Alkene 177 
With all three of the required fragments to hand, the stage was set for the assembly of the target 
macrolactone by coupling of them. The first such coupling was that between the aryl iodide 133 
and alkene 177 by way of a Heck reaction (Scheme 4.5). This was accomplished using the 
optimised conditions described earlier (Chapter Two) to give the E-configured alkene 176 in 
81% yield. The 1H NMR spectrum (Figure 4.3) of this material showed two mutually-coupled 
resonances at ! 7.36 and 5.11 and the magnitude of this (J = 15.6 Hz) suggested that these 
protons were trans-related and, thus, the compound embodied an E-configured C1´-C2´ olefin. 
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A molecular ion observed at m/z 475 in the ESI mass spectrum corresponded to the sodiated 
derivative of alkene 176 and an accurate mass measurement on this species established it was of 
the expected composition, viz C23H32NaO9. 
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Scheme 4.5: Heck reaction between the aryl iodide 133 and alkene 177. 
 
 
Figure 4.3: 400 MHz 1H NMR spectrum of compound 176 derived from the Heck reaction between 
aromatic and diol fragments 133 and 177, respectively (recorded in CDCl3). 
The acid 182, required for the coupling to the secondary alcohol (R)-25, was obtained in 80% 
yield via a Pinnick oxidation (Scheme 4.6) of the aldehyde 176.9 The absence of a signal due to 
an aldehyde proton resonance in the 1H NMR spectrum of compound 182 and the observation of 
a molecular ion m/z 467 in the negative ESI mass spectrum (corresponding to the conjugate 
base of the acid 182) confirmed that the desired oxidation reaction had taken place. 
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Scheme 4.6: Oxidation of benzaldehyde 176 to benzoic acid 182. 
4.4.2 First Approach To RCM Precursor 175 
With acid 182 to hand, attention could now be focused on its elaboration to triene 175, the 
substrate required for the pivotal RCM reaction. It was decided that manipulation of the methyl 
ester residue within compound 182 should occur before the Mitsunobu esterification with 
alcohol (R)-25, due to the difficulties that would be created in distinguishing between the newly 
installed homo-allylic and methyl ester residues. To such ends, methyl ester 182 (Scheme 4.7) 
was subjected to the reduction conditions reported by Ley et al. involving the use of DIBAL-
H.10,11 This afforded an inseparable mixture of aldehyde 183 and primary alcohol 184 in every 
instance, so it became clear that extensive optimisation of the required partial reduction process 
was needed. 
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Scheme 4.7: Outcome of the reduction of methyl ester 182. 
Given this situation it was thought that a simpler, albeit slightly longer, route to aldehyde 183 
would involve a reduction of the methyl ester 182 to the alcohol 184 followed by an oxidation 
of the latter to the aldehyde. Accordingly, methyl ester 182 was subjected to a reaction with 
sodium borohydride (Scheme 4.8). This gave the primary alcohol 184 as a mixture of epimers 
(trans:cis – 1:0.06) in 90% combined yield. The lack of a three-proton singlet associated with 
the precursor methyl ester 182 in the 1H NMR spectrum of the reduction product and the 
presence of a molecular ion m/z 467 in the negative ESI mass spectrum (corresponding to the 
conjugate base of 184) confirmed that the desired reduction had taken place. 
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Scheme 4.8: NaBH4 mediated reduction of methyl ester 182 to alcohol 184. 
Unfortunately, treatment of alcohol 184 with a variety of oxidants failed to generate target 183. 
Only decomposition of the starting material was observed under all the conditions attempted. It 
was presumed that the benzoic acid residue within compound 184 was responsible for these 
failures. Accordingly, this was esterified with the homoallylic alcohol (R)-25 under Mitsunobu 
conditions (Scheme 4.9) to afford ester 185 in 75% yield. All spectral data derived from this 
material were in accord with the assigned structure. 
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Scheme 4.9: Alternate synthesis of triene 175 from primary alcohol 184. 
With the benzoic acid residue no longer present, the primary alcohol 185 was successfully 
oxidised with Dess-Martin Periodinane (Scheme 4.9) to afford aldehyde 186 that was 
contaminated with the by-products from the oxidant. Since compound 186 was unstable to 
chromatography on silica gel, it could not be obtained in pure form. Accordingly, a cleaner 
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oxidation process was sought and it was found that using tetrapropylammonium perruthenate 
(TPAP) in conjunction with N-methylmorpholine-N-oxide (NMO) afforded a pure sample of 
aldehyde 186 after workup. 
With aldehyde 186 in hand, this material was immediately subjected to a Wittig olefination 
reaction (Scheme 4.9) with the ylide prepared from the reaction of 
methylenetriphenylphosphonium bromide and n-butyl lithium. Disappointingly, this resulted in 
the decomposition of the starting material. As a result, various other olefination protocols were 
pursued but none of these gave the required triene 175. 
4.4.3 Second Attempt at Synthesising RCM Precursor 175 
In light of the difficulties encountered in the above-mentioned approach to compound 175 via 
aldehyde 186, an attempt was made to introduce the C7´-C8´ olefin while the free benzoic acid 
residue was still present. Unfortunately, attempts to effect the clean reduction of methyl ester 
182 to aldehyde 184 with DIBAL-H (Scheme 4.10) were unsuccessful as the formation of 
alcohol 184 could not be avoided. Despite the presence of alcohol 184, the reaction mixture 
from the reduction was subjected to the abovementioned Wittig olefination reaction (Scheme 
4.10) and the alkene 187 thereby obtained in yields varying from 30 – 50%. The 1H NMR 
spectrum of this material, displayed a one-proton doublet of doublet of doublets at ! 5.32 and a 
complex two-proton multiplet at ! 5.78, which are attributed to the hydrogens attached to the 
newly installed terminal alkene residue. 
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Scheme 4.10: Synthesis of triene 175 from methyl ester 182. 
Since compound 187 seemed to be unstable it was immediately subjected to a Mitsunobu 
esterification reaction with alcohol (R)-25 (Scheme 4.10). By such means, an impure sample of 
triene 175 was obtained in ca. 25% overall yield from methyl ester 182. The 1H NMR spectrum 
of compound 175 (Figure 4.4) confirmed the successful installation of the ester with the 
presence of a one-proton doublet of doublet of triplet at ! 5.84 and a two-proton complex 
multiplet at ! 5.10 being taken as indicative of the presence of the alkene residue of the homo-
allylic ester. The remainder of the 1H NMR spectrum was consistent with the assigned structure. 
The 13C NMR spectrum of this material displayed the 28 resonances expected for compound 
182 while the ESI mass spectrum displayed a molecular-associated ion at m/z 527 which 
corresponds to the sodiated derivative of compound 175. An accurate mass measurement on this 
species established the expected composition, viz C28H28NaO8. 
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Figure 4.4: 800 MHz 1H NMR spectrum of triene 175 (recorded in CDCl3). 
4.5 RCM Reaction of Triene 175 
4.5.1 Previous Use of RCM Processes in Macrolide Syntheses 
As discussed in Chapter One, many syntheses of aigialomycin D (5) employed a RCM reaction 
to construct the fourteen-membered macrolactone ring. However, a common problem associated 
with this strategy for constructing large (>10-membered) rings is the potential for formation of 
kinetically favoured by-products such as cyclohexenes 44 and 190, as encountered during 
Winssinger’s synthesis of aigialomycin D (Scheme 4.11) and Banwell’s synthesis of (+)-
aspicilin (Scheme 4.12), respectively.12-14 
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Scheme 4.11: Formation of cyclohexene 44 observed by Winssinger et al.15 
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Scheme 4.12: Formation of cyclohexene 190 encountered by Banwell et al.14 
As such, the presence of the C1´-C2´ alkene residue found in aigialomycin D (5) adds another 
level of complexity to its synthesis via an RCM approach.3,15,16  
In order to overcome the type of difficulty mentioned above, most syntheses mask the C1´-C2´ 
alkene residue as a selenide,3 sulfone,17 ketone or silyl ether,18 which is then revealed after the 
RCM reaction. However, Barrett et al. recently demonstrated (Scheme 4.13) that the masking 
isn’t always necessary since they observed that the RCM reaction of substrate 42 favoured the 
formation of macrocycle 43 over cyclohexene 44 (86% yield, 43:44 – 1:0.06 ratio).16 This result 
represents a remarkable improvement over the equivalent transformation involving compound 
191 which gave the desired macrolide in significantly lower yield (56%) and with greater 
quantities of the cyclohexene by-product being formed (43:44 – 1:0.2 ratio).16 
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Scheme 4.13: Barrett’s RCM reactions of trienes 191 and 42.16 
It can be argued that by replacing the C7´-C8´ terminal olefin in triene 191 with a 1,2-
disubstituted olefin, as encountered in triene 42, then the substrate will react more slowly with 
the catalyst. As a consequence, olefin metathesis is initiated preferentially at the C9´-C10´ 
olefin and, therefore, provides the desired macrocycle 43. The formation of some cyclohexene 
by-product (44) could be attributed to the ability of the C7´-C8´ 1,2-disubstituted olefin of 
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compound 42 to participate in the RCM reaction, albeit more slowly when compared to the 
corresponding terminal olefin of substrate 191. 
Although triene 175 lacks the 1,2-disubstitued olefin found in triene 42, it was anticipated that 
the presence of a trans-configured diol instead of the cis-configured one, as encountered in the 
previous examples (see Scheme 4.11 and Scheme 4.13) could deter the catalysts from 
terminating the RCM reaction at the C1´-C2´ double bond due to the greater conformational 
rigidity around this bond. Therefore, it was envisaged that initiation at either terminal olefin 
might still give the desired macrocycle 192. 
4.5.2 RCM Reaction of Triene 175 
With triene 175 in hand, the stage was set for an examination of the pivotal RCM reaction. To 
such ends, a dilute solution of triene 175 was exposed to Grubbs’ 2nd generation catalyst19 
(Scheme 4.14) and this afforded the target macrocycle 192, albeit in ca. 25% yield. 
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Scheme 4.14: RCM reaction of triene 175 with Grubbs’ 2nd generation catalyst. 
The 1H NMR spectrum of compound 192 (Figure 4.5) features a complex one-proton multiplet 
at ! 5.50 and a one-proton doublet of doublet at ! 5.68 which correspond to the hydrogens 
associated with the newly formed (C7´-C8´) alkene. The C1´-C2´ alkene gives rise to a one 
proton doublet at ! 6.37 and a one proton multiplet at ! 5.99. The ESI mass spectrum of this 
material revealed a molecular associated ion at m/z 499, which corresponds to the sodiated 
derivative of 192. An accurate mass measurement on this species established that it possessed 
the expected molecular formula, viz C26H36NaO8. Despite these promising data, full and 
rigorous characterisation on compound 192 could not be achieved with the small and impure 
quantities of material available. Nevertheless, there are some encouraging precedents in the 
literature suggesting that the conversion of triene 175 into the fourteen-membered macrocyclic 
ring 192 has been successful. 
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Figure 4.5: 400 MHz 1H NMR spectrum of macrocycle 192 (recorded in CDCl3). 
So, after attempting the RCM reaction with triene 175 (Scheme 4.14), Takahashi et al. reported 
a similar outcome when the closely related substrate 193 was subjected to an RCM reaction 
(Scheme 4.15).20 
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Scheme 4.15: Takahashi’s RCM reaction of substrate 194.20 
The workers attributed the modest yield of the desired macrocycle (194) to the competing 
generation of cyclohexene 44 although no yield was reported for this by-product.20 In light of 
this, the similarities of the trienes 175 and 193 and the yields of the desired RCM products, it 
seems reasonable to suggest that a cyclohexene by-product was produced in the RCM of the 
former substrate even if this could not be isolated from the reaction mixture.  
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When Takahashi et al. repeated the RCM reaction on substrate 193 with a less active catalyst 
(Scheme 4.15), namely Grubbs’ 1st generation system,21,22 the yield of the macrocycle improved 
significantly (to 68%) although they did not indicate if the cyclohexene by-product 44 was 
produced on this occasion.20 A possible explanation for this improvement in the yield may be 
that the metathesis initiates at the C9´-C10´ olefin and, thus leading to a greater yield of desired 
macrocycle 195. Unfortunately, insufficient material was available to examine the effect of 
subjecting compound 175 to reaction with Grubbs’ 1st generation catalyst. 
4.6 Ongoing Studies Directed Towards the Synthesis of Aigialomycin C (131) 
Further work is now being undertaken within the Banwell group to complete the synthesis of 
aigialomycin C (131). In principle, all that remains in this synthesis is a global deprotection of 
compound 192 followed by a regio- and diastereo-selective epoxidation of triol 174 (Scheme 
4.16) using the conditions reported by Lett et al. or Winssinger et al. in their synthesis of 
hypothemycin (2).23,24 
 
O
O OMe
MeO
OMe
MeO
O
O deprotectionwith BCl3
OH
OH
OH
MeO
O
O
OH
OH
OH
MeO
O
O
O
aigialomycin C
(131)
DMDO/m-CPBA
epoxidation
192 174
 
Scheme 4.16: Conversion of macrocycle 192 into aigialomycin C (131). 
An ability to access synthetically useful quantities of macrocycle 174, would also provide an 
opportunity to synthesise aigialomycin D (5) (Scheme 4.17) through an inversion of the C6´ 
alcohol moiety within compound 195 via a regioselective Mitsunobu esterification reaction 
involving the allylic hydroxyl residue.  
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Scheme 4.17: Proposed synthesis of aigialomycin D (5). 
4.7 Conclusion 
In the work described above, the biocatalytically-derived starting material cDHC 82 (X = Cl) 
has been converted into the macrolactone ring 192. The latter compound represents an advanced 
intermediate in a projected synthesis of aigialomycin C (131). As such completion of this target 
131 seems likely in the near future. This synthesis builds upon the protocols established during 
the preparation of L-783,290 (128), namely the chemoenzymatic resolution of homoallylic 
alcohol (R)-25 and the use of the Heck reaction to couple the aromatic and diol fragments, 133 
and 177, respectively. 
This approach also demonstrates the usefulness of the Heck reaction in RAL synthesis, as the 
alkene derived from the coupling of the aryl halide and olefin of the diol unit directly 
corresponds to the alkene present in 5Z-7-oxozeanol (3) and aigialomycin D (5). but also 
provides a handle for further functionalisation, such as generation of an epoxide, as seen in 
hypothemycin (2) and aigialomycins A to C. 
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5 Chapter Five 
Future Research 
 
 
 
5.1 Introduction 
Chapters Two, Three and Four of this thesis describe modular and versatile approaches to cis- 
and trans-configured enone-containing RALs, as well as members of the aigialomycin family. 
The use of the Heck reaction for the coupling of the aromatic and diol fragments affords a 
product bearing a synthetically useful alkene at the C1´-C2´ position. Although this was 
subsequently reduced to the corresponding alkane in the preparation of L-783,290 (128) and L-
783,277 (1), its retention would provide an opportunity to access RALs that contain this alkene 
or related functionality (e.g. epoxides) within their frameworks. To emphasise such 
opportunities, several possible pathways to RALs containing such functionality are detailed 
below. These are categorised according to the proposed mode of macrocyclisation, namely 
those involving the intramolecular nucleophilic addition reaction (as described in Chapter 
Three) or those employing the RCM reaction (as presented in Chapters Two and Four). 
5.2 Proposed Syntheses of Additional Biologically Active RALs 
5.2.1 Syntheses of RAL Derivatives by Employing an Intramolecular Acetylide Anion 
Addition to a Tethered Weinreb Amide 
It is envisaged that the strategy employed in the synthesis of L-783,277 (1), as described in 
Chapter Three, could be used in the preparation of 5Z-7-oxozeanol (3) and hypothemycin (2). 
Both RALs are potent inhibitors of MAPKs and, thus, present themselves as interesting targets. 
The proposed syntheses exploit the advanced intermediate 153 obtained during the course of the 
synthesis of L-783,290 (128). So, subjection of compound 152 to a Mitsunobu esterification 
reaction with (R)-(–)-4-pentyn-2-ol [(R)-166] would be expected to afford ester 196 (Scheme 
5.1) which should, in turn, yield macrocycle 197 bearing the C1´-C2´ alkene and an alkyne after 
treatment with LiHMDS. It is anticipated that the synthesis of 5Z-7-oxozeanol (3) could be 
completed through a Lindlar reduction of the embodied alkyne to the corresponding Z-
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configured enone (as shown in compound 198), followed by a step-wise deprotection with BCl3. 
The successful acquisition of 5Z-7-oxozeanol (3) by this means also constitutes a formal total 
synthesis of hypothemycin (2) as this has been obtained by Lett et al. and Winssinger et al. 
through diastereoselective epoxidation of compound 3.1,2 
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Scheme 5.1: Proposed synthesis of hypothemycin (2), 5-7Z-oxozeanol (3) and radicicol A (4). 
Replacement of aryl iodide 133 in the above-mentioned sequence with 2-iodo-3,4,6-
trimethoxybenzaldehyde (199) (Scheme 5.1) also provides a plausible approach to radicicol A 
(4).  
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5.2.2 Syntheses of RAL Derivatives by Employing RCM Reaction 
Cochliomycins (A to C, Figure 5.1) are a new class of RALs recently isolated from the fungus 
Cochliobolous lunatus. Interestingly, they have been shown to exhibit potent anti-fouling 
activity.3  
HO
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MeO
O
O
cochliomycin A
(204)
O
O O
O
OH
MeO
O
O
cochliomycin B
(205)
OH
HO
OH
MeO
O
O
OH
OHCl
cochliomycin C
(206)  
Figure 5.1: Cochliomycins A – C isolated from C. lunatus.3 
By retaining the C1´-C2´ alkene derived from the Heck reaction of fragments 127 and 133, a 
divergent synthesis of cochliomycin B (205) could be achieved by employing the same 
approach as used for the preparation of L-783,290 (128) (Chapter Two). Careful deprotection of 
macrocycle 208 with BCl3 should provide triol 209 (Scheme 5.2) which could, in turn, be 
converted into cochliomycin B (205) after “protection” of the diol as an acetonide followed by a 
diastereoselective 1,2-reduction of the enone residue. 
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Scheme 5.2: Proposed synthesis of cochliomycin B (205). 
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5.3 Conclusion 
Based on the total syntheses of L-783,290 (128) and L-783,277 (1), and the significant advances 
towards aigialomycin C (131) – as described in Chapters Two, Three and Four, respectively– a 
unified approach for the preparation of other biologically active RALs should be able to be 
realised. The use of the Heck reaction not only serves as a strategy for the coupling of the 
aromatic and diol fragments, but it also provides the potential for accessing several RALs 
containing functionality at the C1´-C2´ position. In all the syntheses achieved thus far it has 
been shown that a combination of the microbial oxidation, Heck coupling, Mitsunobu 
esterification and one of the two presented modes of macrocyclisation, namely RCM reaction or 
intramolecular acetylide anion addition onto a tethered Weinreb amide, represent significant 
contributions to the preparation of RALs.  
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6 Chapter Six 
Experimental Procedures Associated with Work Described in 
Chapters Two to Four 
 
 
 
6.1 General Procedure 
Starting materials and reagents were obtained from the Sigma-Aldrich, Merck, TCI or Lancaster 
Chemical Companies and used as supplied or, occasionally, recrystallised or distilled. Inorganic 
salts were purchased from the Sigma-Aldrich, Alfa Aesar, AJAX, BDH or Unilab Chemical 
Companies. The cis-1,2-dihydrocatechols 82 (X = Cl) was purchased from Professor Derek 
Boyd of The Queen’s University of Belfast (Belfast, UK). (R)-(–)-4-penten-2-ol, [(R)-25], was 
generously provided by Dr Jens Renner of BASF (Germany). CALB was obtained, as a gift, 
from Novo Nordisk (Denmark). 
THF, DMF, dichloromethane and toluene were dried using a Glass Contour™ solvent 
purification system that is based upon a technology originally described by Grubbs et al.1 
Solvents collected from the purification system were stored over 4 Å molecular sieves that had 
previously been dried in a conventional microwave oven, then cooled under high vacuum and 
stored under anhydrous nitrogen or argon. 
Glassware was rinsed with acetone, dried then soaked in a base bath (Pyroneg® in water) before 
being rinsed with distilled water and oven-dried at 120 °C. Assembled apparatus was evacuated 
(< 0.1 mmHg) and flushed three times with dry nitrogen prior to use. Reaction mixtures were 
manipulated under nitrogen using standard Schlenk techniques. 
Ambient temperature was assumed to be ca. 18 °C. Temperatures higher than ambient were 
attained using oil baths heated on a thermostated hot-plate stirrer. To attain temperatures lower 
than ambient, appropriate cooling baths was used (ice/water slurry, 0 °C; dry ice/acetonitrile, –
40 °C; dry ice/acetone, –78 °C).  
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Organic solutions (extracts) obtained from the work-up of reaction mixtures were dried with 
anhydrous sodium sulfate (Na2SO4) or magnesium sulfate (MgSO4) before being filtered and 
concentrated under reduced pressure on a rotary evaporator with a water bath temperature 
generally not exceeding 25 °C. 
Analytical thin layer chromatography (TLC) was performed on aluminium-backed 0.2 mm thick 
silica gel 60 F254 plates as supplied by Merck. Eluted plates were visualised using a 254 nm UV 
lamp and/or by treatment with a suitable dip followed by heating. These dips included: a) 
potassium permanganate : potassium carbonate : 5% sodium hydroxide aqueous solution : water 
(3 g : 20 g : 5 mL : 300 mL) and b) anisaldehyde : sulfuric acid (conc.) : ethanol (3ml : 4.5 mL : 
200 mL). 
Melting points were measured on a Stanford Research Systems Optimelt – Automated Melting 
Point System and are uncorrected. 
Unless specified otherwise, proton (1H) and carbon (13C) NMR spectra were recorded at 20 °C 
on either a Varian Mercury 300 spectrometer (operating at 300 MHz for proton and 75 MHz for 
carbon nuclei) or a Varian MR400 spectrometer (operating at 400 MHz for proton and 100 
MHz carbon nuclei) using CDCl3 that had been filtered through basic alumina. In certain cases, 
a Varian Inova 500 spectrometer (operating at 500 MHz for proton and 125 MHz for carbon 
nuclei) or a Bruker AV800 spectrometer (operating at 800 MHz for proton and 200 MHz for 
carbon nuclei) was used. Signals arising from the residual protio-forms of the solvent were used 
as the internal standard. Chemical shifts are recorded as $ values in parts per million (ppm). 1H 
NMR data are recorded as follows: chemical shift ($) [multiplicity, coupling constant(s) J (Hz), 
relative integral] where multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = 
quartet; m = multiplet or combinations of the above. For 13C NMR spectra, the chemical shifts 
are reference against with the central peak ($ 77.0) of the CDCl3 “triplet”. 
Infrared spectra (%max) were recorded on a Perkin-Elmer 1800 Series FTIR Spectrometer. Samples 
were analysed as KBr discs (for solids) or as thin films on KBr plates (for liquids/oils). 
Mass spectrometry was performed by the Australian National University’s Mass Spectrometric 
Services Unit located in the Research School of Chemistry, Canberra, Australia. Low- and high-
resolution electron impact (EI) spectra were obtained on a VG Fisions AutoSpec M series three-
sector (E/B/E) double-focusing mass spectrometer. Low and high resolution electrospray (ES) mass 
spectra were recorded on a Micromass-Waters LC-ZMD single quadrupole liquid chromatograph-
MS or a VG Quattro II triple quadrupole MS instrument operating in positive or negative ionisation 
mode. Gas chromatographic analyses (GC) were performed using Agilent 7890A instrument fitted 
with a 25 m ( 0.22 mm permethylated %-cyclodextrin (SGE Cydex B, wall coated to 0.25 microns) 
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capillary column. Peaks were detected using a flame ionisation detector operating at 200 °C. 
Hydrogen served as the carrier gas (flow rate ca. 28.6 cm.s-1) and a gradient temperature program 
ranging from 50 °C (5 min) to 200 °C (20 min) with a heating rate of 10 °C.min-1 was used. High 
performance liquid chromatography (HPLC) were performed on a Waters system consisting of a 
600E quaternary pump and 2996 diode detector system. 
Optical rotations were measured between 17 to 20 °C on a Perkin-Elmer 241 polarimeter at the 
sodium-D line (& = 589 nm) and the concentrations (c) (g/100 mL) indicated using spectroscopic 
grade chloroform (CHCl3) as solvent. The measurements were carried out in a cell with a path length 
(l) of 1 dm. Specific rotations ["]D were calculated using the equation ["]D = (100(")/(c(l) and are 
given in 10-1.deg.cm2.g-1.  
Ozonolyses were performed using a Model 500 Fischer portable ozone-generator with the 
luteinizing power and flow rate adjusted to 80 V and 50 L/h, respectively.  
Flash chromatography2 was performed using analytical grade solvents and silica gel 60 (230 – 400 
mesh, 0.040 – 0.0063 mm) as supplied by Merck.  
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6.2 Experimental Procedures Associated with Work Described in Chapter Two 
1-Iodo-3,5-dimethoxybenzene (135) 
MeO
OMe
NH2 MeO
OMe
I
1. Conc. H2SO4, NaNO3,
    H2O, –15 °C, 0.25 h
2. KI, H2O,
    –15 ! 0 °C, 0.25 h134 135  
A vigorously stirred suspension of 3,5-dimethoxyaniline (134) (3.25 g, 19.50 mmol) in water 
(11 mL) was rapidly cooled to –15 °C and immediately treated, dropwise, with sulfuric acid 
(879 µL of 95 – 97% by weight material). After 0.2 h the reaction mixture was treated, 
dropwise, with a solution of sodium nitrite (680 mg, 9.79 mmol) dissolved in a minimum 
volume of water. After being stirred for a further 0.25 h at –15 °C, the reaction mixture was 
treated with diethyl ether (20 mL) then treated, dropwise, with a solution of potassium iodide 
(3.25 g, 19.57 mmol) in water (2 mL) (Caution: vigorous nitrogen evolution). After leaving the 
reaction mixture to stir for 3 h at 0 °C, the aqueous phase was separated and extracted with 
diethyl ether (3 ( 20 mL). The combined organic phases were washed with sodium thiosulfate 
(2 ( 20 mL of a 10% w/v aqueous solution), sodium bicarbonate (1 ( 20 mL of a saturated 
aqueous solution), water (1 ( 20 mL) and brine (1 ( 20 mL) before being dried (MgSO4), 
filtered and concentrated under reduced pressure to give an orange oil. This material was placed 
on the top of a pad of TLC-grade silica gel that was then eluted with ethyl acetate/hexane (300 
mL of a 1:9 v/v mixture). Concentration of the filtrate under reduced pressure gave the title 
compound 1353 (1.23 g, 71%) as light-yellow crystalline masses, m.p. = 72–74 °C (lit.3 m.p.= 
74–75 °C). The spectroscopic data correlated with those previously reported.3 
2-Iodo-4,6-dimethoxybenzaldehyde (133) 
MeO
OMe
I
135
MeO
OMe
I
133
DMF, POCl3,
100 °C, 5 h
H
O
 
A magnetically stirred solution of aryl iodide 135 (500 mg, 1.01 mmol) in dry DMF (3 mL) 
maintained under a nitrogen atmosphere at 0 °C was treated, dropwise, with freshly distilled 
POCl3 (433 µL, 4.73 mmol). After 0.5 h the reaction mixture was warmed to 18 °C, kept at this 
temperature for 0.5 h, then heated to 100 °C. After 5 h the reaction was cooled to 18 °C and 
poured, with stirring, into ice/water (500 mL). After 3 h the mixture was filtered to give a light-
brown solid that was then subjected to flash chromatography (silica, 2:3 v/v ethyl acetate/hexane 
elution). Concentration of the relevant fractions (Rf = 0.2) afforded the title compound 1334 
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(350 mg, 63%) as light-yellow needles, m.p. = 81–82 °C (lit.4 m.p. = 80–80.5 °C). The 
spectroscopic data correlated with those previously reported.4 
(1S,2S)-3-Chlorocyclohex-3-ene-1,2-diol (136) 
Cl
OH
OH
82
Cl
OH
OH
136
5% Rh on Al2O3, 
EtOH, H2,
18 °C, 0.75 h
 
Following a procedure reported by Banwell and Loong,5 a magnetically stirred solution of diene 
82 (2.00 g, 14.00 mmol) in absolute ethanol (170 mL) maintained at 18 °C was treated with 5% 
rhodium on alumina (200 mg of 10% w/w material, ex. Alfa Aesar). The resulting black slurry 
was evacuated and refilled with dihydrogen three times prior to the contents being stirred at 18 
°C under a dihydrogen atmosphere for 0.75 h. The reaction mixture was then filtered through a 
pad of Celite™ that was washed with ethanol (3 ( 50 mL). The combined filtrates were 
concentrated under reduced pressure to give a grey solid that was subjected to flash 
chromatography (silica, 1:5:0.1 ' 2:3:0.1 v/v/v ethyl acetate/hexane/isopropanol gradient 
elution). Concentration of the relevant fractions (Rf = 0.25 in 1:2 v/v ethyl acetate/hexane) then 
gave the title compound 1365 (1.36 g, 65%) as a white, crystalline solid, m.p. = 113.6–114.1 °C 
(lit.5 m.p. = 115–116 °C). This material was identical, in all aspects, with an authentic sample.5 
(3aS,7aS)-7-Chloro-3a,4,5,7a-tetrahydro-2,2-dimethylbenzo[d][1,3]dioxole (137) 
Cl
OH
OH
Cl
(CH3)2C(OCH3)2,
p-TSA, CH2Cl2,
18 °C, 0.5 h O
O
136 137  
A magnetically stirred solution of diol 136 (1.36 g, 9.15 mmol) in 2,2-dimethoxypropane (3 
mL) maintained at 18 °C under nitrogen was treated with p-toluenesulfonic acid (0.16 g, 0.92 
mmol). After 1 h the reaction mixture was quenched with NaHCO3 (1 ( 20 mL of a saturated 
aqueous solution) and extracted with dichloromethane (4 ( 5 mL). The combined organics 
phases were washed with brine (1 ( 20 mL) then dried (MgSO4), filtered and concentrated 
under reduced pressure to give a brown oil. Subjection of this material to flash chromatography 
(silica, 1:9 ' 3:7 v/v diethyl ether/pentane gradient elution) and concentration of the relevant 
fractions (Rf  = 0.3 in 1:9 v/v ethyl acetate/hexane) then afforded the title compound 1376 (1.68 
g, 97%) as a clear, colourless oil. This material was identical, in all aspects, with an authentic 
sample.6 
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(4S,5S)-Methyl 5-(3-hydroxypropyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (139) 
1. O3, pyridine,
    MeOH, –78 °C, 0.1 h
2. Me2S, 0 °C, 2 h
3. NaBH4, 0 °C, 1h
Cl
O
O
137 139
O O
OMe
O
HO
 
A magnetically stirred solution of alkene 137 (500 mg, 2.7 mmol) and pyridine (2.14 mL, 27.0 
mmol) in methanol (50 mL) was cooled to –78 °C and then treated with a stream of ozone until 
a persistent blue colour was observed. After a further 0.1 h the excess ozone was removed with 
a stream of nitrogen and the resulting clear, colourless solution was treated with dimethyl 
sulfide (7.84 mL, 106.0 mmol) and allowed to warm to 0 °C. After 2 h the reaction mixture was 
treated, portion-wise over 0.5 h, with sodium borohydride (670 mg 17.85 mmol). After an 
additional 0.5 h the reaction mixture was treated with NH4Cl (30 mL of a saturated aqueous 
solution) and extracted with ethyl acetate (9 ( 30 mL). The combined organic phases were 
washed with brine (1 ( 150 mL) then dried (MgSO4), filtered and concentrated under reduced 
pressure to give a light-yellow oil. Subjection of this material to flash chromatography (silica, 
2:3:0.1 ' 3:2:0.1 v/v/v ethyl acetate/hexane/isopropanol gradient elution) and concentration of 
the relevant fractions (Rf = 0.3 in 2:3 v/v ethyl acetate/hexane) gave the title compound 139 (440 
mg, 76%) as a light-yellow oil.  
1H NMR (CDCl3, 300 MHz) $ 4.60 (d, J = 6.8 Hz, 1H), 4.36 (m, 1H), 3.75 (s, 3H), 3.66 (m, 
2H), 1.80–1.65 (complex m, 4H), 1.61 (s, 3H), 1.45 (m, 1H), 1.38 (s, 3H). 
13C NMR (CDCl3, 75 MHz) $ 171.0, 110.7, 77.8, 77.5, 62.2, 52.1, 29.7, 27.1, 26.9, 25.8. 
IR %max(KBr) 3452, 2939, 1757, 1439, 1382, 1161, 1095 cm-1. 
Mass Spectrum (ESI, +ve) m/z 241 [(M + Na)+, 100%], 101 (87). 
HRESIMS Found: (M + Na)+, 241.1048. C10H18O5 requires (M + Na)+, 241.1052. 
Specific Rotation: ["]D = + 0.8 (c 0.45, CHCl3). 
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(4S,5S)-5-(3-Hydroxypropyl)-N-methoxy-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide 
(140) 
139
O O
OMe
O
MeN(OMe)•HCl,
i-PrMgCl, THF,
–15 °C, 1 h O O
N
O
MeMeO
140
HOHO
 
A magnetically stirred solution of ester 139 (490 mg, 1.83 mmol) in THF (3.67 mL) maintained 
under a nitrogen atmosphere was treated with N,O-dimethylhydroxylamine hydrochloride (360 
mg, 3.65 mmol). The resulting mixture was cooled to –15 °C then treated, dropwise over 0.3 h, 
with i-propylmagnesium chloride (4.58 mL of a 2.0 M solution in THF, 9.16 mmol). After 1 h 
at –15 °C the reaction mixture was treated with phosphate buffer (10 mL of a 1 M aqueous 
solution, pH = 4) and extracted with ethyl acetate (10 ( 30 mL). The combined organic phases 
were washed with brine (1 ( 150 mL) before being dried (MgSO4), filtered and concentrated 
under reduced pressure to give a yellow oil. Subjection of this material to flash chromatography 
(silica, 3:2:0.1 ' 9:0:1 v/v/v ethyl acetate/hexane/isopropanol gradient elution) and 
concentration of the relevant fractions (Rf = 0.25 in ethyl acetate) then afforded the title 
compound 140 (410 mg, 89%) as a white, crystalline solid, m.p. = 88–90 °C.  
1H NMR (CDCl3, 300 MHz) $ 4.91 (d, J = 6.8 Hz, 1H), 4.37 (m, 1H), 3.66 (s, 3H), 3.59 (t, J = 
6.2 Hz, 2H), 3.15 (s, 3H), 2.32 (broad s, 1H), 1.80–1.35 (complex m, 4H), 1.57 (s, 3H), 1.35 (s, 
3H). 
13C NMR (CDCl3, 75 MHz) $ 170.4, 110.2, 77.5, 75.6, 62.6, 61.4, 32.5, 29.5, 27.5, 27.3, 25.9. 
IR %max(KBr) 3453, 2982, 2937, 1685, 1459, 1380, 1330, 1248, 1217, 1165, 1067, 1017, 988, 
884 cm-1. 
Mass Spectrum (ESI, +ve) m/z 241 [(M + Na)+, 100%], 101 (87). 
HRESIMS Found: (M + Na)+, 270.1316. C11H21NO5 requires (M + Na)+, 270.1317. 
Specific Rotation: ["]D = – 60.7 (c 0.24, CHCl3). 
This compound has been subjected to a single-crystal X-ray analysis. Details are presented in 
Appendix A1. 
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3-((4S,5S)-5-(Methoxy(methyl)carbamoyl)-2,2-dimethyl-1,3-dioxolan-4-yl)propyl 4-
methylbenzenesulfonate (141) 
O O
N
O
MeMeO
140
p-TsCl, Et3N, THF,
0 ! 18 °C, 3 h
O O
N
O
MeMeO
141
HO TsO
 
A magnetically stirred solution of alcohol 140 (10 mg, 0.4 mmol) in dry dichloromethane (5 
mL) maintained under a nitrogen atmosphere was cooled to 0 °C then treated with triethylamine 
(0.14 mL, 1.0 mmol) and p-toluenesulfonyl chloride (190.7 mg, 1.0 mmol). After 3 h the 
reaction was treated with water (1 ( 10 mL) and extracted with dichloromethane (5 ( 5 mL). 
The combined organic phases were washed with brine (1 ( 10 mL) before being dried (MgSO4), 
filtered and concentrated under reduced pressure to give a yellow oil. 
1H NMR (CDCl3, 300 MHz) $ 7.77 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 4.95 (d, J = 
6.9 Hz, 1H), 4.33 (m, 1H), 3.92–4.13 (complex m, 4H), 3.69 (s, 3H), 3.15 (s, 3H), 2.45 (s, 3H), 
2.01–1.67 (complex m, 2H), 1.55 (s, 3H), 1.35 (s, 3H). 
Due to the ready decomposition of this material and its lack of synthetic utility the compound 
was not fully characterised. 
(4S,5S)-5-(3-(2-Nitrophenylselenyl)propyl)-N-methoxy-N,2,2-trimethyl-1,3-dioxolane-4-
carboxamide (142) 
o-O2NC6H4SeCN,
n-Bu3P, THF,
18 °C, 2 hO O
N
O
MeMeO
140
HO
O O
N
O
MeMeO
142
o-NO2C6H4Se
 
A magnetically stirred solution of alcohol 140 (390 mg, 1.56 mmol) in THF (5.2 mL) 
maintained at 18 °C under a nitrogen atmosphere was treated with o-nitrophenylselenyl cyanate 
(710 mg, 3.12 mmol, ex. Aldrich) then n-tributylphosphine (0.77 mL, 3.12 mmol) was added 
dropwise. The ensuing mixture was stirred at 18 °C for 2 h before being concentrated under 
reduced pressure to give a dark-brown solid. Subjection of this material to flash 
chromatography (silica, 3:7:0.1 ' 1:1:0.1 v/v/v ethyl acetate/hexane/isopropanol gradient 
elution) and concentration of the relevant fractions (Rf = 0.25 in 7:3 v/v ethyl acetate/hexane) 
afforded the title compound 142 (600 mg, 89%) as a brown, crystalline solid, m.p. = 81–83 °C. 
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1H NMR (CDCl3, 300 MHz) $ 8.28 (m, 1H), 7.51 (m, 2H), 7.30 (m, 1H), 4.95 (d, J = 6.8 Hz, 
1H), 4.40 (m, 1H), 3.70 (s, 3H), 3.19 (s, 3H), 2.90 (m, 2H), 2.02 (m, 2H), 1.82 (m, 2H), 1.61 (s, 
3H), 1.39 (s, 3H). 
13C NMR (CDCl3, 75 MHz) $ 170.1, 146.8, 133.6, 133.5, 129.0, 126.5, 125.3, 110.0, 76.9, 75.7, 
61.2, 32.3, 30.8, 27.4, 25.7 (two signals overlapping), 25.3. 
IR %max(KBr) 2981, 2937, 1684, 1590, 1565, 1513, 1453, 1379, 1332, 1304, 1249, 1218, 1169, 
1097, 1071, 1037, 987, 874, 852, 785, 731 cm-1. 
Mass Spectrum (ESI, +ve) m/z 455 [(M + Na)+, 100%], 453 (53), 375 (55), 219 (80). 
HRESIMS Found: (M + Na)+, 455.0703. C17H24N2O6Se requires (M + Na)+, 455.0697. 
Specific Rotation: ["]D = – 58.0 (c 0.56, CHCl3). 
This compound has been subjected to a single-crystal X-ray analysis. Details are presented in 
Appendix A2. 
(4S,5S)-5-Allyl-N-methoxy-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide (127) 
1. m-CPBA, CH2Cl2,
   –78 ! 18 °C, 0.25 h
2. O2, Me2NH, 18 °C, 3 h
O O
N
O
MeMeO
142
o-NO2C6H4Se
O O
N
O
MeMeO
127  
A magnetically stirred solution of selenide 142 (360 mg, 0.84 mmol) in dry dichloromethane  
(11 mL) maintained under a nitrogen atmosphere was cooled to –78 °C then treated, dropwise, 
with a solution of m-CPBA (210 mg of ca. 77% material, 0.93 mmol) in dichloromethane (11 
mL). After 0.25 h the reaction mixture was allowed to warm to 18 °C in the presence of 
atmospheric oxygen. At the end of this period it was treated with dimethylamine (0.35 mL, 3.37 
mmol) and after a further 3 h with NaHCO3 (10 mL of a saturated aqueous solution) then 
diluted with ethyl acetate (1 ( 15 mL). The separated aqueous phase was extracted with ethyl 
acetate (3 ( 10 mL) and the combined organic phases were then washed with brine (1 ( 20 mL) 
before being dried (MgSO4), filtered and concentrated under reduced pressure to give a dark-
brown oil. Subjection of this material to flash chromatography (silica, 3:7:0.1 ' 3:2:0.1 v/v/v 
ethyl acetate/hexane/isopropanol gradient elution) and concentration of the relevant fractions (Rf 
= 0.25 in 2:3 v/v ethyl acetate/hexane) gave the title compound 127 (190 mg, 93%) as a white, 
crystalline solid, m.p. = 92–93 °C. 
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1H NMR (CDCl3, 300 MHz) $ 5.81 (m, 1H), 5.13-5.03 (complex m, 2H), 4.93 (d, J = 6.8 Hz, 
1H), 4.45 (q, J = 6.8 Hz, 1H), 3.71 (s, 3H), 3.18 (s, 3H), 2.23 (m, 2H), 1.62 (s, 3H), 1.39 (s, 
3H). 
13C NMR (CDCl3, 75 MHz) $ 169.9, 134.1, 117.2, 109.9, 77.0, 75.4, 61.2, 35.3, 32.2, 27.3, 
25.6. 
IR %max(KBr) 2988, 2941, 1662, 1463, 1431, 1376, 1363, 1254, 1219, 1166, 1096, 1068, 996, 
981, 922, 897, 736 cm-1. 
Mass Spectrum (ESI, +ve) m/z 252 [(M + Na)+, 100%], 172 (11). 
HRESIMS Found: (M + Na)+, 252.1208. C11H19NO4 requires (M + Na)+, 252.1212. 
Specific Rotation: ["]D = – 97.8 (c 0.28, CHCl3). 
This compound has been subjected to a single-crystal X-ray analysis. Details are presented in 
Appendix A3. 
(R)-(–)-4-Penten-2-yl acetate [(R)-143] 
HO
CALB, vinyl
acetate,
30 °C, 1 h
(±)-25 (R)-143
AcO
 
Following a procedure reported by Banwell and Loong,7,8 a slurry of 4-penten-2-ol [(±)-25] (2 
g, 23.0 mmol) and vinyl acetate (2.71 mL, 0.87 mmol) was treated with CALB (200 mg of 10% 
w/w material, ex. Norvo Nordisk) then agitated vigorously at 30 °C (water bath) for 1 h. The 
cooled slurry was filtered through a glass frit to remove immobilised enzyme particles which 
were washed with diethyl ether (2 ( 20 mL). The combined filtrates were concentrated under 
reduced pressure (200 mbar) at 0 °C to provide a yellow oil. Subjection of this material to flash 
chromatography (silica, 1:9 ' 3:7 v/v diethyl ether/pentane gradient elution) and concentration 
of the relevant fractions (Rf = 0.8 in 1:9 v/v diethyl ether/pentane) under reduced pressure (200 
mbar) at 0 °C gave the title compound (R)-143 as an ethereal solution.7,8 This material was 
identical, in all aspects, with an authentic sample and used immediately in the next reaction. 
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(R)-(–)-4-Penten-2-ol [(R)-25] 
CALB, phosphate 
buffer (pH = 7.3),
30 °C, 12 h
(R)-143
AcO
(R)-25
HO
 
Following a procedure reported by Banwell and Loong,7,8 a slurry of CALB (3.0 g of 10% w/w 
material, ex. Norvo Nordisk) and acetate (R)-143 (29.78 g, 0.25 mol, 55% ee) in phosphate 
buffer (87.44 mL, pH = 7.3) maintained at 30 °C (water bath) was agitated for 12 h then cooled 
to 18 °C and filtered through a pad of Celite™. The filter cake was washed with diethyl ether (5 
( 15 mL) and the separated aqueous layer associated with the filtrate was extracted with diethyl 
ether (10 ( 30 mL). The combined organic fractions were then washed with NaHCO3 (2 ( 100 
mL of a saturated aqueous solution) and brine (1 ( 200 mL) before being dried (MgSO4), 
filtered and concentrated under reduced pressure (200 mbar) at 0 °C to give a yellow solution. 
Subjection of this material to flash column chromatography (1:3 v/v diethyl ether/pentane 
elution) and concentration of the relevant fractions (Rf = 0.3 in 1:9 v/v diethyl ether/pentane) 
under reduced pressure (200 mbar) at 0 °C afforded a liquid that was carefully distilled at 120 
°C (1 atm) to give the alcohol (R)-257,8 (5.75 g, 28% from alcohol (±)-25) b.p. = 114–116 (lit.9 
b.p. = 115 °C). GLC analysis of the derived acetate established it was of 99% ee. This material 
was identical, in all aspects, with an authentic sample.7,8 
(4S,5S)-5-((E)-3-(2-Formyl-3,5-dimethoxyphenyl)allyl)-N-methoxy-N,2,2-trimethyl-1,3-
dioxolane-4-carboxamide (129) 
OMe
MeO I
O
H +
Pd(OAc)2, TBAB, K2CO3
DMF:H2O v/v 10:1,
80 °C, 19 h
133
N
O
MeO
O O
Me
127
N
O
MeO
O
O
Me
OMe
MeO
H
O
129  
A magnetically stirred solution of aryl iodide 133 (39 mg, 0.13 mmol) and alkene 127 (30 mg, 
0.13 mmol) in DMF/water (2 mL of 10:1 v/v mixture) maintained at 18 °C was treated with 
tetra-n-butylammonium bromide (42 mg, 0.13 mmol) and potassium carbonate (45 mg, 0.065 
mmol). The ensuing mixture was evacuated then back-filled with argon three times before being 
treated with palladium acetate (9 mg, 0.03 mmol) in three portions over 0.5 h. The resulting 
mixture was heated at 80 °C for 19 h then cooled and filtered through a pad of Celite™ that was 
washed with ethyl acetate (2 ( 20 mL). The combined filtrates were washed with HCl (1 ( 15 
mL of a 1 M aqueous solution) and the separated aqueous phases extracted with ethyl acetate (4 
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( 10 mL). The combined organic extracts were washed with brine (1 ( 20 mL) before being 
dried (MgSO4), filtered and concentrated under reduced pressure to give a brown oil. Subjection 
of this material to flash chromatography (silica, 3:7:0.1 ' 3:2:0.1 v/v/v ethyl 
acetate/hexane/isopropanol gradient elution) afforded two fractions, A and B. 
Concentration of fraction A (Rf = 0.25 in 2:3 v/v ethyl acetate/hexane) afforded the starting 
amide 127 (4.5 mg, 15% recovery) as a clear, colourless solid. This material was identical, in all 
aspects, with an authentic sample. 
Concentration of fraction B (Rf = 0.25 in 3:2 v/v ethyl acetate/hexane) afforded the title 
compound 129 (26 mg, 56% at 85% conversion) as a cloudy, yellow oil  
1H NMR (CDCl3, 300 MHz) $  10.45 (s, 1H), 7.41 (d, J = 16.0 Hz, 1H), 6.63 (d, J = 2.0 Hz, 
1H), 6.36 (d, J = 2.0 Hz, 1H), 6.20 (ddd, J = 16, 12.6 and 7.1 Hz, 1H), 4.98 (d, J = 7.0 Hz, 1H), 
4.53 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.72 (s, 3H), 3.19 (s, 3H), 2.44 (m, 2H), 1.66 (s, 3H), 
1.40 (s, 3H). 
13C NMR (CDCl3, 75 MHz) $  190.8, 170.3, 165.0, 164.8, 143.2, 131.3, 130.5, 116.1, 110.4,  
104.5, 97.2, 77.7, 75.7, 61.4, 56.1, 55.8, 34.6, 32.5, 27.5, 26.0. 
IR %max(KBr) 2981, 2938, 1677, 1595, 1567, 1459, 1429, 1410, 1379, 1339, 1285, 1238, 1205, 
1153, 1073, 987, 831, 731 cm-1. 
Mass Spectrum (ESI, +ve) m/z 416 [(M + Na)+, 100%], 336 (25), 229 (20). 
HRESIMS Found: (M + Na)+, 416.1685. C20H27NO7 requires (M + Na)+, 416.1685. 
Specific Rotation ["]D = – 72.5 (c 0.64, CHCl3). 
2,4-Dimethoxy-6-((E)-3-((4S,5S)-5-(methoxy(methyl)carbamoyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)prop-1-en-1-yl)benzoic acid (152) 
2-methyl-2-butene
NaClO2, NaH2PO4,
t-BuOH, THF, H2O,
18 °C, 0.5 h
N
O
MeO
O
O
Me
OMe
MeO
OH
O
152
N
O
MeO
O
O
Me
OMe
MeO
H
O
129  
A magnetically stirred solution of aldehyde 129 (80 mg, 0.22 mmol) in t-butanol (3 mL) 
maintained at 18 °C under a nitrogen atmosphere was treated with sodium dihydrogen 
phosphate (0.6 mL of a 2.5 M aqueous solution, 1.51 mmol) and 2-methyl-2-butene (2.2 mL of 
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a 2.0 M THF solution, 4.31 mmol). The ensuing mixture was then treated, dropwise, with 
sodium chlorite (0.6 mL of a 3.5 M aqueous solution, 1.51 mmol) and a further 0.5 h after the 
completion of this addition the reaction mixture was diluted with phosphate buffer (20 mL of a 
1.0 M aqueous solution, pH = 4.0 M) and extracted with ethyl acetate (9 ( 10 mL). The 
combined organic phases were then washed with brine (1 ( 50 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure to give a light-yellow oil. Subjection 
of this material to flash chromatography (silica, 2:5:0.1 ' 7:3:0.1 v/v/v ethyl 
acetate/hexane/acetic acid gradient elution) and concentration of the relevant fractions (Rf = 
0.25 in 2:1:0.1 v/v/v ethyl acetate/hexane/acetic acid) afforded the title compound 152 (50 mg, 
75%) as a clear, colourless oil. 
1H NMR (CDCl3, 300 MHz) $ 6.89 (d, J = 16.0 Hz, 1H), 6.69 (d, J = 2.0 Hz, 1H), 6.38 (d, J = 
2.0 Hz, 1H), 6.16 (ddd, J = 16.0, 12.6 and 7.1 Hz, 1H), 4.96 (d, J = 7.0 Hz, 1H), 4.51 (m, 1H), 
3.87 (s, 3H), 3.84 (s, 3H), 3.69 (s, 3H), 3.19 (s, 3H), 2.40 (m, 2H), 1.63 (s, 3H), 1.38 (s, 3H) 
(signal due to carboxylic acid group proton not observed). 
13C NMR (CDCl3, 75 MHz) $ 169.9, 169.2, 162.0, 158.7, 140.8, 130.4, 129.1, 112.4, 110.0, 
103.6, 97.6, 77.2, 76.5, 75.3, 56.2, 55.4, 34.3, 32.2, 27.2, 25.6. 
IR %max(KBr) 2984, 2940, 1724, 1682, 1600, 1578, 1459, 1425, 1380, 1325, 1204, 1161, 1075, 
986, 732 cm-1. 
Mass Spectrum (ESI, –ve) m/z 442 (11%), [(M – H+)–, 408 (100)], 276 (3), 258 (3), 219 (32). 
HRESIMS Found: (M – H+)–, 408.1660. C20H27NO8 requires (M – H+)–, 408.1658. 
Specific Rotation ["]D = – 60.3 (c 0.27, CHCl3). 
2,4-Dimethoxy-6-(3-((4S,5S)-5-(methoxy(methyl)carbamoyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)propyl)benzoic acid (153) 
5% Pd on C
H2 (50 psi), EtOH,
18 °C, 48 h
N
O
MeO
O
O
Me
OMe
MeO
OH
O
152
N
O
MeO
O
O
Me
OMe
MeO
OH
O
153  
A solution of carboxylic acid 152 (100 mg, 0.24 mmol) in ethanol (5 mL) maintained at 18 °C 
in a Parr hydrogenator was treated with palladium on charcoal (10 mg of 10% w/w material). 
The reaction vessel was then evacuated and refilled with dihydrogen three times prior to the 
contents being shaken under a dihydrogen atmosphere (50 psi) at 18 °C for 48 h. The reaction 
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mixture was then filtered through a pad of Celite™ that was washed with ethanol (2 ( 10 mL). 
The combined filtrates were concentrated under reduced pressure to give a light-yellow oil that 
was subjected to flash chromatography (silica, 2:5:0.1 ' 7:3:0.1 v/v/v ethyl 
acetate/hexane/acetic acid gradient elution). Concentration of the relevant fractions (Rf = 0.25 in 
2:1:0.1 v/v/v ethyl acetate/hexane/acetic acid) gave the title acid 153 (100 mg, 97%) as a clear, 
colourless oil. 
1H NMR (CDCl3, 300 MHz) $  6.43 (d, J = 2.0 Hz, 1H), 6.37 (d, J = 2.0 Hz, 1H), 4.93 (d, J = 
7.0 Hz, 1H), 4.39 (m, 1H), 3.92 (s, 3H), 3.83 (s, 3H), 3.68 (s, 3H), 3.12 (s, 3H), 2.99 (m, 1H), 
2.80 (m, 1H), 1.75 (m, 3H), 1.53 (s, 3H), 1.50 (m, 2H), 1.37 (s, 3H). 
13C NMR (CDCl3, 75 MHz) $ 170.5, 170.2, 161.9, 158.8, 145.2, 114.0, 109.9, 107.1, 96.5, 77.6, 
75.5, 61.1, 56.2, 55.4, 34.1, 32.2, 30.1, 27.9, 27.2, 25.7. 
IR %max(KBr) 3174, 2982, 2940, 1725, 1682, 1603, 1460, 1380, 1328, 1204, 1160, 1091, 1073, 
987, 731 cm-1. 
Mass Spectrum (ESI, –ve) m/z 410 [(M – H+)–, 100%], 278 (11), 260 (13), 219 (12). 
HRESIMS Found: (M – H+)–, 410.1816. C20H29NO8 requires (M – H+)–, 410.1815. 
Specific Rotation ["]D = – 20.7 (c 0.44, CHCl3). 
(S)-Pent-4-en-2-yl 2,4-dimethoxy-6-(3-((4S,5S)-5-(methoxy(methyl)carbamoyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)propyl)benzoate (154) 
+
HO
(R)-25
Ph3P, DIAD, PhMe,
0 ! 18 °C, 2 h
N
O
MeO
O
O
Me
OMe
MeO
OH
O
153
N
O
MeO
O
O
Me
OMe
MeO
O
O
154  
A magnetically stirred solution of carboxylic acid 153 (50 mg, 0.1 mmol) in dry toluene (2 mL) 
maintained at 18 °C under a nitrogen atmosphere was treated with triphenylphosphine (50 mg, 
0.2 mmol) and (R)-(–)-4-penten-2-ol [(R)-25] (0.02 mL, 0.2 mmol) then cooled to 0 °C. After 
0.2 h the reaction mixture was treated, dropwise, with diisopropyl azodicarboxylate (0.04 mL, 
0.2 mmol) and then the reaction mixture was warmed to 18 °C. After a further 2 h the reaction 
mixture was concentrated under reduced pressure to give a yellow resin that was subjected to 
flash chromatography (silica, 3:7 ' 7:3 v/v ethyl acetate/hexane gradient elution). 
Concentration of the relevant fractions (Rf = 0.4 in 2:3 v/v ethyl acetate/hexane) then gave the 
title compound 154 (50 mg, 90%) as a clear, light-yellow oil. 
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1H NMR (CDCl3, 300 MHz) $ 6.31 (m, 2H), 5.83 (m, 1H), 5.23–5.05 (complex m, 3H), 4.91 (d, 
J = 7.0 Hz, 1H), 4.36 (m, 1H), 3.88 (s, 3H), 3.77 (s, 3H), 3.67 (s, 3H), 3.16 (s, 3H), 2.57 (t, J = 
7.0 Hz, 2H), 2.50–2.30 (complex m, 2H), 1.83 (m, 1H), 1.61 (s, 3H), 1.46 (m, 2H), 1.37 (s, 3H), 
1.32 (d, J = 7.0 Hz, 3H), 1.25 (m, 1H). 
13C NMR (CDCl3, 75 MHz) $ 170.4, 167.8, 161.2, 157.8, 141.8, 133.8, 117.6, 116.8, 109.8, 
105.6, 96.3, 77.5, 76.8, 75.6, 70.9, 55.8, 55.3, 40.2, 33.4, 32.2, 30.2, 27.8, 27.3, 25.7, 19.4. 
IR %max(KBr) 2979, 2938, 1720, 1687, 1604, 1586, 1459, 1379, 1341, 1262, 1204, 1160, 1099, 
1073, 991 cm-1. 
Mass Spectrum (ESI, +ve) m/z 502 [(M + Na)+, 100%], 394 (22), 336 (42). 
HRESIMS Found: (M + Na)+, 502.2417. C25H37NO8 requires (M + Na)+, 502.2417. 
Specific Rotation ["]D = – 32.0 (c 0.24, CHCl3). 
(3aS,8R,17aS,E)-11,13-Dimethoxy-2,2,8-trimethyl-7,8,15,16,17,17a-hexahydro-3aH-
benzo[c][1,3]dioxolo[4,5-h][1]oxacyclotetradecine-4,10-dione (156) 
1. CH2CHMgBr, THF
    –30 °C, 0.1 h
2. Grubbs' 2nd 
    Generation 
    Catalyst, CH2Cl2
    37 °C, 3 h
O
O
O
O
O
OMe
MeO
156
N
O
MeO
O
O
Me
OMe
MeO
O
O
154  
A magnetically stirred solution of amide 154 (40 mg, 0.075 mmol) in dry THF (0.8 mL) 
maintained under a nitrogen atmosphere was cooled to –30 °C and then treated, dropwise, with 
vinylmagnesium bromide (0.30 mL of a 1.0 M solution in THF, 0.3 mmol, ex Aldrich). After a 
further 0.1 h the reaction mixture was treated with acetic acid/water (5 mL a of 5:1 v/v mixture) 
then warmed to 18 °C, treated with NH4Cl (5 mL of a saturated aqueous solution) and extracted 
with diethyl ether (4 ( 10 mL). The combined organic phases were then dried (Na2SO4), filtered 
and concentrated under reduced pressure to afford a light-yellow oil presumed to contain the 
enone 132. This oil was dissolved in dry dichloromethane (37 mL) and the reaction vessel 
containing the resulting solution was evacuated then filled with nitrogen. This process was 
repeated twice more before Grubbs’ 2nd generation catalyst10 (4 mg, 0.001 mmol, ex Aldrich) 
was added and the ensuing mixture heated at reflux for 19 h. The cooled reaction mixture was 
concentrated under reduced pressure to give a light-brown oil that was subjected to flash 
chromatography (silica, 1:4:0.1 ' 1:1:0.1 v/v/v ethyl acetate/hexane/isopropanol gradient 
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elution). Concentration of the appropriate fractions (Rf  = 0.45 in 2:1 v/v ethyl acetate/hexane) 
then gave the title compound 156 (20 mg, 48% from 154) as a clear, colourless oil.  
1H NMR (CDCl3, 300 MHz) $ 6.95 (ddd, J = 15.8, 12.8 and 6.8 Hz, 1H), 6.64 (d, J = 15.8 Hz, 
1H), 6.29 (s, 2H), 5.43 (m, 1H), 4.73 (d, J = 4.6 Hz, 1H), 4.49 (m, 1H), 3.80 (s, 3H), 3.78 (s, 
3H), 2.63 (m, 1H), 2.60-–2.50 (complex m, 2H), 2.35 (m, 1H), 1.58 (m, 3H), 1.45 (s, 3H), 1.43 
(d, J = 6.0 Hz, 3H), 1.34 (s, 3H), 1.25 (m, 1H). 
13C NMR (CDCl3, 75 MHz) $ 197.4, 168.1, 161.7, 158.4, 144.2, 143.0, 129.1, 116.6, 109.9, 
106.1, 96.8, 81.5, 77.7, 69.9, 56.0, 55.6, 39.9, 33.2, 30.6, 27.7, 26.9, 25.1, 21.0. 
IR %max(KBr) 2935, 1717, 1690, 1627, 1604, 1457, 1422, 1380, 1320, 1263, 1203, 1160, 1099 
cm-1. 
Mass Spectrum (ESI, +ve) m/z 441 [(M + Na)+, 98%], 307 (100). 
HRESIMS Found: (M + Na)+, 441.1878. C23H30O7 requires (M + Na)+, 441.1889. 
Specific Rotation ["]D = – 43.5 (c 0.14, CHCl3). 
L-783,290 (128) 
O
O
O
O
O
OMe
MeO
156
O
O
O
OH
HO
OH
MeO
128
BCl3, CH2Cl2,
–78 °C, 0.5 h
 
A magnetically stirred solution of macrolide 156 (30 mg, 0.06 mmol) in dry dichloromethane 
(6.2 mL) maintained under nitrogen was cooled to –78 °C then treated, dropwise, with boron 
trichloride (0.25 mL of a 1.0 M solution in dichloromethane, 0.25 mmol). After 0.5 h the 
reaction mixture was treated, dropwise, with isopropanol (5 mL) and phosphate buffer (5 mL of 
1M aqueous solution, pH = 6.0) before being slowly warmed to 18 °C then diluted with 
dichloromethane (10 mL). The separated aqueous phase was extracted with dichloromethane 
(10 ( 5 mL) and the combined organic phases were then dried (MgSO4), filtered and 
concentrated under reduced pressure to yield a light-yellow solid that was subjected to semi-
preparative HPLC (22 ( 250 mm 5 µm C18 Alltima column, 0.1:100:150 v/v/v acetic 
acid/water/methanol as eluent, flow rate of 11.5 mL/min). Concentration of the relevant 
fractions (Rt = 22.57 min) then gave the title compound 12811 (16 mg, 60%) as a white, 
crystalline solid, m.p. = 127.5–136.5 °C. 
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1H NMR (CD2Cl2, 800 MHz) $ 11.83 (s, 1H), 7.00 (dt, J = 15.9 and 8.0 Hz, 1H), 6.40 (d, J = 
15.9 Hz, 1H), 6.33 (d, J = 5.3 Hz, 2H), 5.57 (m, 1H), 4.68 (s, 1H), 3.96 (s, 1H), 3.80 (s, 3H), 
3.06 (t, J = 12.8 Hz, 1H), 2.84 (broad s, 1H), 2.54 (m, 2H), 1.71 (broad s, 2H), 1.62 (s, 1H), 
1.45 (d, J = 6.1 Hz, 3H), 1.30 (m, 1H) (signals due to two protons not observed). 
13C NMR (CD2Cl2, 200 MHz) $ 199.3, 171.4, 166.3, 164.7, 147.7, 143.8, 131.5, 109.5, 104.9, 
99.3, 77.4, 73.3, 71.3, 55.7, 38.0, 36.2, 32.8, 26.9, 19.2. 
IR %max(KBr) 3347, 2938, 1695, 1642, 1615, 1353, 1316, 1250, 1202, 1161, 1131, 1111, 1089, 
1045, 995 cm-1. 
Mass Spectrum (EI, 70 eV) m/z 364 (M+•, 17%), 221 (80), 202 (43), 193 (58), 192 (100), 177 
(48), 164 (75). 
HRESIMS Found: M+•, 364.1532. C19H24O7 requires M+•, 364.1522. 
Specific Rotation: ["]D = + 9.7 (c 0.23, CHCl3). 
This compound has been subjected to a single-crystal X-ray analysis. Details are presented in 
Appendix A4. 
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6.3 Experimental Procedures Associated with Work Described in Chapter 
Three 
(R)-(–)-4-Pentyn-2-yl acetate [(R)-167] 
HO
CALB, vinyl acetate,
30 °C, 1 h AcO
(±)-166 (R)-167 !
A modification of a procedure reported by Banwell and Loong was used.7,8 Thus, a slurry of 4-
pentyn-2-ol [(±)-166] (2 g, 26.75 mmol) and CALB (0.2 g of 10% w/w material, ex. Norvo 
Nordisk) in vinyl acetate (2.4 mL, 23.11 mmol) was vigorously agitated at 30 °C (water bath) 
for 1 h. The cooled reaction mixture was filtered through a pad of Celite™ and the immobilised 
enzyme particles thus retained were washed with diethyl ether (3 ( 20 mL). The combined 
filtrates were concentrated under reduced pressure (200 mbar) at 0 °C to provide a yellow oil. 
Subjection of this material to flash chromatography (silica, 1:9 ' 3:7 v/v diethyl ether/pentane 
gradient elution) and concentration of the relevant fraction (Rf = 0.25 in 1:9 v/v diethyl 
ether/pentane) under reduced pressure (200 mbar) at 0 °C gave a light-yellow oil. Distillation (1 
atm) of this material then gave the title compound (R)-16712 (0.96 g, 60%) as a clear, colourless 
oil, b.p. 110–115 °C (1 atm). GLC analysis of the derived acetate established that this was of 
89% ee. This material was identical, in all aspects, with an authentic sample.12 
R-(–)-4-Pentyn-2-ol [(R)-166] 
30 °C, 12 h
CALB, phosphate
buffer (pH = 7.3),
AcO
(R)-167
HO
(R)-166 !
A modification of a procedure reported by Banwell and Loong was used.7,8 Thus, a slurry of 
CALB (703 mg) and (R)-167 acetate (5.9 g, 0.14 mmol, 89% ee) in phosphate buffer (15 mL of 
a 0.5 M aqueous solution, pH = 7.3) maintained at 30 °C (water bath) was vigorously agitated 
for 12 h then cooled to 18 °C and filtered through a pad of Celite™. The filter cake was washed 
with diethyl ether (5 ( 5 mL) and the separated aqueous layer associated with the filtrate was 
extracted with diethyl ether (10 ( 30 mL). The combined organic fractions were washed with 
NaHCO3 (2 ( 100 mL of a saturated aqueous solution) and brine (1 ( 200 mL) before being 
dried (MgSO4), filtered and concentrated under reduced pressure (200 mbar) at 0 °C to give a 
yellow oil. Subjection of this material to flash column chromatography (1:3 v/v diethyl 
ether/pentane elution) and concentration of the relevant fractions (Rf = 0.3 in 1:9 v/v diethyl 
ether/pentane) under reduced pressure (200 mmbar) at 0 °C afforded a light-yellow oil. 
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Distillation of this material (1 atm) then gave the title compound [(R)-166]13,14 (3.81 g, 60%), as 
clear, colourless oil, b.p 127–128 °C (1 atm) (lit.14 b.p. = 126 °C). GLC analysis of the derived 
acetate established it was of 98.9% ee. This material was identical, in all aspects, with an 
authentic sample.12,14 
1H NMR (CDCl3, 300 MHz) $ 3.97 (m, 1H), 2.45–2.28 (complex m, 2H), 2.08–2.05 (complex 
m, 1H), 1.93 (s, 1H), 1.27 (d, J = 6.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) $ 80.8, 70.7, 66.1, 28.9, 22.2. 
IR %max(KBr) 3921, 3299, 2973, 2932, 2914, 2590, 2119, 1718, 1640, 1458, 1421, 1377, 1350, 
1311, 1267, 1216, 1116, 1087, 1067, 958, 936, 913, 886, 829, 793 cm-1. 
Mass Spectrum (EI, 70 eV) m/z 84 (M+•, <1%), 69 (11), 45 (100), 39 (36). 
HRESIMS Found: M+•, 84.0570. C5H8O requires M+•, 84.0575. 
Specific Rotation: ["]D = – 16.3 (0.46, CHCl3) {lit.14 ["]D = – 17.7 (0.13, CHCl3)}. 
(S)-Pent-4-yn-2-yl 2,4-dimethoxy-6-(3-((4S,5S)-5-(methoxy(methyl)carbamoyl)-2,2- 
dimethyl-1,3-dioxolan-4-yl)propyl)benzoate (165) 
+
Ph3P, DIAD, PhMe,
0 ! 18 °C, 1 h
OMe
MeO
O
OH
O
N OMeO
O
153
HO
OMe
MeO
O
O
O
N OMeO
O
165(R)-166  
A magnetically stirred solution of carboxylic acid 153 (200 mg, 0.48 mmol) in dry toluene (49 
mL) maintained at 18 °C under a nitrogen atmosphere was treated with triphenylphosphine (252 
mg, 0.96 mmol) and (R)-(–)-4-pentyn-2-ol [(R)-166] (0.02 mL, 0.2 mmol). The ensuing mixture 
was cooled to 0 °C and after 0.2 h the reaction mixture was treated, dropwise, with diisopropyl 
azodicarboxylate (0.19 mL, 0.96 mmol) then warmed to 18 °C. After 1 h the reaction mixture 
was concentrated under reduced pressure to give a yellow resin. Subjection of this material to 
flash chromatography (silica, 3:7 ' 7:3 v/v ethyl acetate/hexane gradient elution) and 
concentration of the relevant fractions (Rf = 0.4 in 2:3 v/v ethyl acetate/hexane) afforded the title 
compound 165 (162 mg, 70%) as a clear, light-yellow oil. 
1H NMR (CDCl3, 800 MHz): ! 6.32 (d, J = 2.2 Hz, 1H), 6.30 (d, J = 2.2 Hz, 1H), 5.25 (m, 1H), 
4.91 (d, J = 16.4 Hz, 1H), 4.36 (ddd, J = 9.6, 6.7 and 3.7 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 
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3.68 (s, 3H), 3.17 (s, 3H), 2.65–2.48 (complex m, 4H), 2.04 (t, J = 2.7 Hz, 1H), 1.85 (m, 1H), 
1.64 (m, 1H), 1.61 (s, 3H), 1.43 (d, J = 6.2 Hz, 3H), 1.40–1.50 (complex m, 2H), 1.37 (s, 3H). 
13C NMR (CDCl3, 100 MHz): ! 170.4, 167.5, 161.3, 158.0, 142.0, 116.4, 109.8, 105.7, 96.3, 
79.9, 77.4, 75.6, 70.7, 69.3, 61.1, 55.8, 55.3, 33.4, 32.2, 30.3, 27.8, 27.2, 25.6, 25.5, 19.0. 
IR %max(KBr) 2979, 2938, 1720, 1687, 1604, 1586, 1459, 1379, 1341, 1262, 1204, 1160, 1099, 
1073, 991 cm-1. 
Mass Spectrum (ESI, +ve), m/z 500 [(M + Na)+, 58%], 497 (13), 478 [(M + H)+, 9%], 394 (62), 
376 (11), 336 (100). 
HRESIMS Found: (M + H)+, 478.2446. C25H35NO7 requires (M + H)+, 478.2441. 
  Found: (M + Na)+, 500.2262. C25H35NO7 requires (M + Na)+, 500.2260. 
Specific Rotation: ["]D = – 20.2 (c 0.4, CDCl3). 
(3aS,8S,17aS)-11,13-Dimethoxy-2,2,8-trimethyl-5,6-didehydro-7,8,15,16,17,17a-hexahydro-
3aH-benzo[c][1,3]dioxolo[4,5-h][1]oxacyclotetradecine-4,10-dione (164) 
OMe
MeO
O
O
O
N OMeO
O
165
LiHMDS, THF,
–35 ! 18 °C, 0.25 h
OMe
MeO
O
O
O
O O
164  
A magnetically stirred solution of lithium bis(trimethylsilyl)amide (1.63 mL of a 1.0 M solution 
in THF, 1.63 mmol) in dry THF (2.17 mL) maintained at –35 °C under a nitrogen atmosphere 
was treated, dropwise, with a solution of ester 165 (27 mg, 0.06 mmol) in dry THF (33 mL). 
After completion of the addition the reaction mixture was warmed to and then maintained at 18 
°C for 0.25 h. At the end of this period it was treated with acetic acid/water (2 mL of 5:1 v/v 
mixture), phosphate buffer (1 ( 100 mL of a 1 M aqueous solution, pH = 6.0) and extracted 
with diethyl ether (3 ( 50 mL). The combined organic extracts were washed with water (3 ( 100 
mL) and brine (2 ( 100 mL) before being dried (Na2SO4), filtered and concentrated under 
pressure at 18 °C to give a light-yellow oil. Subjection of this material to flash chromatography 
(silica, 1:1 ' 3:1 v/v diethyl ether/pentane gradient elution) and concentration of the relevant 
fractions (Rf = 0.8 in 0.9:1:0.1 v/v/v ethyl acetate/hexane/acetic acid) afforded the title 
compound 164 (9 mg, 45%) as a white, crystalline solid, m.p. = 125.6–132.1 °C. 
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1H NMR (CDCl3, 800 MHz): ! 6.33 (s, 2H), 5.30 (m, 1H), 4.68 (d, J = 6.4 Hz, 1H), 4.31 (m, 
1H), 3.82 (s, 3H), 3.80 (s, 3H), 2.82 (dd, J = 17.4 and 3.3 Hz, 1H), 2.74–2.70 (complex m, 1H), 
2.71 (dd, J = 17.4 and 3.3 Hz, 2 H), 2.64 (m, 1H), 1.81-1.78 (complex m, 3H), 1.57 (s, 3H), 
1.48 (d, J = 6.2 Hz, 3H), 1.36 (s, 3H). 
13C NMR (CDCl3, 75 MHz) ! 184.7, 167.0, 161.7, 158.6, 142.7, 115.7, 110.0, 106.1, 96.7, 93.4, 
83.2, 81.5, 78.6, 69.2, 55.9, 55.4, 33.8, 29.7, 28.8, 26.8, 26.4, 25.7, 19.5 
IR %max(KBr) 2260, 2925, 2853, 2215, 1721, 1683, 1604, 1586, 1458, 1422, 1380, 1370, 1341, 
13419, 1260, 1223, 1203, 1160, 1095, 1044, 831, 733 
Mass Spectrum (ESI, +ve), m/z 440 [(M + Na)+, 100%], 418 [(M + H)+, 44%], 359 (31), 341 
(13), 315 (6), 235 (14), 207 (7), 177 (8), 85 (25). 
HRESIMS Found: (M + H)+, 417.1913. C23H28O7 requires (M + H)+, 417.1914. 
  Found: (M + Na)+, 439.1732. C23H28O7 requires (M + Na)+, 439.1733. 
Specific Rotation: ["]D = + 103.6 (c 0.05, CHCl3). 
This compound has been subjected to a single-crystal X-ray analysis. Details are presented in 
Appendix A5. 
(3S,8S,9S)-8,9,16-Trihydroxy-14-methoxy-3-methyl-3,4,5,6,9,10,11,12-octahydro-1H-
benzo[c][1]oxacyclotetradecine-1,7(8H)-dione (168) 
164
OMe
MeO
O
O
O
O O
O
OH
MeO
O
O
HO
OH
2. H2 (1 atm.), pyr.,
    Pb-poisoned 
    5% Pd on CaCO3
    PhMe, 18 °C, 6 h
1. BCl3, CH2Cl2
    –78 °C, 0.25 h
168  
A magnetically stirred solution of macrolactone 164 (8 mg, 0.014 mmol) in dry 
dichloromethane (2 mL) maintained at –78 °C under nitrogen atmosphere was treated, 
dropwise, with boron trichloride (0.07 mL of a 1.0 M solution in dichloromethane, 0.07 mmol). 
After 0.5 h the reaction mixture was treated, dropwise, with isopropanol (2 mL) and phosphate 
buffer (10 mL of a 1 M aqueous solution, pH = 6.0) before being warmed to 18 °C. The 
separated aqueous was extracted with dichloromethane (3 ( 5 mL) and the combined organic 
phases were then dried (Na2SO4), filtered and concentrated under reduced pressure at 18 °C to 
afford a pale-yellow solid that was presumed to be the deprotected material. This solid was 
dissolved in dry toluene (2.5 mL) and the resulting solution treated with freshly distilled 
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pyridine (0.02 mL, 0.22 mmol) and 5% palladium on calcium carbonate; poisoned with lead (1 
mg of 10% w/w material, ex. Aldrich). The resulting black slurry was evacuated and refilled 
with dihydrogen three times prior to the contents being stirred under a hydrogen atmosphere (1 
atm) at 18 °C for 10 h. The reaction was then filtered through a pad of Celite™ that was washed 
with acetonitrile (2 ( 5 mL). The combined filtrates were concentrated under reduced pressure 
at 18 °C to give a light-yellow solid that was subjected to flash chromatography (silica, 
6.9:3:0.1 v/v/v ethyl acetate/hexane/isopropanol). Concentration of the relevant fractions (Rf = 
0.2 in 1:1 v/v ethyl acetate/hexane) gave the title compound 168 (4 mg, 60%) as a white 
crystalline, solid, m.p. = 113–133.0 °C. 
1H NMR (CD2Cl2, 800 MHz) ! 12.20 (s, 1H), 6.35 (d, J = 2.7 Hz, 1H), 6.32 (d, J = 2.7 Hz, 1H), 
5.22–5.18 (complex m, 1H), 4.39 (dd, J = 5.1 and 2.5 Hz, 1H), 3.97 (s, 1H), 3.82 (s, 2H), 3.62 
(d, J = 5.3 Hz, 1H), 3.21 (td, J = 12.3 and 3.0 Hz, 1H), 2.87 (m, 1H), 2.53 (td, J = 12.4 and 6.3 
Hz, 1H), 2.36–2.33 (complex m, 1H), 1.86–1.77 (complex m, 3H), 1.76–1.71 (complex m, 5H), 
1.37 (d, J = 6.2 Hz, 3H), 1.15 (ddt, J = 14.9, 11.3 and 3.9 Hz, 1H). 
13C NMR (CD2Cl2, 75 MHz ) ! 210.2, 172.3, 167.1, 164.7, 148.2, 128.9, 110.6, 99.7, 80.8, 74.0, 
73.6, 55.9, 39.8, 37.6, 35.2, 34.1, 30.8, 22.0, 21.2. 
IR  %max(KBr) 3346, 2927, 2852, 1699, 1644, 1611, 1576, 1462, 1381, 1353, 1313, 1254, 1205, 
1160, 1117, 1054, 976, 956, 872, 809, 738, 710 cm-1. 
Mass Spectrum (ESI, +ve), m/z 389 [(M+Na)+, 100%], 331 (9), 301 (6), 287 (7), 279 (6), 235 
(9), 221 (13), 193 (9), 177 (17), 149 (11). 
Specific Rotation: ["]D = + 103.6 (c 0.05, CHCl3). 
L-783,277 (1) and L-783,290 (128) 
OMe
MeO
O
O
O
O O
OH
MeO
O
O
HO
OH
O
O
O
O
OH
OH
MeO
HO
+
1. H2 (1 atm), pyr.,
    Pb-poisoned
    5% Pd on CaCO3,
    PhMe, 18 °C, 2 h
2. BCl3, CH2Cl2,
    –78 °C, 0.5 h
164
L-783.277
(1)
L-783.290
(128)  
A magnetically stirred solution of macrolactone 164 (9 mg, 0.06 mmol) in dry toluene (6 mL) 
maintained at 18 °C was treated with pyridine (0.03 mL, 0.35 mmol) and 5% palladium on 
calcium carbonate, poisoned with lead (1 mg of 10% w/w material, ex. Aldrich). The ensuing 
black slurry was evacuated and refilled with dihydrogen three times prior to the contents being 
stirred under a hydrogen atmosphere (1 atm) at 18 °C for 2 h. The reaction mixture was filtered 
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through a pad of Celite™ that was then washed with acetonitrile (2 ( 10 mL). The combined 
filtrates were concentrated under reduced pressure at 18 °C to give a light-yellow oil presumed 
to contain the cis-configured enone 167. This oil was dissolved in dry dichloromethane (6 mL) 
and the reaction vessel containing the resulting solution was cooled to –78 °C under nitrogen 
atmosphere and treated, dropwise, with boron trichloride (0.24 mL of a 1.0 M solution in 
dichloromethane, 0.24 mmol). After a further 0.5 h the reaction mixture was treated, dropwise, 
with isopropanol (5 mL) and phosphate buffer (20 mL of a 1.0 M aqueous solution, pH = 6.0) 
before being warmed to 18 °C. The separated aqueous was extracted with dichloromethane (3 ( 
10 mL) and the combined organic phases were dried (Na2SO4), filtered and concentrated under 
reduced pressure to afford a light-yellow solid that was subjected to preparative HPLC (22 x 
250 mm 5 µm C18 Alltima column, 0.05:65:35 v/v/v acetic acid/water/acetonitrile as eluent, 
flow rate of 11.5 mL/min) and thus affording two major fractions, A and B. 
Fraction A (Rt = 29.95 min) had the same retention time as an authentic sample of L-783,290 
(12811) and was, therefore, presumed to be this compound.  
Concentration of fraction B (Rt = 38.50 min) followed by freeze-drying afforded L-783,277 
(111) (6 mg, 40% over 2 steps) as an off-white solid, m.p. = 110.1–133.1 °C. 
1H NMR (CD2Cl2, 800 MHz) ! 12.21 (s, 1H), 6.46 (ddd, J = 11.2, 3.2 and 0.8 Hz, 1H), 6.39 (d, 
J = 2.4 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 6.32 (td, J = 11.2 and 2.4 Hz, 1H), 5.48 (m, 1H), 4.57 
(d, J = 2.4 Hz, 1H), 3.87 (m, 1H), 3.86 (s, 3H), 3.41 (m, 1H), 3.03 (m, 1H), 2.62 (dm, J = 17.6 
Hz, 1H), 2.55 (m, 1H), 1.79 (m, 1H), 1.59 (m, 2H), 1.49 (d, J = 5.6 Hz, 3H) (signals due to 
aliphatic hydroxyl groups not observed).  
13C NMR (CD2Cl2, 100 MHz) ! 200.4, 172.2, 167.0, 164.8, 148.0, 146.7, 126.7, 109.7, 104.9, 
99.4, 81.6, 74.0, 73.6, 55.9, 37.6, 37.0, 33.5, 29.4, 21.2.  
IR %max(KBr) 3315, 2921, 2850, 1727, 1683, 1648, 1615, 1568, 1461, 1420, 1379, 1350, 1313, 
1291, 1252, 1220, 1203, 1053, 1038, 1016, 902, 870, 838, 795, 748, 712 cm-1. 
Mass Spectrum (ESI, +ve), m/z 387 [(M + Na)+, 38%], 369 (13), 301 (6), 221 (5), 149 (10), 79 
(100).  
HRESIMS Found: (M + Na)+, 387.1418. C19H24O7 requires (M + Na)+, 387.1418. 
Specific Rotation ["]D = + 103.6 (c 0.05, CHCl3). 
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6.4 Experimental Procedures Associated with Work Described in Chapter Four 
(1R,6S)-2-Chloro-6-hydroxycyclohex-2-en-1-yl 4-nitrobenzoate (178) 
OH
OH
Cl
OH
OC(O)C6H4NO2
Cl
p-nitrobenzoic acid,
DIAD, PPh3, PhMe,
0 ! 18 °C, 19 h
136 178  
Following a procedure reported by Banwell and Loong,5 a magnetically stirred slurry of diol 
136 (2.64 g, 17.7 mmol) in dry toluene (250 mL) maintained under a nitrogen atmosphere at 0 
°C was treated with 4-nitrobenzoic acid (9.90 g, 53.24 mmol) and triphenylphosphine (6.98 g, 
26.62 mmol). After 0.2 h the reaction mixture was treated, dropwise, with diisopropyl 
azodicarboxylate (4.55 mL, 24.85 mmol) then warmed to 18 °C over 19 h and concentrated 
under reduced pressure to give a yellow paste. Subjection of this material to flash 
chromatography (silica, 1:9 ! 3:5 v/v ethyl acetate/hexane gradient elution) and concentration 
of the relevant fractions (Rf = 0.2 in 1:1 v/v ethyl acetate/hexane) gave the title compound 1785 
(4.13 g, 77%) as a yellow resin. This material was identical, in all aspects, with an authentic 
sample.5 
(1S,2R)-3-Chlorocyclohex-3-ene-1,2-diol (179) 
K2CO3, MeOH, OH
OH
Cl
OH
OC(O)C6H4NO2
Cl
18 °C, 19 h
178 179  
Following a procedure reported by Banwell and Loong,5 a magnetically stirred solution of 
nitrobenzoate 178 (4.12 g, 13.56 mmol) in methanol (215 mL) maintained at 18 °C was treated 
with potassium carbonate (7.49 g, 54.24 mmol). After 19 h the reaction mixture was treated 
with silica gel (8 g, type 60) and the mixture so-formed was concentrated under reduced 
pressure to give a free-flowing yellow powder. This powder was added to the top of a flash 
chromatography column (silica, 7:13 ! 4:1 v/v ethyl acetate/hexane gradient elution) and 
concentration of the relevant fractions (Rf = 0.3 in diethyl ether) afforded the title compound 
1795 (1.4 g, 68%) as a white, crystalline solid, m.p. = 69.7–71.4 °C (lit.5 m.p. = 71–71.5 °C). 
This material was identical, in all aspects, with an authentic sample.5 
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(2R,3R,4aS,8aR)-8-Chloro-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,6,8a-
hexahydrobenzo[b][1,4]dioxine (180).  
OH
OH
Cl
CH(OMe)3, [CH3C(OMe2)]2,
CSA, MeOH, O
Cl
O
OMe
OMereflux, 19 h
179 180  
Following a procedure reported by Banwell and Loong,15 a magnetically stirred solution of 
trans-diol 179 (1.46 g, 9.85 mmol) in methanol (73 mL) maintained at 18 °C under a nitrogen 
atmosphere was treated with trimethyl orthoformate (4.3 mL, 39.38 mmol), [CH3C(OMe)2]2 
(2.11 g, 11.82 mmol) and (+)-camphorsulfonic acid (0.14 g, 0.59 mmol) then heated at reflux 
for 19 h. The cooled reaction mixture was quenched with NaHCO3 (1 " 200 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3 " 200 mL). The combined organic phases 
were washed with brine (1 " 200 mL) then dried (MgSO4), filtered and concentrated under 
reduced pressure to give a brown oil. Subjection of this material to flash chromatography (silica, 
0:100 ! 1:9 v/v ethyl acetate/hexane gradient elution) and concentration of the relevant 
fractions (Rf  = 0.4 in 1:9 v/v ethyl acetate/hexane) gave the title compound 18015 (2.19 g, 85%) 
as a white, crystalline solid, m.p. = 74.5–76.1 °C (lit.15 m.p. = 78–81 °C). This material was 
identical, in all aspects, with an authentic sample.15 
(2R,3S,5R,6R)-Methyl 3-(but-3-en-1-yl)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxane-2-
carboxylate (177) 
1. O3, pyridine, MeOH
    –78 °C, 0.2 h
2. DMS, 0 °C, 2 h
3. MePPh3Br, LiHMDS
    THF, 0 °C, 1h
O
Cl
O
OMe
OMe
180
O
O
MeO
OMe
177
MeO O
 
Following a procedure established by Banwell and Loong,15 a magnetically stirred solution of 
alkene 180 (1.2 g, 4.58 mmol) in methanol (200 mL) maintained at –78 °C was treated with 
pyridine (3.69 mL, 45.8 mmol) and then with a stream of ozone until a persistent blue colour 
was observed. After a further 0.4 h the excess ozone was removed with a stream of nitrogen and 
the resulting colourless solution was treated with dimethyl sulfide (6.8 mL, 91.6 mmol) and 
allowed to warm to 0 °C. After 2 h the reaction mixture was warmed to 18 °C then diluted with 
water (1 " 250 mL) and the separated aqueous layer was extracted with ethyl acetate (6 " 100 
mL). The combined organic extracts were washed with water (2 " 100 mL) and brine (1 " 200 
mL) before being dried (MgSO4), filtered and concentrated under reduced pressure to give 
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aldehyde 181 as an unstable, yellow oil. This material was used immediately in the next step of 
the reaction sequence. 
A magnetically stirred solution of methyltriphenylphosphonium bromide (2.4 g, 6.87 mmol) in 
dry THF (30 mL) maintained at 0 °C under a nitrogen atmosphere was treated with potassium 
bis(trimethylsilyl)amide (13.73 mL of a 0.5 M solution in toluene, 6.4 mmol). The resulting 
yellow mixture was allowed to warm to 18 °C over 0.5 h then re-cooled to 0 °C and treated, via 
cannula, with a solution of aldehyde 181 in THF (30 mL). After 19 h the reaction mixture was 
treated with NH4Cl (1 " 150 mL of a saturated aqueous solution) and the separated aqueous 
phase was extracted with ethyl acetate (3 " 50 mL). The combined organic phases were washed 
with water (2 " 100 mL) and brine (1 " 100 mL) before being dried (MgSO4), filtered and 
concentrated under reduced pressure to give a yellow oil. Subjection of this material to flash 
chromatography (silica, 1:20 ! 1:9 v/v ethyl acetate/hexane gradient elution) and concentration 
of the relevant fractions (Rf = 0.5 in 1:3 v/v ethyl acetate/hexane) gave the title compound 17715 
(0.79 g, 60%) as a clear, light-yellow oil. This material was identical, in all aspects, with an 
authentic sample.15 
(2R,3S,5R,6R)-Methyl 3-((E)-4-(2-formyl-3,5-dimethoxyphenyl)but-3-en-1-yl)-5,6-
dimethoxy-5,6-dimethyl-1,4-dioxane-2-carboxylate (176) 
O
O
OMe
MeO I
O
H +
Pd(OAc)2, TBAB,
K2CO3, 10:1 - DMF: H2O,
OMe
MeO
80 °C, 16 h
OMe
MeO
O
H
O
O OMe
MeO
177133 176
MeO O
OMeO
 
A magnetically stirred solution of aryl iodide 133 (80 mg, 0.27 mmol) and alkene 177 (60 mg, 
0.021 mmol) in DMF/water (2 mL of 10:1 v/v mixture) maintained at 18 °C was treated with 
tetra-n-butylammonium bromide (74 mg, 0.23 mmol) and potassium carbonate (72 mg, 0.53 
mmol). The ensuing mixture was evacuated and filled with argon three times before being 
treated with palladium acetate (9 mg, 0.02 mmol) in three portions over 0.5 h and then heated to 
80 °C for 16 h. The reaction mixture was then cooled and filtered through a pad of Celite™ that 
was washed with ethyl acetate (3 ! 20 mL). The combined filtrates were washed with HCl (1 " 
15 mL of a 1 M aqueous solution) and the separated aqueous phase extracted with ethyl acetate 
(4 ! 10 mL). The combined organic extracts were washed with brine (1 ! 20 mL) before being 
dried (MgSO4), filtered and concentrated under reduced pressure to give a brown oil. Subjection 
of this material to flash chromatography (silica, 3:7:0.1 ! 3:2:0.1 v/v/v ethyl 
acetate/hexane/isopropanol gradient elution) and concentration of the relevant fractions (Rf = 
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0.25 in 1:3 v/v ethyl acetate/hexane) afforded the title compound 176 (76 mg, 81%) as a light-
yellow oil. 
1H NMR (CDCl3, 300 MHz) " 10.45 (s, 1H), 7.36 (dd, J = 15.7 and 1.2 Hz, 1H), 6.56 (d, J = 
2.3 Hz, 1H), 6.35 (d, J = 2.3 Hz, 1H), 6.10 (ddd, J = 15.7, 12.6 and 7.1 Hz, 1H), 4.19 (d, J = 9.9 
Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.78 (s, 3H), 3.73 (t, J = 3.5 Hz, 1H), 3.30 (s, 3H), 3.26 (s, 
3H), 2.64–2.52 (complex m, 1H), 2.36–2.28 (complex m, 1H), 1.71–1.64 (complex m, 2H), 
1.35 (s, 3H), 1.31 (s, 3H). 
13C NMR (CDCl3, 75 MHz) # 190.4, 169.3, 164.7, 143.2, 134.1, 129.3,115.7, 104.0, 98.9, 98.6,  
96.7, 72.7, 67.9, 55.8, 55.4, 52.3 (2 overlapping peaks), 48.3, 48.0, 30.1, 28.5, 17.7, 17.4 
IR $max(KBr) 3307, 2993, 2950, 2837, 2785, 2332, 1748, 1675, 1595, 1567, 1455, 1431, 1411, 
1378, 1327, 1304, 1281, 1235, 1205, 1151, 1142, 1119, 1091, 1051, 1037, 888, 872, 851, 827, 
808, 734, 693, 660 cm-1. 
Mass Spectrum (ESI, +ve) m/z 475 [(M + Na)+, 100%], 389 (53). 
HRESIMS Found: (M + Na)+, 475.1934. C23H32O9 requires (M + Na)+, 475.1944. 
Specific Rotation: [%]D = – 8.3 (c 0.09, CHCl3).  
2-((E)-4-((2S,3R,5R,6R)-5,6-Dimethoxy-3-(methoxycarbonyl)-5,6-dimethyl-1,4-dioxan-2-
yl)but-1-en-1-yl)-4,6-dimethoxybenzoic acid (182) 
OMe
MeO
O
H
O
O
NaClO4, NaH2PO4,
2-methyl-2-butene
t-BuOH, H2O,
18 °C, 0.25 h
OMe
MeO
O
OH
O
O
MeO
OMeOMe
MeO
176 182
OMeO OMeO
 
A magnetically stirred solution of aldehyde 176 (94 mg, 0.2 mmol) in t-butanol (10 mL) 
maintained at 18 °C under a nitrogen atmosphere was treated with sodium dihydrogen 
phosphate (1 mL of a 1.4 M aqueous solution, 1.4 mmol) and 2-methyl-2-butene (4 mL of a 2.0 
M THF solution, 4.00 mmol). The ensuing mixture was treated, dropwise, with sodium chlorite 
(1 mL of a 2.0 M aqueous solution, 2.0 mmol). After a further 0.25 h the reaction mixture was 
treated with phosphate buffer (20 mL of a 1.0 M aqueous solution, pH = 4.0) and extracted with 
ethyl acetate (9 ! 10 mL). The combined organic phases were then washed with brine (1 ! 50 
mL) before being dried (MgSO4), filtered and concentrated under reduced pressure to give a 
light-yellow oil. Subjection of this material to flash chromatography (silica, 2:5:0.1 ! 7:3:0.1 
v/v/v ethyl acetate/hexane/acetic acid gradient elution) and concentration of the relevant 
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fractions (Rf = 0.25 in 0.9:1:0.1 v/v/v ethyl acetate/hexane/acetic acid) afforded the title 
compound 182 (80 mg, 80%) as a cloudy, yellow oil. 
1H NMR (CDCl3, 400 MHz) # 9.36 (broad s, 1H), 6.58 (d, J = 1.4 Hz, 1H), 6.34 (d, J = 15.6 
Hz, 1H), 6.36 (d, J = 1.4 Hz, 1H), 6.10 (ddd, J = 15.6, 12.6 and 7.1 Hz, 1H), 3.91 (complex m, 
1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.75 (s, 3H), 3.27 (s, 3H), 3.23 (s, 3H), 2.82 (m, 1H), 2.45 (m, 
1H), 2.30 (m, 1H), 1.64 (m, 2H), 1.32 (s, 3H), 1.28 (s, 3H). 
13C NMR (CDCl3, 75 MHz) # 177.5, 169.8, 162.3, 158.8, 140.8, 133.6, 128.7, 103.5, 99.3, 99.0, 
97.8, 73.0, 68.2, 56.6, 55.8, 52.7, 48.6, 30.3 (2 overlapping peaks), 28.7, 18.0, 17.7.  
IR $max(KBr) 2950, 1748, 1675, 1595, 1567, 1455, 1431, 1378, 1327, 1281, 1205, 1151, 1119, 
1037, 888, 851 cm-1. 
Mass Spectrum (ESI, –ve) m/z 467 [(M – H+)–, 25%], 391 (4), 359 (100). 
HRESIMS Found: (M – H+)–, 467.1917. C23H31O10 requires (M – H+)–, 467.1917. 
Specific Rotation: [%]D = – 70.9 (c 0.02, CHCl3). 
2-((E)-4-((2S,5R,6R)-3-(Hydroxymethyl)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)but-
1-en-1-yl)-4,6-dimethoxybenzoic acid (184) 
OMe
MeO
O
OH
O
O
MeO
OMe
NaBH4, MeOH
THF,
80 °C, 19 h
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O
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182 184
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A magnetically stirred solution of methyl ester 182 (67.5 mg, 0.16 mmol) in dry THF (0.25 mL) 
maintained at 18 °C under nitrogen was treated with sodium borohydride (18 mg, 0.48 mmol), 
and methanol (0.1 mL, 2.88 mmol) and then heated at 80 °C for 19 h. The cooled reaction 
mixture was quenched with phosphate buffer (1 " 20 mL of a 1.0 M aqueous solution, pH = 4.0) 
and extracted with ethyl acetate (4 " 10 mL). The combined organic extracts were washed with 
brine (1 " 30 mL) before being dried (MgSO4), filtered and concentrated under reduced pressure 
to give a yellow oil. Subjection of this material to flash chromatography (silica, 2:5:0.1 ! 
7:3:0.1 v/v/v ethyl acetate/hexane/acetic acid gradient elution) and concentration of relevant 
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fractions (Rf = 0.6 in 0.9:1:0.1 v/v/v ethyl acetate/hexane/acetic acid) afforded the title 
compound 184** (64.1 mg, 90%) as a clear, colourless oil.  
1H NMR (CDCl3, 400 MHz) " 6.82 (d, J = 15.7 Hz, 1H), 6.50 (d, J = 2.3 Hz, 1H), 6.39 (d, J = 
2.3 Hz, 1H), 6.08 (ddd, J = 15.7, 6.0 and 7.0 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.71 (m, 2H), 
3.58 (m, 1H), 3.27 (s, 3H), 3.25 (s, 3H), 2.40 (m, 2H), 2.40 (broad s, 1H), 1.63 (m, 2H), 1.31 (s, 
3H), 1.31 (s, 3H) (signal due to carboxylic acid group proton not observed). 
13C NMR (CDCl3, 75 MHz) # 169.3, 161.8, 158.4, 140.8, 134.0, 129.0, 104.0, 98.9, 98.8, 97.6,  
72.4, 66.7, 62.1, 56.4, 55.6, 48.1, 48.1, 30.5, 29.8, 28.1, 17.9, 17.7. 
IR $max(KBr) 3185, 2995, 2952, 2838, 2639, 2086, 1901, 1736, 1600, 1580, 1457, 1438, 1378, 
1326, 1288, 1204, 1161, 1141, 1120, 1037, 965, 888, 851, 735, 701, 661, 626, 600, 573 cm-1. 
Mass Spectrum (ESI, –ve) m/z 439 [(M – H+)–, 100%]. 
HRESIMS Found: (M – H+)–, 439.1968. C22H31O9 requires (M – H+)–, 439.1968. 
(S)-Pent-4-en-2-yl 2-((E)-4-((2S,5R,6R)-3-(hydroxymethyl)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxan-2-yl)but-1-en-1-yl)-4,6-dimethoxybenzoate (185) 
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O
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O
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O
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+
HO
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A magnetically stirred solution of carboxylic acid 184 (5 mg, 0.02 mmol) in dry toluene (2.7 
mL) maintained at 18 °C under a nitrogen atmosphere was treated with triphenylphosphine (14 
mg, 0.05 mmol) and (R)-(–)-4-penten-2-ol [(R)-25] (0.03 mL, 0.27 mmol) then cooled to 0 °C. 
After 0.2 h the reaction mixture was treated, dropwise, with diisopropyl azodicarboxylate (0.01 
mL, 0.05 mmol) and after a further 0.25 h the reaction mixture was re-warmed to 18 °C. After 2 
h the reaction mixture was concentrated under reduced pressure to give a yellow resin. 
Subjection of this material to flash chromatography (silica, 1:4 ! 1:2 v/v ethyl acetate/hexane 
gradient elution) and concentration of the relevant fractions (Rf = 0.4 in 2:3 v/v ethyl 
acetate/hexane) gave the title compound 185 (7 mg, 70%) as a clear, light-yellow oil. 
 
** This material was contaminated with ca. 10% of the corresponding C6´ epimer. 
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1H NMR (CDCl3, 400 MHz) # 6.56 (d, J = 2.2 Hz, 1H), 6.42 (m, 1H), 6.34 (d, J = 2.2 Hz, 1H), 
6.18 (dt, J = 15.6 and 6.9 Hz, 1H), 5.84 (m, 1H), 5.22 (m, 1H), 5.11 (m, 2H), 3.81 (s, 3H), 3.78 
(s, 3H), 3.73 (m, 1H), 3.65-3.60 (complex m, 2H), 3.26 (s, 3H), 3.22 (s, 3H), 2.50-2.32 
(complex m, 3H), 2.25 (m, 1H), 2.09 (m, 1H), 1.69#1.47 (complex m, 2H), 1.32 (d, J = 10.0 Hz, 
3H), 1.31 (s, 3H), 1.31 (s, 3H) (signal due to hydroxyl group proton not observed).  
13C NMR (CDCl3, 75 MHz) # 167.7, 161.3, 158.1, 137.5, 143.0, 133.4, 127.2, 117.7, 116.2, 
101.4, 98.9, 98.8, 97.7, 72.4, 71.3, 67.0, 62.3, 56.0. 55.6, 48.1, 40.3, 30.3, 29.8, 28.8, 19.7, 17.9,
17.7. 
IR $max(KBr) 3413, 2925, 2851, 1720, 1641, 1601, 1579, 1457, 1374, 1346, 1228, 1262, 1233, 
1203, 1159, 1124, 1099, 1047, 964, 917, 873 cm-1. 
Mass Spectrum (ESI, +ve) m/z 531 [(M + Na)+, 100%]. 
HRESIMS Found: (M + Na)+, 531.2571. C27H40O9 requires (M + Na)+, 531.2570. 
Specific Rotation: [%]D = – 106.0 (c 0.05, CHCl3). 
(S)-Pent-4-en-2-yl 2-((E)-4-((2S,5R,6R)-5,6-dimethoxy-5,6-dimethyl-3-vinyl-1,4-dioxan-2-
yl)but-1-en-1-yl)-4,6-dimethoxybenzoate (175) 
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2. MePPh3Br, n-BuLi, THF,
    –78 ! 18 °C, 19 h
3. (R)-25, DIAD, PPh3,
    PhMe, 0 ! 18 °C, 0.5 h
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A magnetically stirred solution of methyl ester 182 (15 mg, 0.03 mmol) in dry dichloromethane 
(3 mL) maintained at –78 °C under a nitrogen atmosphere was treated dropwise with DIBAL-H 
(0.08 mL of a 1.0 M solution in hexane, 0.08 mmol). After an additional 0.03 h the reaction 
mixture was treated with methanol (0.4 mL) and HCl (1 mL of a 1.0 M aqueous solution) then 
allowed to warm to 18 °C. The separated aqueous phase was extracted with dichloromethane (3 
" 10 mL) and the combined organic fractions were washed with brine (2 " 10 mL) before being 
dried (Na2SO4), filtered and concentrated under reduced pressure to give the aldehyde 183 as an 
unstable yellow oil. This material was used immediately in the next step of the reaction 
sequence. 
A magnetically stirred solution of methyltriphenylphosphonium bromide (16 mg, 0.21 mmol) in 
dry diethyl ether (0.4 mL) maintained at 0 °C under nitrogen was treated with n-butyllithium 
(0.21 mL of a 1.0 M solution in hexane, 0.21 mmol). The resulting yellow mixture was allowed 
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to warm to 18 °C over 0.5 h then re-cooled to 0 °C and treated, via cannula, with a solution of 
aldehyde 183 in dry diethyl ether (0.6 mL) and the resulting mixture allowed to stir at 18 °C for 
19 h. The resulting suspension was treated with phosphate buffer (20 mL of a 1.0 M aqueous 
solution, pH = 4.0) then extracted with ethyl acetate (5 " 10 mL). The combined organic 
extracts were washed with brine (1 ! 20 mL) before being dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford a yellow, cloudy oil presumed to contain the 
olefin 187. This material was used immediately in the next step of the reaction sequence.  
A magnetically stirred solution of olefin 187, obtained as described above, in dry toluene (1 
mL) maintained at 0 °C under a nitrogen atmosphere was treated with triphenylphosphine (26 
mg, 0.1 mmol) and (R)-(–)-4-penten-2-ol [(R)-25] (0.04 mL, 0.4 mmol). After 0.25 h the 
ensuing mixture was treated, dropwise, with diisopropyl azodicarboxylate (0.02 mL, 0.4 mmol) 
and then the reaction mixture was warmed to 18 °C. After 2 h at this temperature the reaction 
mixture was concentrated under reduced pressure to give a yellow resin. Subjection of this 
material to flash chromatography (silica, 3:7 ! 7:3 v/v ethyl acetate/hexane gradient elution) 
and concentration of the relevant fractions (Rf = 0.4 in 2:3 v/v ethyl acetate/hexane) gave the 
title compound 175 (10 mg, ca. 25% from methyl ester 182) as a clear, light-yellow oil. 
1H NMR (CDCl3, 800 MHz) # 6.55 (t, J = 2.3 Hz, 1H), 6.40 (dt, J = 15.6 and 1.4 Hz, 1H), 6.34 
(d, J = 2.3 Hz, 1H), 6.17 (ddd, J = 15.6, 12.6 and 7.1 Hz, 1H), 5.83 (m, 1H), 5.76 (m, 2H), 5.36 
(m, 1H), 5.26 (m, 1H), 5.22 (m, 1H), 5.12 (m, 2H), 5.09-5.05 (complex m, 2H), 5.02 (dt, J = 
10.2 and 0.9 Hz, 1H), 3.94 (m, 1H), 3.80 (m, 3H), 3.76 (m, 3H), 3.58 (m, 1H), 3.27 (m, 3H), 
3.24 (m, 3H), 2.49-2.43 (complex m, 3H), 2.37–2.33 (complex m, 2H), 2.22 (m, 2H), 1.57 (m, 
3H), 1.33 (d, J = 6.3 Hz, 3H), 1.31 (s, 3H), 1.30 (s, 3H) (certain of these signals are due to the 
presence of unidentified impurities present in the same). 
13C NMR (CDCl3, 75 MHz) # 167.7, 161.3, 158.1, 137.5, 134.4, 134.0, 133.6, 127.0, 120.1, 
117.7, 101.4, 98.8, 97.6, 74.6, 71.2, 70.3 (2 overlapping peaks), 55.7, 55.5, 48.1 (2 overlapping 
peaks), 40.3, 30.3, 29.0 (2 overlapping peaks), 19.7, 17.9, 17.8.  
IR $max(KBr) 3883, 3747, 3359, 2923, 2852, 1724, 1644, 1600, 1579, 1458, 1375, 1325, 1261, 
1203 1158, 1120, 1049, 930, 875, 848, 800 cm-1. 
Mass Spectrum (ESI, +ve) m/z 528 [(M + Na)+, 100%]. 
HRESIMS Found: (M +Na)+, 527.2621. C28H40O8 requires (M + Na)+, 527.2621. 
Specific Rotation: [%]D = – 38.4 (c 0.05, CHCl3). 
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(2R,3R,4aS,5E,8S,15E,18aS)-2,3,11,13-Tetramethoxy-2,3,8-trimethyl-4a,7,8,17,18,18a-
hexahydro-2H-benzo[c][1,4]dioxino[2,3-i][1]oxacyclotetradecin-10(3H)-one (192) 
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O
O OMe
MeO
OMe
MeO
O
O
175 192
 
A magnetically stirred solution of triene 175 (10 mg, 0.02 mmol) in dry dichloromethane (13.2 
mL) maintained under a nitrogen atmosphere at 18 °C was evacuated then filled with nitrogen. 
This process was repeated twice more before Grubbs’ 2nd generation catalyst10 (2 mg, 0.002 
mmol) was added and the ensuing mixture was then heated at reflux for 12 h. The cooled 
reaction mixture was concentrated under reduced pressure to give a light-brown oil that was 
subjected to flash chromatography (silica, 1:4 ! 1:1 v/v ethyl acetate/hexane gradient elution). 
Concentration of the appropriate fractions (Rf  = 0.45 in 2:1 v/v ethyl acetate/hexane) then gave 
the title compound 192 (6 mg, ca. 25%) as a clear, colourless oil.  
1H NMR (CDCl3, 400 MHz) # 6.57 (d, J = 2.2 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 5.99 (m, 1H), 
5.68 (m, 1H), 5.64–5.72 (complex m, 1H), 4.93–5.09 (complex m, 2H), 3.93 (m, 1H), 3.81 (s, 
3H), 3.80 (s, 3H), 3.75 (complex m, 1H), 3.27 (s, 3H), 3.18 (s, 3H) (due the presence of 
aliphatic impurities the resonances appearing below # 2.00 could not be assigned). 
Mass Spectrum (ESI, +ve) m/z 499 [(M + Na)+, 100%], 446 (11), 327 (14), 313 (76), 309 (14), 
227 (14), 193 (43), 121 (13), 102 (13), 77 (49). 
HRESIMS Found: (M +Na)+, 499.2307. C26H36O8 requires (M + Na)+, 499.2308. 
No other spectral data could be obtained on this material because of significants amounts of 
contamination by aliphatic impurities. 
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7 Appendix A1 
 
 
X-ray Crystal Structure Report for Compound 140 
A full X-ray crystallographic report for compound 140 (as compiled by Anthony C. Willis of 
the Australian National University) is provided in PDF-format on the compact disc found on the 
inside back cover of this thesis. 
X-ray report 140.pdf 
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8 Appendix A2 
 
 
X-ray Crystal Structure Report for Compound 142 
A full X-ray crystallographic report for compound 142 (as compiled by Anthony C. Willis of 
the Australian National University) is provided in PDF-format on the compact disc found on the 
inside back cover of this thesis. 
X-ray report 142.pdf 
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X-ray Crystal Structure Report for Compound 127 
A full X-ray crystallographic report for compound 127 (as compiled by Anthony C. Willis of 
the Australian National University) is provided in PDF-format on the compact disc found on the 
inside back cover of this thesis. 
X-ray report 127.pdf 
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X-ray Crystal Structure Report for Compound 128 
A full X-ray crystallographic report for compound 128 (as compiled by Anthony C. Willis of 
the Australian National University) is provided in PDF-format on the compact disc found on the 
inside back cover of this thesis. 
X-ray report 128.pdf 
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X-ray Crystal Structure Report for Compound 164 
A full X-ray crystallographic report for compound 164 (as compiled by Anthony C. Willis of 
the Australian National University) is provided in PDF-format on the compact disc found on the 
inside back cover of this thesis. 
X-ray report 164.pdf 
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